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ABSTRACT  
Joel Matthew Brittain 
 
DUAL REGULATION OF VOLTAGE- AND LIGAND-GATED CALCIUM CHANNELS BY 
COLLAPSIN RESPONSE MEDIATOR PROTEIN 2 
 
Synaptic transmission is coordinated by a litany of protein-protein interactions that rely 
on the proper localization and function of pre- and post-synaptic Ca2+ channels.  The axonal 
guidance/specification collapsin response mediator protein-2 (CRMP-2) was identified as a 
potential partner of the pre-synaptic N-type voltage-gated Ca2+ channel (CaV2.2).  CRMP-2 
bound directly to CaV2.2 in two regions; the channel domain I-II intracellular loop and the distal 
C-terminus.  Both proteins co-localized within presynaptic sites in hippocampal neurons. 
Overexpression in hippocampal neurons of a CRMP-2 protein fused to EGFP caused a significant 
increase in Ca2+ channel current density whereas lentivirus-mediated CRMP-2 knockdown 
abolished this effect.  Cell surface biotinylation studies showed an increased number of CaV2.2 at 
the cell surface in CRMP-2–overexpressing neurons.  Both activity- and CRMP-2-
phosphoryation altered the interaction between CaV2.2 and CRMP-2.  I identified a CRMP-2-
derived peptide (called CBD3) that bound CaV2.2 and effectively disrupted the interaction 
between CaV2.2 and CRMP-2.  CBD3 peptide fused to the HIV TAT protein (TAT-CBD3) 
decreased neuropeptide release from sensory neurons and excitatory synaptic transmission in 
dorsal horn neurons, and reversed neuropathic hypersensitivity produced by an antiretroviral 
drug.  
Unchecked Ca2+ influx via N-methyl-D-aspartate receptors (NMDARs) has been linked to 
activation of neurotoxic cascades culminating in cell death (i.e. excitotoxicity).  CRMP-2 was 
suggested to affect NMDAR trafficking and possibly involved in neuronal survival following 
excitotoxicity.  Based upon these studies, I hypothesized that a peptide from CRMP2 could 
viii 
 
preserve neurons in the face of excitotoxic challenges.  Lentiviral–mediated CRMP2 knockdown 
or treatment with TAT-CBD3 blocked neuronal death following glutamate exposure likely via 
blunting toxicity from NMDAR-mediated delayed calcium deregulation.  TAT-CBD3 induced 
internalization of the NMDAR subunit NR2B in dendritic spines without altering somal surface 
expression.  TAT-CBD3 reduced NMDA-mediated Ca2+-influx and currents in cultured neurons.  
The presented work validates CRMP-2 as a novel modulator of pre- and post-synaptic Ca2+ 
channels and provides evidence that the TAT-CBD3 peptide could be useful as a potential 
therapeutic for both chronic neuropathic pain and excitotoxicity following stroke or other 
neuronal insults.  
 
Rajesh Khanna, Ph.D., Chair 
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FOREWORD 
 I begin my thesis with an Introduction to the three main areas covered in my thesis 
research: CaV2.2, CRMP-2, and NMDARs.  I then describe the Materials and Methods (Chapter 
2) used to perform the experiments that comprise my thesis research.  Next, I describe the results 
of my studies on the regulation of CaV2.2 by CRMP-2.  This spans the initial biochemical and 
functional characterization between CaV2.2 and CRMP-2, the potential role CRMP-2 
phosphorylation by Cdk5 plays in regulation of CaV2.2, and finally the development and 
characterization of the CRMP-2-CaV2.2 disrupting CRMP-2 peptide CBD3 and the use of a cell 
penetrant version of the CBD3 peptide in cell biology and animal studies (Chapter 3).  The 
second part of my results present evidence for CRMP-2 regulation of NMDARs and putative 
roles in neuroprotection (Chapter 4).  This is followed by an overall Discussion (Chapter 5), 
which synergizes the results, discusses the relevance to the literature, and presents future 
directions for the CRMP-2 and calcium channel fields.  
1 
 
CHAPTER 1. INTRODUCTION 
2 
 
1.1. CaV2.2 
1.1.1. Identification of an “N-type” calcium current 
The field of Ca2+ channels likely began with the seminal observation of a Ca2+ current 
during an examination of the electrical properties of crustacean muscle fibers (Fatt and Katz, 
1953).  During the course of recording Na+ current dependent action potentials, Paul Fatt and 
Bernard Katz noted that despite complete removal of Na+, action potentials persisted.  It was not 
until five years later that Fatt and Bernard Ginsborg concluded that Ca2+ was sufficient to support 
action potentials (Fatt and Ginsborg, 1958).  Building on these early studies on Ca2+-dependent 
excitability, using squid giant axons, Hodgkin and Keynes first measured activity-dependent 
45Ca2+ flux leading to their postulate that Ca2+ influx triggers neurosecretion (Hodgkin and 
Keynes, 1957).  These early findings were prescient of a route for rapid entry of Ca2+ into the cell 
thereby paving the road for all subsequent studies on synaptic transmission and all other forms of 
fast Ca2+ signaling.  The pathway for Ca2+ entry was eventually found to be pore-forming proteins 
called Ca2+ channels (Llinas et al., 1976).  Importantly, these Ca2+ channels are responsible for 
converting the electrical signal contained in an action potential to the chemical signal of a 
neurotransmitter, were found to be regulated by the voltage across the cell membrane.  Hence, 
these channels are now known as voltage-gated Ca2+ channels.  A hint of diversity of Ca2+ 
channel first emerged when it was shown that two Ca2+ channels with unique properties existed in 
star fish eggs (Hagiwara et al., 1975).  Some years later, two subtypes of Ca2+ channels that could 
be separated by the voltages at which they open were discovered in chick sensory neurons 
(Carbone and Lux, 1984).  These subclasses of Ca2+ channels would be coined low voltage-
activated (LVA) and high voltage-activated (HVA) channels.  Using specific agonists and 
antagonists in cardiac cells, long lasting HVA currents that were termed “L-type” currents were 
identified (Hess et al., 1984).  In neurons, despite complete block of L-type currents, an additional 
current was also present.  This current was designated “N-type” (non-L-type and neuronal) and 
while requiring high voltage to activate like the L-type, it was biophysically different particularly 
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in its inactivation and activation properties (Nowycky et al., 1985).  This neuronal N-type Ca2+ 
channel is the focus of my dissertation work but is it is important to acknowledge that there also 
exist other Ca2+ channels in neurons.  A compendium of voltage-gated Ca2+ channels expressed in 
neurons is shown in Figure 1.1.  These channel subtypes are distinguishable by their biophysical 
properties and/or drug sensitivities.  Importantly, the identification of N-type Ca2+ currents 
explained previous reports of neurotransmitter release insensitive to L-type currents blockade.  
The isolation and detailed analyses of N-type Ca2+ currents was greatly advanced by the 
discovery of the cone snail toxin ω-conotoxin GVIA (ω-CTX) (Kerr and Yoshikami, 1984; 
Olivera et al., 1984) which was capable of blocking neurotransmission via directly antagonizing 
N-type Ca2+ currents (Dooley et al., 1987; Kasai et al., 1987).  The N-type Ca2+ channel was 
subsequently purified and genetically isolated (Williams et al., 1992).  Like the majority of Ca2+ 
channels, the N-type channel is composed of multiple subunits including the α1, β, α2δ, and γ 
subunits.  The α1 subunit (classified as α1B) is the primary subunit and determines toxin 
selectivity and synaptic targeting (discussed in §1.1.8).  Ca2+ channel α1 subunits contain four 
domains each consisting of six transmembrane regions.  Richard Tsien, William Catterall and 
others proposed a nomenclature for Ca2+ channels that was approved by the International Union 
of Pharmacology and has been widely accepted (Catterall et al., 2005; Ertel et al., 2000).  This 
nomenclature groups and labels the 10 known Ca2+ channels (as defined by their α1 subunit) 
using a CaVX.Y where X = number of Ca2+ channel subfamily and Y = number of the Ca2+ 
channel within this subfamily.  According to this nomenclature, the N-type channel is known as 
CaV2.2 and the P/Q-type channel, which is part of the same subfamily, is designated as CaV2.1.  
A compendium of Ca2+ channels is outlined in Figure 1.1B.  Ca2+ channel subtypes will be 
referred to using this nomenclature for the remainder of this thesis.  A more indepth descriptive 
history of Ca2+ channels can be found elsewhere (Dolphin, 2006). 
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A 
 
B 
Channel Current alpha 1 subunit HVA or LVA Function 
CaV1.1 L S LVA Excitation-contraction coupling 
CaV1.2 L C LVA Excitation-contraction coupling, gene transcription, peptide release 
CaV1.3 L D LVA Gene transcription, peptide release, cardiac pacemaking 
CaV1.4 L F LVA Neurotransmitter release from photoreceptors 
CaV2.1 P/Q A LVA Release of neurotransmitters and peptides 
CaV2.2 N B LVA Release of neurotransmitters and peptides 
CaV2.3 R E LVA Regulation of firing patterns 
CaV3.1 T G HVA Regulation of firing patterns 
CaV3.2 T H HVA Regulation of firing patterns 
CaV3.3 T I HVA Regulation of firing patterns 
 
Figure 1.1.  Ca2+ channel structure and family 
(A)  This figure depicts the predicted structure of CaV2.2 based upon sequence analysis and 
homology to Na+ channels.  Included in this depiction is the auxiliary subunits β and α2δ, in 
addition the synprint region of CaV2.2 (aa 718-963) is highlighted.  (B)  Table of Ca2+ channel 
family subtypes, the nomenclature used and proposed functions. 
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1.1.2. Relationship of Ca2+ influx via CaV2.2 to synaptic release 
 Even prior to the actual identification of Ca2+ currents and channels, it was well known 
that Ca2+ was required for synaptic transmission through classical experiments of Locke, 
Overton, and Mines (Mines, 1911; Rubin, 1970).  As mentioned above it was further postulated, 
following discovery of Ca2+ currents, that Ca2+ influx was required for neurotransmitter release 
(Hodgkin and Keynes, 1957).  Furthermore, it was observed that increasing Ca2+ leads to an 
increase in release despite a decrease in pre-synaptic response (Katz and Miledi, 1965a).  These 
findings linked Ca2+ influx to neurotransmitter release and led to more intense studies into the 
relationship between Ca2+ and neurotransmitter release.  In a seminal study exploring this 
relationship, Frederick Dodge Jr. and Rami Rahamimoff observed that the relationship between 
Ca2+ and post-synaptic response was exponential (Dodge and Rahamimoff, 1967).  The exponent 
in their particular set of experiments in the frog muscular junction was found to be four.  This 
number, designated cooperativity, states that for a quantum of neurotransmitter to be released 
four Ca2+ molecules are required.  It was later found that the single quantum of release consisted 
of a single neurotransmitter containing vesicle (Heuser et al., 1979).  Cooperativity has been 
proposed as a means to assess the efficiency of coupling of Ca2+ channels to synaptic vesicle 
release.  Using the calyx of Held – a large mammalian auditory synapse which can be isolated 
intact – the cooperativity was found to be ~6 (Fedchyshyn and Wang, 2005).  Synaptic 
connections within the cerebellum were found to have a cooperativity value of between 2.5 and 4, 
likely due to the differential contributions of CaV2.1 and CaV2.2 or CaV2.2 channels alone, 
respectively (Mintz et al., 1995).  Consistent with the finding in the cerebellum and frog 
neuromuscular junction, experiments in hippocampal autapses predicted a cooperativity value of 
4 (Reid et al., 1998).  The observed variance in cooperativity values across synapses can be 
attributed to stronger coupling to specific channel subtypes (as shown by Mintz and colleagues 
for CaV2.1) which may ultimately be due to changes in the developmental program of the 
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channels themselves (see §1.1.4) as well as protein-protein interactions involved in transmitter 
release.    
The coupling of pre-synaptic Ca2+ channels to vesicle machinery facilitates the release of 
neurotransmitters by allowing Ca2+ influx to trigger vesicle fusion.  The resting cytosolic 
concentration of Ca2+ within the nerve terminal is quite low (~50-100 nM), which upon opening 
of Ca2+ channels rises locally near the mouth of the Ca2+ channels (~5-30 μM) (Evans and 
Zamponi, 2006; Tay et al., 2012).  The increase in Ca2+ is detected by Ca2+ sensing proteins (i.e. 
synaptotagmins) present on neurotransmitter containing vesicles leading to vesicle fusion with the 
synaptic membrane (Chapman, 2008).  The delay between Ca2+ influx and release of 
neurotransmitter is very short (~ 1ms) suggesting that Ca2+ channels must be in tight spatial 
proximity to the release machinery (Katz and Miledi, 1965b; Llinas et al., 1981).  It is therefore 
not surprising that CaV2.2 directly couples to vesicle exocytotic proteins enabling the rapid 
release of neurotransmitter (Khanna et al., 2007a; Zamponi, 2003).  The regions of pre-synaptic 
terminals that are responsible for release are commonly referred to as “active zones” and are 
defined as regions opposite of post-synaptic terminals that contain all of the machinery needed for 
synaptic release.  The tight coupling of CaV2.2 and the synaptic release complex is further 
supported by the finding that current passing via a single channel is sufficient for release of 
neurotransmitter in some neurons (Stanley, 1993).  CaV2.2 is the primary source of Ca2+-influx 
required for transmitter release at many synapses throughout the central nervous system (Hirning 
et al., 1988; Maggi et al., 1990b; Weber et al., 2010; Wheeler et al., 1994).  At most synapses 
where CaV2.2 is not dominant, CaV2.1 is responsible for regulating release (Meir et al., 1999).  
At most synapses, however, release is regulated by more than one channel subtype (Reid et al., 
2003; Wheeler et al., 1994; Wu et al., 1999).   
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1.1.3. CaV2.2 expression and localization 
 The presence of CaV2.2 currents is defined by their pharmacological sensitivity to ω-
CTX.  Through the use of ω-CTX, CaV2.2 current has been found in many different neurons both 
in the peripheral and central nervous system.  CaV2.2 currents were first observed in dorsal root 
ganglion sensory neurons (Nowycky et al., 1985).  Since their initial discovery, CaV2.2 have 
been found in soma and axodendritic compartments of various types of neurons including 
sympathetic (Hirning et al., 1988), cortical (Lorenzon and Foehring, 1995), hippocampal 
(Wheeler et al., 1994), cerebellar (Haws et al., 1993), and thalamic (Kammermeier and Jones, 
1997).  While some of the CaV1 family of Ca2+ channels are expressed in many different tissues 
(Catterall et al., 2005), expression of CaV2.2 is primarily limited to neuro- and neuroendocrine 
tissues (Artalejo et al., 1992; Williams et al., 1992), although it has also been observed in glia and 
sperm  (D'Ascenzo et al., 2004; Wennemuth et al., 2000).  
One of the proposed theories for regulation of Ca2+ channels in the presynaptic terminals 
states that there are modular units of release machinery within the active zone that couple to a set 
number of channels defining a “slot”.  This concept arose from work performed in the 19070’s 
hinting that Ca2+ channels associate with synaptic vesicles in an ordered manner along the active 
zone (Heuser et al., 1979).  Because different synapses express a different complement of Ca2+ 
channels contributing to release, this theory posits that synapses have different “allotments” of 
subtype-specific slots.  Using cultured cortical neurons from mice deficient in CaV2.1, Tsien and 
co-workers showed that (i) over-expression of CaV2.1 leads to competition for native CaV2.1 
channels more so than with other channel subtypes and (ii) that the amplitude of excitatory post-
synaptic current (EPSCs) in neurons lacking CaV2.1 or expressing low conductance CaV2.1 was 
not altered (Cao et al., 2004).  These data suggested that while CaV2.1 selectively occupies a 
subset of slots, CaV2.2 is able to compensate for the reduction in active zone CaV2.1.  The basis 
for the compensation by CaV2.2 was explored in a subsequently study which reported that there 
exists two slots of differential Ca2+ channel preference (Cao and Tsien, 2010).  In this model, two 
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kinds of slots exist: those with CaV2.2, which only accommodate CaV2.2, and those with a 
CaV2.1 preference, which prefer CaV2.1 but may accommodate CaV2.2 if CaV2.1 are limiting.  
This may be explained by differential binding of synaptic proteins to specific Ca2+ channels, a 
mechanism which would also allow neurons to fine-tune slot preference by regulating expression 
of these synaptic proteins. 
 
1.1.4. Developmental regulation of CaV2.2 
Although CaV2.2 is the prominent source of Ca2+ influx at many synapses in the adult 
animal, CaV2.1 dominates other synapses within the adult.  During ontogeny, there is a switch in 
expression of CaV2.2 to CaV2.1 at several synapses (Iwasaki et al., 2000; Iwasaki and Takahashi, 
1998; Scholz and Miller, 1995).  In order to monitor the effects of these Ca2+ channels in synaptic 
release, post-synaptic responses were monitored by recording EPSCs.  The Ca2+ channel switch 
was first observed in hippocampal neuronal in cultures, where it was found that EPSCs were 
initially more sensitive to block by ω-CTX in immature cultures (grown for 10-15 days in vitro 
(DIV)) but were more sensitive to block by the CaV2.1 selective toxin ω-agatoxin IVA in cells 
grown in culture for longer times (20-25 DIV) (Mintz et al., 1992).  A similar change was 
observed in brainstem slices maintaining the calyx of Held synapse where ω-CTX sensitivity 
decreased in animals at post-natal day (PN) 7-10.  Expression of CaV2.2 within the hippocampus 
seems to follow a similar trend with expression peaking PN10-20 and reducing by about half by 
PN40 (Jones et al., 1997b).  Another study examining multiple types of synapses through 
development found that this switch was specific to certain synapses: dorsal horn and cerebral 
cortical synapses showed no change in ω-CTX sensitivity while thalamic, cerebellar, and 
brainstem auditory synapses completely lost ω-CTX sensitivity in PN20 animals (Iwasaki et al., 
2000).  The mechanism for why some synapses remain sensitive to ω-CTX and why some lose 
their sensitivity is at present unknown.  Still other studies using the calyx of Held found that the 
slow Ca2+ buffering reagent EGTA displayed stronger inhibition of synaptic release in immature 
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synapses (PN8-12) than in mature synapses (PN16-P18) (Fedchyshyn and Wang, 2005).  As 
EGTA has a slow onset for the binding of Ca2+ it prevents release that occurs spatially distant 
from the Ca2+ channel.  In constract, the fast Ca2+ buffering reagent BAPTA inhibited release 
regardless of the age of the synapse.  The fast Ca2+ binding kinetics of BAPTA are able to prevent 
Ca2+ mediated signaling, including neurotransmission, independent of whether the release site is 
near the channel.  These findings lead to the deduction that mature synapses likely have their 
release machinery that is spatially closer or tightly associated with the Ca2+ channel while a 
portion of immature release occurs via spatially distant release machinery.  In addition the 
efficiency of transmission correlates with increased Ca2+ exposure within the pre-synaptic calyx 
(Yang and Wang, 2006).  However, despite mature synapses exhibiting a net decrease in Ca2+ 
influx into the presynaptic terminal, the Ca2+ that enters the terminal initiates release more 
effectively.  Collectively, these findings suggest that changes in the coupling of Ca2+ channels to 
the release machinery reflect the maturation of a synapse designed to ensure synaptic fidelity.  A 
recent study also found that among the voltage-gated Ca2+ channels it appears that CaV2.2 has the 
largest single channel conductance (Weber et al., 2010), suggesting that CaV2.2 may be more 
efficient than CaV2.1 in initiating release when a larger amount of Ca2+ is required.  The 
developmental regulation of CaV2.2 likely coincides with that of a protein partner – perhaps 
collapsin response mediator protein 2 (CRMP-2) (see §1.2) – which is also present during 
neurogenesis and changes with development. 
 
1.1.5. Structure and function of CaV2.2 
 Voltage-gated Ca2+ channels are multimeric proteins (Figure 1.1) consisting of  the pore 
forming α1 subunit as well as ancillary subunits  β, α2δ, and γ (Ahlijanian et al., 1990; Catterall, 
1991a; Catterall, 1991b; Catterall et al., 1989; De Jongh et al., 1989).  While the α1 subunit is 
sufficient to form the pore of the channel and conduct current, the other subunits largely facilitate 
proper trafficking and localization of the α1 subunit.  When the first Ca2+ channel α1 subunit was 
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fully sequenced it was found to have high homology to previously identified Na+ channels and 
was hence proposed to have a similar structure (Noda et al., 1986; Noda et al., 1984; Tanabe et 
al., 1987).  As depicted in Figure 1.1, the α1 subunit of CaV2.2 (like all voltage-gated Ca2+ 
channels) contains four domains that each have six transmembrane regions.  These domains are 
connected via large cytosolic linker sequences.  It is within these intracellular regions where the 
majority of protein interactions with the channel occur (Chan et al., 2007; Li et al., 2006b; 
Maximov et al., 1999; Sheng et al., 1994; Sheng et al., 1997; Vance et al., 1999; Yokoyama et al., 
1997b).  CaV2.2, the focus of this dissertation, is encoded by the α1B subunit which is made up 
of 2339 amino acids (although with splice variants this can vary) and contains the sequences 
responsible for the Ca2+ permeation, ω-CTX sensitive interaction site, and voltage-dependent 
gating (Williams et al., 1992).  While the expression of α1B alone in heterologous cells is 
sufficient to produce Ca2+ current, the presence of the auxiliary subunits greatly enhances the 
current amplitude (Kang et al., 2001; Yasuda et al., 2004) as described in the sections below.   
The Ca2+ channel β-subunit is a family of cytosolic proteins translated from four genes 
(β1-4) with ~24 splice variants yielding very diverse protein products (Buraei and Yang, 2010; 
Dolphin, 2003a).  While CaV2.2 is known to associate with several different β-subunits in native 
tissues (e.g. β3 in hippocampal neurons), the complete compliment of β-subunits that are 
important for CaV2.2 function is not clear (Jones et al., 1997b; Ludwig et al., 1997; Scott et al., 
1996).  All four β-subunits do, however, interact with the α1 subunit through a conserved region 
(379-396) within the I-II linker (commonly referred to as the I-II loop or L1) via binding to the 
alpha interaction domain (AID) of the β-subunit (Pragnell et al., 1994).  The N- and C-termini of 
α1 subunits have also been suggested to interact with β-subunits (Qin et al., 1997; Stephens et al., 
2000; Walker et al., 1998; Walker et al., 1999) although this data is considered controversial.  
The primary function of the β-subunit appears to assist with proper folding and trafficking of the 
α1 subunit to the membrane (Birnbaumer et al., 1998; Brice et al., 1997; Chien et al., 1995; 
Dolphin, 2003a); a detailed description of the contribution of the β-subunit on trafficking will be 
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discussed in §1.1.8.  In heterologous expression studies, the β-subunits lead to changes in 
biophysical properties when co-expressed with α1 subunits.  Expression of all four β-subunits 
appears to kinetically enhance activation and cause a hyperpolarizing shift in activation (Buraei 
and Yang, 2010).  The effects of β-subunit expression on other properties, such as inactivation, 
seem to vary depending on the β-subunit (Buraei and Yang, 2010). 
 There are four isoforms of the α2δ subunit, a subunit that is made by disulfide bonds 
bridging of an α2 subunit and a δ subunit, (Davies et al., 2007).  Co-expression of α2δ with α1B 
leads to a 2-4 fold increase in current and maximum conductance (Gao et al., 2000; Kang et al., 
2001; Yasuda et al., 2004).  The open probability and surface expression of CaV2.2 was found to 
be increased (4- and 3-fold respectively) by co-expression of α2δ with α1 in Xenopus oocytes 
(Shistik et al., 1995).  Subsequent studies, however, using mammalian cells observed no change 
in open probability (Barclay et al., 2001; Brodbeck et al., 2002).  The increase in conductance 
without an increase in the open probability suggested a role for a2δ in trafficking of the α1 
subunit; the role of α2δ in trafficking of CaV2.2 will be discussed further in section 1.1.8.  In 
addition to trafficking, the α2δ subunit also acts to regulate channel activation and inactivation 
(Kang et al., 2001; Yasuda et al., 2004).  Altered biophysical properties of CaV2.2 by the α2δ 
subunit have been reported, however; these two studies reported effects in opposite directions for 
both the half voltage (V1/2) of activation and steady state inactivation.  These effects on 
biophysical properties appear to be synergistic with expression of the β-subunit.  The synergism 
between α2δ and β-subunits also contributes to the enhancement of current amplitude. 
The γ subunit is peculiar in its function as, in contrast to the other subunits, it appears to 
antagonize the function of the α1 subunit (Kang and Campbell, 2003; Kang et al., 2001).  Out of 
all the subunits γ has been studied the least and may have gone even less studied if not for several 
studies linking mutations in the γ subunit to epilepsy (Leitch et al., 2009; Letts et al., 1998; Letts 
et al., 2003).  The observed antagonism of CaV2.2 by γ only occurs in the presence of α2δ and 
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reduces expression in what appears to be via an unfolded protein response (Sandoval et al., 
2007a; Sandoval et al., 2007b).    
 
1.1.6. Activation and inactivation of CaV2.2 
The voltage-gated ion channel family is defined by its responses to voltage across the cell 
membrane leading to changes in the gating of the channel.  Gating refers to mechanisms by which 
an ion channel regulates its conductance (ability for ions to pass through the channels’ pore) and 
transitions from one state of conductance to another.  Using a relatively simple model, Ca2+ 
channels can exist in three states: closed, open, and inactivated.  The properties of each state can 
vary greatly amongst the Ca2+ channel subtypes (Carbone and Lux, 1984; Nowycky et al., 1985).  
The closed state is the resting state in which the voltage-gate of the pore is in a non-conducting 
configuration.  The transition between the closed state and the conducting open state is termed 
activation.  LVA channels are closed at polarized potentials (~ –100 mV) and activate when the 
membrane is depolarized to intermediate voltages (~ –50 mV).  Conversely HVA channels 
(including CaV2.2) activate at significantly lower potentials (~ –10 mV).  Activation of Ca2+ 
channels, similar to voltage-gated Na+ channels, relies on charged residues in the S4 
transmembrane region.  The S4’s charged residues are conserved between Na+ channels and 
CaV2.2 suggesting that the mechanism of activation is also conserved (Catterall, 1988; Williams 
et al., 1992).  These charged residues move in response to changes in voltage causing a 
conformational change of the channel, which makes the channel conduct Ca2+.  Collectively, 
these residues are responsible for Ca2+ channel activation and are commonly referred to as the 
voltage sensor.  Furthermore, activation can be indirectly observed through measuring gating 
current, which is due to charges within the sensor moving in relation to the membrane (Adams 
and Gage, 1976; Jones et al., 1999; Jones et al., 1997a).            
 During activation, Ca2+ channels transition to a state that is distinct from the closed state 
termed the inactivated state.  The inactivated channel, like the closed state, is a conformation of 
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the channel that is unable to conduct current.  This state, however, differs from the closed state as 
it is unable to directly transition to an open state, but rather must first transition to a closed state 
and is therefore refractory.  CaV2.2 preferentially undergoes closed-state inactivation, which 
contrasts with classical open-state inactivation (Patil et al., 1998).  CaV2.2 has a U-shaped curve 
for inactivation as a function of prepulse voltage, which is indicative of closed-state inactivation 
(Cox and Dunlap, 1994; Goo et al., 2006; Jones and Marks, 1989).  Principally, this mechanism 
of inactivation leads to more channels becoming inactivated during a train of action potentials, a 
stimulation that engages in repetitive opening and closing, rather than a long depolarization.  In 
addition to voltage-dependent inactivation CaV2.2 also displays Ca2+ dependent inactivation 
(CDI).  CDI involves Ca2+ entering through the channel and binding an intracellular partner to 
induce channel inactivation.  This phenomenon was first observed in Paramecium where the 
replacement of Ca2+ with Sr2+ or Ba2+ prevented inactivation of Ca2+ channel current without a 
reduction in current amplitude (Brehm and Eckert, 1978).  In studies on L-type Ca2+ channels, it 
was ter determined that CDI occurs due to binding of the Ca2+ binding protein calmodulin (CaM) 
(Peterson et al., 1999; Zuhlke et al., 1999).  CaV2.2 also displays CDI via this mechanism 
through a conserved CaM-binding sequences in the cytosolic C-terminus (Cox and Dunlap, 1994; 
Liang et al., 2003).  Thus CDI is an important mechanism that allows CaV2.2 to regulate its own 
activity and control Ca2+ influx (Goo et al., 2006).  
  
1.1.7. Pharmacology of CaV2.2 
 The most well studied and characterized antagonist that targets CaV2.2 is ω-CTX.  Its 
discovery occurred through purification and isolation of toxins from the mollusk Conus 
geographus (Olivera et al., 1984).  Commonly known as the cone snail, this organism rapidly 
immobilizes its prey by injecting it with venom containing ω-CTX .  The finding that ω-CTX 
blocked presynaptic release at the frog neuromuscular junction supported the notion that this 
toxin is responsible for paralyzing prey (Kerr and Yoshikami, 1984).  Composed of 27 amino 
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acids, ω-CTX is a peptide that contains three disulfide bridges giving the peptide its functional 
structure (Olivera et al., 1984; Olivera et al., 1994).  Binding of ω-CTX occurs within the 
extracellular loops of CaV2.2 DIII (1334-5) leading to pore occlusion (Ellinor et al., 1994).  In 
addition to ω-CTX there are several other toxins that also inhibit CaV2.2 (Catterall et al., 2005).  
Notably, ω-conotoxin MVIIA shows selective and reversible inhibition of CaV2.2, unlike the 
irreversible inhibition observed by ω-CTX (Yoshikami et al., 1989).  A synthetic form of MVIIA, 
termed Ziconotide, was developed and is currently approved as a pain therapeutic (Schmidtko et 
al., 2010). 
The role of CaV2.2 in pain (discussed in § 1.1.9) has led to extensive drug development 
efforts seeking specific antagonists of CaV2.2.  Through utilization of fluorescence based high 
through-put screening, a recent study identified an N-triazole oxindole, named TROX-1, which 
targets CaV2.2 and appears to display increased potency under depolarized conditions (Abbadie 
et al., 2010).  This drug displayed a more preferable therapeutic window compared to Ziconotide 
although a subsequent study found it to not be specific for CaV2.2 as it inhibited other CaV2 
channels with similar potencies (Swensen et al., 2012).  Several other chemical structures (e.g. 
piperidines, aliphatic monoamines) have been identified that inhibit CaV2.2, but there are 
currently no non-peptide specific inhibitors of CaV2.2 (Catterall et al., 2005; Hu et al., 1999a; Hu 
et al., 1999b; Hu et al., 2000; Lukyanetz et al., 2002).  
 
1.1.8. Trafficking of CaV2.2 
 While the ability of CaV2.2 to function as a Ca2+-conducting protein is vital to its 
function, the ability of Ca2+ influx via CaV2.2 in inducing synaptic release is reliant on proper 
channel localization and targeting (Simms and Zamponi, 2012).  CaV2.2 must be translated from 
α1B mRNA, be post-translationally modified, co-assemble with α2δ, and β-subunits to form a 
functional channel complex that must then be trafficked to pre-synaptic active zones to facilitate 
coupling of CaV2.2 to neurotransmitter release.  As such,  trafficking of CaV2.2 may directly 
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impart its function as a regulator of synaptic release.  As previously discussed, the accesory 
subunits, such as β and α2δ, aid in trafficking of CaV2.2, but there are also additional protein 
interactions required for localizing the channel to the active zone that are unique to CaV2 
channels that will be discussed below.   
The relative amount of surface expressed CaV2.2 is determined by the sum of forward 
trafficking and stability of channels once in the membrane.  Forward trafficking of CaV2.2 
requires export from the ER and transportation through the Golgi network to the surface (Simms 
and Zamponi, 2012; Waithe et al., 2011).  Studies with CaV2.1 constructs reported that the 
interaction between the β-subunit and I-II loop of the Ca2+ channel masks an ER retention signal 
(aa415-90) leading to channels being exported from the ER ( (Bichet et al., 2000).  It was 
subsequently observed that the I-II loop of CaV2.2 had a similar level of retention (Cornet et al., 
2002).  More recent studies have not supported this conclusion, however, and rather suggest that 
the proximal portion of the C-terminus of CaV2.2 (1749-96) has a retention sequence (Altier et 
al., 2011; Waithe et al., 2011).  
Recent elegant studies from the Dolphin and Zamponi groups have further delineated the 
mechanism whereby the β-subunit enhances total channel expression, namely by reducing 
proteasomal degradation of Ca2+ channels.  While investigating the discrepancies between ER 
retention of CaV1.2 and CaV2.1 Ca2+ channels, it was observed that co-expression of the β1b 
subunit greatly enhanced total channel expression (Altier et al., 2011).  Investigations into how 
this may happen led to the intriguing discovery that the β1b subunit reduces ubiquitination and 
subsequent degradation of L-type channels.  Another study verified these findings for CaV2.2, 
leading to the conclusion that β-subunits prevent proteasomal degradation of other Ca2+ channels 
as well (Waithe et al., 2011). 
In addition to the β-subunit, the α2δ subunit has also been implicated in CaV2.2 
trafficking.  Trafficking of the α1 subunits by α2δ has been observed in mammalian cells where 
mutations in α2δ greatly reduce surface expression of α1 subunits (Barclay et al., 2001; Canti et 
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al., 2005).  However, in contrast to the forward trafficking bestowed by β-subunits upon Ca2+ 
channels, it appears that the α2δ subunit increases the amount of undegraded channels recycled 
back to the membrane during endosomal sorting (Tran-Van-Minh and Dolphin, 2010).  Perhaps 
the most interesting aspect regarding the role of α2δ in CaV2.2 trafficking is the evidence 
supporting it as the target for the drugs Gabapentin (Neurontin) and Pregabalin (Lyrica) (Bauer et 
al., 2009; Belliotti et al., 2005; Field et al., 2006; Hendrich et al., 2008; Joshi and Taylor, 2006).  
Gabapentin and pregabalin are medications commonly prescribed for the treatment of epilepsy 
and neuropathic pain.  The proposed mechanism for these drugs is to target α2δ and disrupt its 
ability to enhance surface expression of CaV2.2.  This mechanism is further supported by the 
finding that only chronic (several days), but not acute, application of pregabalin or gabapentin 
reduces Ca2+ channel current density (Heblich et al., 2008; Hendrich et al., 2008; Vega-
Hernandez and Felix, 2002).  The α2δ subunit has been shown to be upregulated in models of 
neuropathic pain (Bauer et al., 2009; Field et al., 2000; Li et al., 2006a; Nguyen et al., 2009).  The 
upregulation of α2δ leads to enhanced Ca2+ channel regulated synaptic transmission due to an 
enhancement in surface expression of Ca2+ channels.  Presumably, this increase in transmission is 
what is targeted by gabapentin and pregabalin leading to a reduction in pain.         
Consistent with its role in synaptic transmission, CaV2.2 is targeted to synaptic terminals 
in neurons (Westenbroek et al., 1992; Westenbroek et al., 1998).  Maximov and Bexprozvanny 
specifically investigated synaptic targeting of the CaV2 family of channels, as these channels are 
known to mediate synaptic transmission (Maximov et al., 1999; Wheeler et al., 1994; Wu et al., 
1998).  They discovered that the synaptic-specific trafficking of CaV2.2 appears to be regulated 
by several binding sites within its C-terminus (Maximov and Bezprozvanny, 2002; Maximov et 
al., 1999).  Specifically, there are PDZ (post synaptic density protein (PSD-95), Drosophila disc 
large tumor suppressor (Dlg1), zonula occludens-1 protein (zo-1)) and Src homology 3 (SH3) 
binding domains in the C-terminus which are responsible for binding to scaffolding proteins that 
aid in synaptic localization.  PDZ domains are present in signaling molecules that commonly link 
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the PDZ containing protein to a transmembrane protein (Romero et al., 2011).  The SH3 domain 
is found in many signaling molecules that interact with SH3 binding proteins to activate various 
cascades (Kaneko et al., 2008).  The adaptor protein munc18 interacting protein 1 (Mint-1) 
contains a PDZ domain which binds to the last four amino acids in CaV2.2 (i.e. DHWC), while 
the SH3 domain in the adaptor protein Ca2+ activated serine kinase (CASK) binds to CaV2.2 
through a SH3 binding domain in the medial C-terminus.  Deletions of either the DHWC or the 
SH3 binding domain of CaV2.2 dramatically reduced localization of CaV2.2 with the synaptic 
marker synapsin, suggesting interactions with CASK and Mint-1 are vital for synaptic targeting 
of CaV2.2 (Maximov and Bezprozvanny, 2002).  Trafficking of CaV2.2 through CASK also 
appears to be dynamically regulated through phosphorylation of CASK by cyclin dependent 
kinase 5 (Cdk5) (Samuels et al., 2007b).  Namely phosphorylation of CASK by Cdk5 allows 
CASK to bind to CaV2.2 and facilitate an increase in channel surface expression.  In a recent 
study, it was also shown that Cdk5 can directly phosphorylate CaV2.2 and lead to enhanced 
surface expression (Su et al., 2012).  Mutation of potential Cdk5 sites in CaV2.2 was able to 
prevent this increase in surface expression.  The regulation of CaV2.2 by Cdk5 has important 
implications for my thesis studies described in Chapter 3, which investigates the potential role of 
Cdk5-mediated phosphorylation of CRMP-2 as it relates to CaV2.2 interaction and function. 
In addition to the C-terminus, the synaptic protein interaction (synprint) region (718-963) 
within the II-III loop also assists in synaptic targeting (Szabo et al., 2006).  The synprint region is 
so named as it is responsible for binding to several synaptic proteins, the most well characterized 
being syntaxin (Leveque et al., 1994; Sheng et al., 1996; Sheng et al., 1994).  The synprint region 
is specific to CaV2.2 and CaV2.1 channels.  Splice variants of CaV2.2 lacking portions of the 
synprint region ( Δ756-1139 and Δ737-1001) reduce synaptic localization, further supporting that 
these interactions are critical for synaptic localization of CaV2.2 (Szabo et al., 2006).  In addition 
to being necessary, the synprint sequence appears to be sufficent for synaptic targeting as 
transplanting the CaV2.1 synprint region into L-type channels localizes them ectopically to 
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synapses (Mochida et al., 2003).  Summarizing then, it it appears that synaptic targeting of 
CaV2.2 is achieved by interactions with proteins with the II-III loop and the C-terminus regions 
of the channel itself.  
Once CaV2.2 reaches the membrane, it can be internalized and degraded or internalized 
and recycled back to the membrane.  Recent work has shown that the closely related CaV2.1 is 
recycled via a ras associated in brain 11(Rab11)-dependent endocytic sorting mechanism (Tran-
Van-Minh and Dolphin, 2010).  This finding is likely true for CaV2.2 as well as this recycling 
pathway relies on interaction with the conserved Ca2+ channel subunit α2δ.  Labeling of a 
heterlogous cell line expressing α1B/α2δ/β1b with radioactive ω-CTX found that ~55% of the 
channels were internalized in 24 hours (Bernstein and Jones, 2007).  A similar time scale for 
internalization was previously observed using the same approach in hippocampal rat membranes 
(Jones et al., 1997b).  These studies suggest that the lifetime of a channel on the membrane is 
likely on the order of a few days.  This is consistent with results from siRNA knockdown 
experiments in animals and sensory neurons in culture which demonstrated efficient knockdown 
3 days after siRNA treatments (Altier et al., 2007).  CaV2.2 surface expression can also be 
rapidily decreased (> 50% in 30 min) following G-protein coupled receptor (GPCR) activation 
(Altier et al., 2006; Kisilevsky et al., 2008; Kisilevsky and Zamponi, 2008a).  CaV2.2 is co-
internalized along with the GPCR following application of dopamine or nociceptin, which 
activate dopamine 1/2 and nociceptin receptors respectively, through a direct interaction between 
CaV2.2 and the GPCR (Altier et al., 2006). 
   
1.1.9. The CaV2.2 interactome 
 Synaptic transmission requires a diverse complement of proteins to facilitate the proper 
localization of pre-synaptic Ca2+ channels within proximity of vesicle fusion proteins.  The 
formation of an almost autonomous pre-synaptic release site complex containing CaV2.2 along 
with scaffolding, endocytotic, vesicle fusion, and cell-cell adhesion proteins has been 
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demonstrated (Khanna et al., 2007a; Khanna et al., 2007b; Weiss and Zamponi, 2012).  Key in 
this CaV2.2-containing release site complex are Soluble NSF Attachment REceptor (SNARE) 
proteins that facilitate vesicular fusion of neurotransmitter-containing vesicles following calcium 
influx via CaV2.2.   
 The first biochemical interaction implicating specific proteins in the formation of a pre-
synaptic release complex was observed between CaV2.2 and synaptotagmin (Leveque et al., 
1992).  Synaptotagmin is a Ca2+ binding protein that is localized to synaptic vesicles and has been 
implicated as the Ca2+ sensor for synaptic release (Chapman, 2008; Matthew et al., 1981; Perin et 
al., 1990).  The interaction between CaV2.2 and synaptotagmin supported the proposed 
hypothesis that pre-synaptic Ca2+ channels link to synaptic vesicles.  Biochemical purification of 
synaptic vesicles found that CaV2.2 formed a complex with both synaptotagmin and syntaxin, 
suggesting association of CaV2.2 with both vesicle delimited and membrane-associated SNARE 
proteins, respectively (Leveque et al., 1994).  Later studies, however, found that CaV2.2 was 
unable to directly bind syntaxin and synaptotagmin concomitantly as they competed for binding 
(Sheng et al., 1997).  Syntaxin and synaptotagmin were determined to bind to the synprint region 
of CaV2.2 (Sheng et al., 1994; Sheng et al., 1997).  Subsequently, it was found that the SNARE 
SNAP-25 also interacts with CaV2.2 in the synprint region (Sheng et al., 1996).  Adding a level 
of complexity to this protein complex, it was discovered that binding of synaptic proteins to 
CaV2.2 is dynamically regulated by protein kinase C (PKC) and Ca2+ calmodulin activated kinase 
II (CaMKII) where phosphorylation of the synprint region by these kinases inhibits binding of 
syntaxin and SNAP-25 (Yokoyama et al., 1997b).  Furthermore, both syntaxin and SNAP-25 
show bi-phasic Ca2+ dependent interactions with the synprint such that maximal binding is 
observed at ~10-30 μM Ca2+ and little binding is observed below 5 or above 35 μM Ca2+ (Sheng 
et al., 1996).  That the binding between SNAREs and CaV2.2 displays a Ca2+ dependence may 
provide an activity-dependent mechanism to allow for rearrangement of the pre-synaptic 
complex.  Importantly, introduction of exogenous synprint peptides inhibited neurotransmitter 
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release supporting the notion that coupling of synaptic proteins to CaV2.2 at the synprint region is 
required for neurotransmitter release (Mochida et al., 1996).  The synprint peptide also reduced 
the coupling of Ca2+ influx to neurotransmitter release suggesting it reduces the spatial 
localization of vesicles within the mouth of CaV2.2 (Rettig et al., 1997).   
Both syntaxin and SNAP-25 regulate biophysical properties of CaV2.2 (Bezprozvanny et 
al., 1995; Mochida et al., 1995; Wiser et al., 1996).  Expression of syntaxin leads to inhibition of 
CaV2.2 current amplitude, likely due to a hyperpolarizing shift in steady state inactivation.  This 
effect can be reversed by introduction of a synprint peptide or by co-expression with CaV2.2 
binding target-SNAREs SNAP-25 or Munc18-1 (Chan et al., 2007; Jarvis and Zamponi, 2001).  It 
has been suggested that the relief of syntaxin-mediated inhibition of CaV2.2 by co-expression of 
other t-SNAREs may be a mechanism for cells to inhibit channels which are not in a complete 
pre-synaptic complex (Zamponi, 2003).  The syntaxin-mediated inhibition of CaV2.2 can also be 
reversed using strong depolarizing prepulses (Jarvis et al., 2000; Jarvis and Zamponi, 2001).      
As synaptic transmission is the basis of communication between neurons, it is not 
surprising that neurons have developed rapid and efficient mechanisms to regulate transmission.  
Perhaps the most-well characterized example relating to pre-synaptic Ca2+ channels is GPCR-
mediated inhibition of CaV2.2 (De Waard et al., 2005; Tedford and Zamponi, 2006).  GPCR-
mediated inhibition occurs through many different GPCRs as approximately 20 GPCR ligands 
have been found to induce CaV2.2 inhibition (Dolphin, 2003b; Tedford and Zamponi, 2006).  
GPCR-mediated inhibition of CaV2.2 is responsible in part for the analgesic efficacy of opioids 
such as morphine (Rhim and Miller, 1994; Scott et al., 2002).  Sympathetic neurotransmitter 
release through CaV2.2 is inhibited by adrenergic GPCRs among others (Beech et al., 1992; 
Boehm and Huck, 1996; Zhu and Ikeda, 1994).  Mechanistically GPCRs regulate CaV2.2 through 
direct interaction of G-proteins (Gα and Gβγ) with several cytosolic regions within CaV2.2 (De 
Waard et al., 2005; Tedford and Zamponi, 2006).  For example, Gα interacts with the C-terminus 
of CaV2.2 whereas Gβγ interacts with the I-II loop and C-terminus of CaV2.2 (Zamponi et al., 
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1997).  G protein modulation of CaV2.2 is plastic as CaV2.2 splice variants have been identified 
that can alter GPCR-induced inhibition (Andrade et al., 2010; Raingo et al., 2007). 
Studies in the Khanna laboratory (Khanna et al., 2007c) as well as in others (Muller et al., 
2010) point to an incredible diversity in the CaV2.2 proteome.  To illustrate the diverse nature of 
these interactions, I next highlight only a limited set of these interactors, focusing on those with a 
functional impact on CaV2.2: 
(i) 14-3-3:  14-3-3 proteins (seven isoforms β, γ, ε, ζ, η, σ, and τ/θ) were originally 
identified in brain by Moore and Perez in 1967 and are so named due to the method in which they 
were purified (Carlson et al., 1968).  These proteins are very abundant in the brain (~1% of 
soluble protein) and although they interact with a multitude of proteins (~100), their functions are 
poorly understood (Berg et al., 2003; Takahashi, 2003).  Several 14-3-3 isoforms (ε, η, γ, β, and 
ζ) are present in synapses suggesting they may interact with synaptic proteins (Martin et al., 
1994).  This led to the discovery that the C-terminus of CaV2.2 (2121-39) binds to 14-3-3 
proteins and that 14-3-3 expression can modulate channel function (Li et al., 2006b).  
Overexpression of 14-3-3 proteins (β, γ, ε, ζ, and τ/θ) led to slowed inactivation and a 
depolarizing shift in the voltage-dependence of inactivation culminating in decreased CaV2.2 
inactivation.  A short follow up study also found that 14-3-3 protein self-dimerization is not 
required for decreasing CaV2.2 inactivation (Li et al., 2007b).  Collectively these two studies 
have shown 14-3-3 to be an important CaV2.2 regulatory protein that likely aids in proper 
synaptic function.            
(ii) RIM:  Rab3a interacting molecule (RIM), is a large protein with many synaptic 
interactions that have suggested it functions as a scaffolding protein to assist with 
neurotransmission (Calakos et al., 2004; Wang et al., 1997).  In this context, RIM1 was initially 
observed to interact with CaV2.2 via its synprint region (Coppola et al., 2001).  However, there is 
some controversary as to whether RIM1 and CaV2.2 are present in the same biochemical 
complex as neither immunohistological nor immunoprecipitations approaches demonstrated co-
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localization or interaction of RIM1 with CaV2.2 in the chick ciliary ganglion calyx pre-synaptic 
terminal (Khanna et al., 2006a; Wong and Stanley, 2010).  In support of the latter findings, it was 
reported the interaction between RIM1 and Ca2+ channel was via the β-, not the α- subunits for 
the CaV2.1 complex (Kiyonaka et al., 2007).  Consistent with the involvement of the β-subunit in 
the interaction, expression of RIM1 led to an ~30-60 mV depolarizing shift (depending on the β-
subunit expressed) in the V1/2 of inactivation (Kiyonaka et al., 2007; Weiss et al., 2011).  Despite 
the controversy, RIM1 appears to modulate GPCR signaling-mediated inhibition of CaV2.2 as 
well as enhancing recovery from inhibition (Weiss et al., 2011).   
(iii) Munc18:  Munc18-1, also referred to as nSec1, was classically identified as a 
syntaxin binding protein (Hata et al., 1993).  Munc18-1 has subsequently been identified as an 
important player in vesicle priming, docking, and fusion (Deak et al., 2009; Gerber et al., 2008; 
Voets et al., 2001; Zilly et al., 2006).  Munc18-1 was further linked to the pre-synaptic release 
complex through observations that Munc18-1 interacts directly with CaV2.2 (Chan et al., 2007).  
It appears that Munc18-1 expression is not limiting, as overexpression does not alter CaV2.2’s 
properties, but siRNA knockdown of Munc18-1 causes a ~10 mV hyperpolarizing shift in steady-
state inactivation (Chan et al., 2007).  Collectively, these results suggested that Munc18-1 plays a 
minimal role in CaV2.2 activity but rather may function as a scaffold to link other synaptic 
proteins to CaV2.2. 
In Table 1.1, I summarize the currently known interactome of CaV2.2.  To qualify as a 
CaV2.2-interacting protein, the protein must meet one of the following criteria: (i) biochemical 
interaction as demonstrated by protein pull downs or immunoprecipitations, or (ii) a functional 
effect on CaV2.2 function.  This section has introduced the CaV2.2 interactome as a web of 
protein interactions that can regulate synaptic release through modulation of CaV2.2.  In addition 
these proteins identify many possible targets for CaV2.2-related pathology.  In Chapter 3 of my 
thesis, I introduce CRMP-2 as a novel interactor of CaV2.2 and modulator of CaV2.2 activity and 
relate it to previously identified interactions.     
  
 
23 
Table 1.1 CaV2.2 interacting proteins 
CaV2.2  
interaction 
partner 
Validated 
Biochemical 
Interaction 
Site of 
Interaction 
(CaV2.2) 
Site of Interaction 
(CaV2.2) 
Reference(s) 
14-3-3 Y C-terminus 
(2121-2139) 
 
Interaction leads to slowed channel 
inactivation 
(Khanna et al., 2007c; Li et al., 2007b; Li 
et al., 2006b) 
Actin Y ND Interaction with MAP1A LC2 links to CaV2.2 
stabilizing it in the synapse 
(Khanna et al., 2007b; Khanna et al., 
2007c; Leenders et al., 2008) 
Adaptin N ND Associates with endocytotic channel complex (Khanna et al., 2007b; Khanna et al., 
2007c; Muller et al., 2010) 
AP180 Y ND Associates with endocytotic channel complex (Khanna et al., 2007c) 
β1-4 Y I-II loop 
(378-396) 
& C-terminus 
Interaction retards proteasomal degradation of 
CaV2.2, enhances surface expression, 
modulates biophysical properties 
(De Waard et al., 1994; Pragnell et al., 
1994) 
Clathrin HC-
1 
Y ND Associates with endocytotic channel complex (Khanna et al., 2007b; Khanna et al., 
2007c; Muller et al., 2010) 
CaM Y C-terminus 
(1788-1868) 
Binds to C-terminus of CaV2.2 to induce CDI (Liang et al., 2003) 
CaMKII N ND Phosphorylates synprint region of CaV2.2 
reducing synaptic protein binding 
(Yokoyama et al., 1997a) 
CASK Y C-terminus 
(2039-2194) 
Interaction with CaV2.2 aids in synaptic 
targeting of the channel 
(Khanna et al., 2006b; Maximov and 
Bezprozvanny, 2002; Maximov et al., 
1999) 
Catenin α/β Y ND Associates with endocytotic channel complex (Khanna et al., 2007b; Li et al., 2006b; 
Maximov et al., 1999) 
Cdk5 N ND Phosphorylation of CaV2.2 C-terminus leads 
to enhanced surface expression, current 
density, and transmitter release 
(Su et al., 2012) 
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CaV2.2  
interaction 
partner 
Validated 
Biochemical 
Interaction 
Site of 
Interaction 
(CaV2.2) 
Site of Interaction 
(CaV2.2) 
Reference(s) 
CSP Y Synprint 
(718-963) 
Interaction of CSP along with G-proteins 
leads to tonic inhibition of CaV2.2 
(Magga et al., 2000; Miller et al., 2003a; 
Miller et al., 2003b) 
Dopamine 
1/2 receptors 
Y II-III loop and 
C-terminus 
 
D1/2 receptors display GPCR-mediated 
inhibition of CaV2.2, but also regulate 
CaV2.2 surface expression which is reduced 
upon receptor activation 
(Kisilevsky et al., 2008; Kisilevsky and 
Zamponi, 2008a) 
Dynamin Y ND Associates with endocytotic channel complex (Khanna et al., 2007a; Khanna et al., 
2007b; Khanna et al., 2007c; Muller et al., 
2010) 
ENH Y C-terminus 
 
Forms complex with CaV2.2 and PKCε which 
enhances PKC mediated potentiation of 
CaV2.2 
(Maeno-Hikichi et al., 2003) 
G-protein α Y C-terminus 
 
Leads to inhibition of CaV2.2 following 
GPCR activation and subsequent disassembly 
of trimeric G protein complex 
(Furukawa et al., 1998; Simen et al., 2001) 
G-protein βγ Y I-II loop and C-
terminus 
Couples GPCR activation to inhibition of 
CaV2.2 through direct interaction with 
CaV2.2 
(Herlitze et al., 1997; Jones et al., 1997a; 
Zamponi et al., 1997) 
Huntingtin Y Synprint Competes with syntaxin for binding of 
CaV2.2 
(Swayne et al., 2005) 
Intersectin Y ND Associates with pre-synaptic CaV2.2 complex (Khanna et al., 2007b) 
MAP 1A/B Y C-terminus 
(2046-2069) 
Interacts with CaV2.2 and assists with 
trafficking and synaptic localization of 
CaV2.2 
(Khanna et al., 2007c; Leenders et al., 
2008; Muller et al., 2010) 
Mint-1 Y C-terminus 
(2336-2339) 
Interaction with CaV2.2. aids in synaptic 
targeting of CaV2.2 
(Maximov et al., 1999) 
Munc18-1 Y I-I and II-III 
loop 
 
Associates with pre-synaptic release complex, 
knockdown by siRNA leads to a 10mV 
hyperpolarizing shift in CaV2.2 inactivation 
(Chan et al., 2007) 
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CaV2.2  
interaction 
partner 
Validated 
Biochemical 
Interaction 
Site of 
Interaction 
(CaV2.2) 
Site of Interaction 
(CaV2.2) 
Reference(s) 
NSF Y ND Associates with pre-synaptic release complex (Khanna et al., 2007a; Khanna et al., 
2007c) 
ORL1 Y C-terminus ORL1 receptor mediates GPCR inhibition of 
CaV2.2 as well as agonist induced 
internalization of CaV2.2 
(Altier et al., 2006; Beedle et al., 2004) 
PKC Y 
(PKCε) 
C-terminus 
(PKCε) 
Phosphorylates synprint region of CaV2.2 
reducing synaptic protein binding, formation 
of complex with ENH and CaV2.2 allows for 
enhanced potentiation of CaV2.2 by PKC 
(Maeno-Hikichi et al., 2003; Yokoyama et 
al., 1997b) 
PP2Cα Y C-terminus Interacts and dephosphorylates CaV2.2 at 
synprint site reversing PKC mediated 
potentiation 
(Li et al., 2005) 
REM Y β-subunt Co-expression of REM with CaV2.2 α1 and 
β-subunits leads to tonic inhibition of CaV2.2 
currents 
(Chen et al., 2005; Finlin et al., 2003; 
Finlin et al., 2005; Flynn et al., 2008) 
RGS12 Y Synprint Interacts with synprint phospho-tyrosine 
likely leading to enhanced G protein 
modulation of CaV2.2 
(Richman et al., 2005; Richman and verse-
Pierluissi, 2004) 
RIM 1 
 
Y* Synprint/ 
β-subunit 
Co-expression induce depolarizing shift in 
CaV2.2 inactivation, also enhances recovery 
from G-protein inhibition 
(Coppola et al., 2001; Kiyonaka et al., 
2007; Weiss et al., 2011; Wong and 
Stanley, 2010) 
SNAP-25 
 
Y Synprint Associates with CaV2.2 in pre-synaptic 
release complex 
(Sheng et al., 1996; Vance et al., 1999; 
Wiser et al., 1996; Yokoyama et al., 
1997b) 
Spectrin-α/β 
 
Y ND Associates CaV2.2 with submembrane matrix (Khanna et al., 2007a; Khanna et al., 
2007b; Khanna et al., 2007c) 
Synaptobrevi
n/VAMP 
 
Y Synprint Associates with CaV2.2 in pre-synaptic 
release complex 
(el et al., 1995; Khanna et al., 2007a; 
Sheng et al., 1996) 
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CaV2.2  
interaction 
partner 
Validated 
Biochemical 
Interaction 
Site of 
Interaction 
(CaV2.2) 
Site of Interaction 
(CaV2.2) 
Reference(s) 
Synaptotagmi
n 
 
Y Synprint Associates with pre-synaptic release complex (Leveque et al., 1994; Sheng et al., 1997) 
Syntaxin 
 
Y Synprint Assists with association of synaptic vesicle to 
CaV2.2 complex, expression leads to tonic 
inhibition of CaV2.2  
(Leveque et al., 1994; Sheng et al., 1994) 
TCTEX-1 
 
Y C-terminus 
(2090-2164) 
Disrupting interaction between CaV2.2 and 
TCTEX-1 reduces CaV2.2 surface expression 
(Lai et al., 2005) 
Tubulin 
 
Y ND Associates with CaV2.2-cytoskeletal complex (Li et al., 2006b; Maximov et al., 1999) 
Ubiquitin 
 
Y I-II loop Ubiquitination of CaV2.2 targets it for 
proteosomal degradation 
(Marangoudakis et al., 2012; Waithe et al., 
2011) 
AP180, assembly protein 180; CaMKII, Ca2+ Calmodulin dependent kinase II; CASK, Ca2+ Calmodulin activated serine kinase;  Cdk5, Cyclin-
dependent kinase 5; CSP, Cysteine string protein; ENH, enigma homolog; microtubule associated protein 1 A/B, MAP1A/B; Munc18 interacting 
protein 1, Mint1; mammalian uncoordinated 18, Munc18-1;  NSF, N-ethylmaleimide-sensitive factor; ORL1, opioid receptor like receptor 1; 
PKC, protein kinase C; PP2C, protein phosphatase 2 C, REM, Rad and Gem-like GTP-binding protein 1; RGS12, regulator of G protein 
signaling 12; RIM-1, Rab3a interacting molecule 1; SNAP-25, synaptosomal associated protein 25; TCTEX-1,  t-complex testis-expressed 1; 
VAMP-2, Vesicle-associated membrane protein 2.   
*:  Biochemical interaction is controversial (Wong and Stanley, 2010) 
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1.1.10. CaV2.2 and pain  
 The role of CaV2.2 in pathology and physiology has been gleaned from the use of 
antagonists and knockout animals.  In this section, I focus specifically on CaV2.2 in pain as pain 
represents a serious medical problem where targeting of CaV2.2 appears to have been successful 
in the development of novel therapeutics.  Following discovery of CaV2.2-specific conotoxins, 
the biological role of this channel could be observed in animals through the use of thesis specific 
inhibitors.  Specific interest in the role of CaV2.2 in sensation arose from the observation that ω-
CTX was able to block transmitter release from sensory neurons and spinal nerve terminals 
(Gruner and Silva, 1994; Maggi et al., 1990a; Maggi et al., 1990b; Santicioli et al., 1992).  The 
role of CaV2.2 in sensory neuron transmitter release and pain sensation is also supported by 
studies showing that analgesic opioids and adrenergic agonists inhibit CaV2.2 (Bean, 1989; 
Schroeder et al., 1991).  Furthermore, inhibition of spinal CaV2.2 leads to a marked decrease in 
tactile hypersensitivity due to peripheral nerve injury and nociceptive behavior in response to 
formalin (Chaplan et al., 1994; Malmberg and Yaksh, 1994).  The delivery of CaV2.2 blocking 
conopeptides requires direct application to the spinal synapse between sensory neurons and spinal 
neurons.  This method of delivery is accomplished by intrathecal injection of the peptides into the 
cerebrospinal space.  That intrathecal application is required and sufficient for analgesia also 
supports the notion that presynaptic blockade of CaV2.2 is responsible for targeting pain.  More 
recently, the development of α1B knockout mice has allowed further validation of CaV2.2’s role 
in pain.  Several independent α1B knockout mice have been made with each mouse showing 
reductions in pain responses (Hatakeyama et al., 2001; Kim et al., 2001; Saegusa et al., 2001).  
Interestingly several CNS effects were also observed in the mice including; decreased anxiety 
behavior, changes in vigilance, and enhanced aggressive behavior (Beuckmann et al., 2003; Kim 
et al., 2009; Saegusa et al., 2001).  Unlike the peripheral effects on pain, little is known about the 
role of CaV2.2 in the CNS, although patients treated with the CaV2.2 blocker Ziconotide have a 
long list of side effects that include dizziness, anxiety, and memory impairment (Rauck et al., 
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2009; Schmidtko et al., 2010; Webster et al., 2009).  In Chapter 3 of my thesis I will discuss the 
targeting of the CRMP-2-CaV2.2 interaction as a novel pain treatment without some of the 
deleterious side effects present with Ziconotide treatment.  In the following section I will 
introduce CRMP-2 as a prelude to my studies investigating the functional and biochemical 
interactions between CRMP-2 and CaV2.2. 
 
1.2. CRMP-2 
1.2.1. Identification of CRMP-2 
CRMP-2 was discovered as the linchpin for chicken semaphorin-3A (Sema3A) activated 
growth cone collapse in sensory neurons.  At the time of its discovery it was named CRMP-62 
due to its observed molecular weight of 62 kDa (Goshima et al., 1995).  While this study was the 
first to link CRMP-2 to Sema3A signaling, other groups also identified CRMP-2 analogues in 
several additional species.  In a proteomic study aimed at identifying genes responsible for rat 
mammalian cortical development, CRMP-2 was identified as being upregulated following 
neurogenesis (Geschwind and Hockfield, 1989).  This led these researchers to name the protein 
turned on after development 64 (TOAD-64), based upon its observed molecular weight being ~64 
kDa (Minturn et al., 1995a; Minturn et al., 1995b).  While this identification appears to be the 
first CRMP-2 analogue in mammals, an earlier study identified the nematode analogue in 
Caenorhabditis elegans (C. elegans).  This occurred during a screen of random mutations in 
nematodes that led to animals with uncoordinated movements.  Analysis of these animals for 
alterations in axonal structure showed that mutations in the CRMP-2 analogue uncoordinated 
protein 33 (Unc-33) displayed what appeared to be axon guidance malfunction (Hedgecock et al., 
1985).  In mice, CRMP-2, named Unc-33 like phosphoprotein (Ulip) by the discovering group, 
was found to be upregulated during development and phosphorylated in response to nerve growth 
factor (NGF) and retinoic acid (Byk et al., 1996; Gaetano et al., 1997).  This study was important 
as it linked the CRMP-2 family of proteins to regulation by growth factors in addition to repulsive 
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cues such as Sema3A.  Finally, another group identified a CRMP-2 analogue in humans through 
its homology with a liver enzyme dihydropyrimidinase (Hamajima et al., 1996).  Probing of the 
genome has led to identification of a total of five CRMP proteins designated CRMPs 1-5 (Fukada 
et al., 2000; Wang and Strittmatter, 1996).  In an attempt to unify the various naming schemes of 
CRMP family the TUC (TOAD/Ulip/CRMP) nomenclature was proposed, although few 
subsequent publications have adopted this nomenclature (Quinn et al., 2003).  CRMP-2 is the best 
studied and understood member of the CRMP family.  CRMP-2 exists as two isoforms which 
arise from alternative splicing occurring in the N-terminus (Quinn et al., 2003).  The majority of 
studies regarding CRMP-2 have focused on the short isoform, sometimes referred to as CRMP-
2A or CRMP-2S.  The long isoform (CRMP-2B or CRMP-2L) is identical from residues 1-572 
with an additional 112 amino acids located on the N-terminus.  In this thesis, I will refer to 
CRMP-2A as CRMP-2, unless otherwise specified.  As will be described throughout this 
introduction, the main function – known prior to this dissertation – of CRMP-2 appears to be 
aiding in proper formation of neuritic processes leading to synaptic connectivity.   
 
1.2.2. Structure of CRMP-2 
 CRMP-2 forms both homo- and heterotetramers with other members of the CRMP family 
(Wang and Strittmatter, 1997).  The long (684 amino acids) and short (572 amino acids) forms of 
CRMP-2 have also been shown to interact suggesting they form tetramers together (Yoneda et al., 
2012).  This tetrameric structure is similar to the closely related dihydropyrimidinase, although it 
is important to note that unlike dihydropyrimidinases, CRMP-2 lacks the required residues for 
enzymatic activity (Holm and Sander, 1997; Wang and Strittmatter, 1997).  The structure of 
CRMP-2 was not solved until 2006, ~10 years following its discovery although the structure of 
the closely related CRMP-1 was reported earlier (Deo et al., 2004; Stenmark et al., 2007).  The 
crystallization of CRMP-1 revealed a “bilobed lung shaped” configuration that was hypothesized 
to be shared amongst the CRMP family based upon sequence homology.  This hypothesis was 
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Figure 1.2 Crystal structure of CRMP-2 
(A) Crystal structure of tetrameric CRMP-2 at 1.90 Å (Majava et al., 2008).  Tetrameric 
CRMP-2 (14-490) was crystalized in the presence of Mg2+.  Each momomer is colored 
differently for clarity.  (B) CRMP-2 monomer from same crystal structure as depicted in (A).  
Yellow sequences represents C-terminal region of CRMP-2 (484-490), this will be discussed 
in detail in Chapter 3.10.  
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substantiated when the structure of a C-terminally-truncated (missing aa 491-572 to allow for 
crystallization) version of CRMP-2 was elucidated several years later and found to have the same 
general shape (Figure 1.2) (Stenmark et al., 2007).  The majority of CRMP-2 is packed within 
this structure although the residues 491-572 are predicted to be unstable and are not included in 
the structure.  Crystallization of CRMP-2 required the presence of a divalent metal (such as Ca2+ 
or Mg2+).  This requirement is most likely due to tetramerization of CRMP-2 induced by these 
metal ions (Majava et al., 2008; Stenmark et al., 2007).  Despite early work on CRMP-2 and its 
tetrameric structure, little is known as to how the tetrameric structure relates to the function of 
CRMP-2, although one study observed that calmodulin bound nearly exclusively to the 
monomeric form of CRMP-2 (Zhang et al., 2009).  At present, it is not known if any other 
proteins bind preferentially to one form or the other.  It is usually assumed, however, that as 
CRMP-2 was crystallized as a tetramer and was found as a tetramer when isolated from brain, 
that a tetramer is the most likely native configuration. 
    
1.2.3. Expression and developmental regulation of CRMP-2 
 Regulation of axon growth and neuronal polarity support CRMP-2 as an important 
protein in neuronal development (Arimura et al., 2004; Inagaki et al., 2001; Nishimura et al., 
2003; Yoshimura et al., 2005).  Furthermore, it appears that CRMP-2 could be a potential marker 
of neuronal differentiation as neuronal cell lines and primary cells increase their expression of 
CRMP-2 following differentiation (Byk et al., 1996; Gaetano et al., 1997; Minturn et al., 1995a).  
This increase following differentiation is also consistent with CRMP-2’s role in axonogenesis.  
Initial studies of CRMP-2 observed wide spread expression of CRMP-2 in neuronal tissues such 
as brain, retinal ganglia, enteric nerves, spinal cord, and dorsal root ganglia (Goshima et al., 1995; 
Inagaki et al., 2000; Minturn et al., 1995a).  Expression in the chicken brain peaks around 
embryonic day 7 although there is still substantial expression in the adult animal.  CRMP-2 
expression in the rat and mouse brains is upregulated slightly later with the peak occurring within 
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a few days of birth (Byk et al., 1998; Minturn et al., 1995a).  While the other CRMPs have similar 
expression profiles during development, they show minimal expression in the adult compared to 
CRMP-2 which still has substantial expression (Wang and Strittmatter, 1996).  These findings 
together paint a picture of CRMP-2 protein expression turning on during neurogenesis and 
staying on, perhaps to assist in plasticity.   
CRMP-2 is also expressed in non-neuronal cells within the nervous system such as 
oligodendrocytes (Fernandez-Gamba et al., 2012; Ricard et al., 2000).  Oligodendrocytes are 
responsible for wrapping neurons in the central nervous system with myelin; this sheath of myelin 
is imperative for fast nerve impulse conduction (Baumann and Pham-Dinh, 2001).  The function 
of CRMP-2 in oligodendrocytes is unclear although it appears to regulate process retraction in 
response to Sema3A or the oxidative agent 3-nitropropionic acid (Fernandez-Gamba et al., 2012; 
Ricard et al., 2000).  Despite initial studies that reported minimal expression of CRMP-2 outside 
of the nervous system, several recent papers have highlighted expression of CRMP-2 in non-
neuronal cells (Vincent et al., 2005; Vuaillat et al., 2008; Yoneda et al., 2012).  A study found 
that CRMP-2 is expressed in fibroblasts and regulates proliferation and possibly tumorigenesis 
(Tahimic et al., 2006).  CRMP-2 was also identified as being specifically secreted by colon 
cancer cell lines and has been proposed as a biomarker (Wu et al., 2008).  Outside of the nervous 
system, CRMP-2 has been most heavily investigated in T-cells were its expression correlates with 
activation and migration (Varrin-Doyer et al., 2012; Varrin-Doyer et al., 2009; Vincent et al., 
2005; Vuaillat et al., 2008).  These studies show CRMP-2 expression in a non-neuronal cell that 
is proliferating rapidly (i.e. an activated T-cell).  A very recent study also found ubiquitous 
expression of CRMP-2 in a multitude of non-neuronal cell lines, further supporting the notion 
that CRMP-2 is expressed outside of the nervous system (Yoneda et al., 2012). 
As mentioned previously, CRMP-2 expression appears to be highest during neurogenesis 
which is consistent with its role in axon guidance and outgrowth.  It is still unclear; however, as 
to what signals are responsible for upregulation of CRMP-2 expression during this time period.  
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A chromatin-immunoprecipitation screen for targets of the SMAD (a portmanteau of mothers 
against decapentaplegic (MAD) and small body size (SMA)) family of transcription factors) 
identified CRMP-2 as a protein whose expression could be regulated by SMAD (Fei et al., 2010).  
SMAD factors are activated by extracellular bone morphogenetic proteins (BMPs) that are vital 
cues for proper neuronal differentiation and migration (LaBonne and Bronner-Fraser, 1999).  This 
finding was foreshadowed by a prior report that suggested BMP4 regulates CRMP-2 expression 
in Xenopus (Kamata et al., 1998).  Consistent with the role of BMPs in neuronal migration and 
neurite outgrowth (Guan and Rao, 2003), it was found that CRMP-2 expression is down regulated 
by BMP exposure which is expected to cause reduced migration and neuritic outgrowth of 
neurons (Fei et al., 2010).  This down regulation is likely due to repression of transcription by the 
binding of SMAD1 and 4 to the CRMP-2 promoter.  This study also found that knockdown of 
CRMP-2 in utero leads to deficiencies in neuronal migration and neurite outgrowth.  Conversely, 
several years earlier it was demonstrated that application of glia-derived growth factor (GDNF) to 
a neuronal cell line enhances expression of CRMP-2 (Kodama et al., 2004).  The exact 
mechanism(s) leading to the increase in CRMP-2 expression are currently unknown, although 
GDNF is responsible for differentiation of many different neuronal cell populations (Enomoto, 
2005), suggesting CRMP-2 is a common factor in determining neuronal fate. 
 
1.2.4. CRMP-2 signaling 
 Despite knowing for over 15 years that CRMP-2 is an obligatory signaling molecule in 
Sema3A-induced growth cone collapse, the exact function served by CRMP-2 in this process 
remains poorly characterized.  Treatment of the neuronal PC12 cell line with nerve growth factor 
(NGF) leads to a substantial reduction in CRMP-2 phosphorylation (Byk et al., 1996). This 
finding is interesting as NGF induces neuronal differentiation along with neuritic process growth 
in PC12 cells suggesting that dephosphorylation of CRMP-2 may be a positive effector of axon 
outgrowth.  Pre-treatment of neurons with neurotrophins, including NGF, also attenuates 
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Sema3A-induced growth cone collapse (Tuttle and O'Leary, 1998).  These findings laid the 
foundation for subsequent exploration of the role of CRMP-2 phosphorylation in axonal growth.   
Sema3A binds to and activates the neuropilin-1/plexin-A receptor complex, which 
transduces Sema3A binding into intracellular signaling culminating with growth cone collapse 
(Sasaki et al., 2002; Takahashi et al., 1999).  Exploration of the signaling pathways involved in 
Sema3A-induced growth cone collapsed identified the Src family kinase Fyn as an obligatory 
signaling protein (Sasaki et al., 2002).  Following binding of Sema3A to its receptor, Fyn kinase 
binds to the intracellular portion of the receptor complex and activates cyclin dependent kinase 5 
(Cdk5).  In addition to activating Cdk5, Fyn also phosphorylates CRMP-2 at Tyr-32 following 
application of Sema3A and a Y32F CRMP-2 mutant greatly reduces Sema3A-induced collapse 
(Uchida et al., 2009).  Cdk5 was subsequently found to phosphorylate CRMP-2 in vitro at Ser-
522 (Brown et al., 2004).  The phosphorylation of CRMP-2 by Cdk5 is vital for Sema3A-induced 
collapse as expression of a phospho-null mutant (S522A) shows reduced growth cone collapse in 
DRG cultures.  A previous report found that in addition to Cdk5 and Fyn, Sema3A-induced 
collapse also relied on activity of glycogen synthase kinase 3 (GSK3β) in the growth cone 
(Eickholt et al., 2002).  Consistent with this finding, GSK3β is able to phosphorylate CRMP-2 at 
Thr-509, Thr-514, and Ser-518 (Brown et al., 2004; Cole et al., 2004; Yoshimura et al., 2005).  
The phosphorylation of CRMP-2 by GSK3β is prevented by inhibition of Cdk5 or a phospho-null 
mutation of the Cdk5 site, implicating Cdk5 in a ‘priming’ role for subsequent phosphorylation 
by GSK3β.  Furthermore, Sema3A application requires phosphorylation of CRMP-2 by GSK3β 
to induce growth cone collapse (Uchida et al., 2005).  Collectively, Sema3A-induced signaling 
requires activation and phosphorylation of CRMP-2 by three distinct kinases (Cdk5, Fyn, and 
GSK3β) encompassing a total of 5 phosphorylation sites.  In addition to Cdk5, Fyn, and GSK3β, 
it has been shown that the Src kinases Fes and Fer are also able to phosphorylate CRMP-2 
(Mitsui et al., 2002; Shapovalova et al., 2007).  Similar to Fyn, CRMP-2 is phosphorylated by Fes 
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at Tyr-32 (Uchida et al., 2009).  The exact site of phosphorylation and role of Fer 
phosphorylation of CRMP-2 in growth cone collapse is at present unknown. 
Lysophosphatidic acid (LPA) also signals through CRMP-2 for growth cone collapse 
although the pathway is distinct from that of Sema3A (Arimura et al., 2000; Arimura et al., 
2005).  Interestingly, while Sema3A relies on multiple phosphorylation events, growth cone 
collapse in response to LPA requires phosphorylation of only Thr-555 by ras homolog (Rho) 
associated protein kinase 1 (ROCK I).  Also of interest is that its original identification in 
Sema3A signaling found that CRMP-2 was required for Sema3A induced inward current, but had 
no effect on LPA-induced current (Goshima et al., 1995).  This finding is consistent with Sema3A 
and LPA working to induce growth cone collapse through diverse pathways.  Though both 
pathways induce growth cone collapse, a divergence in intermediary signaling likely leads to the 
downstream current observed in response to LPA only.  A recent report identified isoform 
specific interactions between CRMP-2 and ROCKs (Yoneda et al., 2012).  Despite previous 
evidence describing phosphorylation of CRMP-2 by ROCK I (Arimura et al., 2000), it was found 
that CRMP-2 (both short and long forms) binds to ROCK II but not ROCK I.  Furthermore, while 
both forms bind ROCK II only CRMP-2L inhibits ROCK II-dependent cell migration, suggesting 
that CRMP-2L has a unique ROCK II interaction site not present in CRMP-2S.  Notably, despite 
several studies showing how kinases can modulate CRMP-2, this is the first study suggesting that 
CRMP-2 regulates kinase activity.  
Perhaps the most diverse signaling cascade that CRMP-2 has been found to take part in 
occurs in T-cells rather than neurons.  Through a handful of studies it has become clear that in 
addition to regulating axon outgrowth, CRMP-2 regulates migration of T-cells (Varrin-Doyer et 
al., 2012; Varrin-Doyer et al., 2009; Vincent et al., 2005; Vuaillat et al., 2008).  The chemo-
attractive molecule chemokine C-X-C ligand 12 (CXCL12) induces phosphorylation of CRMP-2 
which facilitates migration of T-cells.  This finding is a solitary example of phosphorylation as a 
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positive regulator of CRMP-2 function.  A tabular representation of known CRMP-2 
phosphorylation sites are shown in Table 1.2.    
As phosphorylation of CRMP-2 leads to axon retraction, it is not surprising that 
dephosphorylation of CRMP-2 (e.g. by phosphatases) leads to enhanced neuritic growth (Astle et 
al., 2011; Zhu et al., 2010).  Protein phosphatase 1 (PP1) dephosphorylates CRMP-2 at the 
GSK3β sites Thr509/514 (Cole et al., 2008).  PP1 seems to work specifically on these sites as the 
Cdk5 site Ser-522 is resistant to phosphatase activity.  Interestingly, NGF treatment leads to 
activation of Cdk5 which in turn phosphorylates and activates PP1, which despite activating Cdk5 
has a net increase in axon outgrowth (Li et al., 2007a).  Under these conditions CRMP-2 would 
be p522+ and p509-/p514-, which appears to still lead to enhancement of axon growth.  This 
finding reaffirms the assertion that phosphorylation at Ser-522 is functionally significant as a 
priming kinase for subsequent phosphorylation by GSK3β.  In addition to PP1, protein 
phosphatase 2 A (PP2A) is able to dephosphorylate CRMP-2 at GSK3β sites, resulting in the 
formation of new axons (Zhu et al., 2010).  Collectively, there appears to be an inverse 
correlation between CRMP-2’s phosphorylation state, not considering Tyr-479 which appears to 
downregulate GSK3β phosphorylation (Varrin-Doyer et al., 2009), and axonogenesis/axon 
outgrowth.  Phosphorylation of CRMP-2 likely regulates axon growth via effects on interactions 
between CRMP-2 and proteins involved in cytoskeletal rearrangements (for example, see §1.2.6 
on tubulin). 
 
1.2.5. CRMP-2: protein interactions 
CRMP-2 interacts with a litany of proteins that have diverse functions.  Given that 
CRMP-2 regulates axonogenesis and outgrowth, processes which rely heavily on cytoskeletal 
proteins (Baas, 1997; Bradke and Dotti, 1999; Bradke and Dotti, 2000; Joshi and Baas, 1993), it 
is not surprising that the first protein found to bind CRMP-2 was the cytoskeleton protein tubulin 
(Fukata et al., 2002).  CRMP-2’s interaction with tubulin has been extensively studied and will be 
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discussed in §1.2.6.  In addition to tubulin, CRMP-2 binds to the cytoskeletal proteins actin and 
vimentin (Arimura et al., 2005; Vincent et al., 2005).  The observed interactions with cytoskeletal 
proteins support the role of CRMP-2 in regulating axon growth through aiding in cytoskeletal 
rearrangements.  As an extension to interacting with actin, CRMP-2 binds to the actin related 
complex of Sra-1/WAVE that is an obligatory component of CRMP-2’s ability to enhance axon 
length and axonogenesis (Kawano et al., 2005).  CRMP-2 also binds to Numb and α-adaptin and 
likely facilitates endocytosis through these interactions (Nishimura et al., 2003).  CRMP-2 has 
also been described as a regulator of protein trafficking through interactions with motor proteins.  
Namely, a biochemical complex containing tubulin and kinesin light chain 1 (KLC1) allows 
CRMP-2 to transport tubulin to the growing axon (Kimura et al., 2005).  The residues of CRMP-2 
required for KLC1 binding (aa 440-572) are also required for distal axonal accumulation of 
CRMP-2, although it is unknown if this interaction is the sole reason for this observation.  A 
complex containing CRMP-2 is also responsible for promoting anterograde transport of tyrosine 
related kinase B (TrkB) receptors (Arimura et al., 2009b).  This complex includes the motor 
protein dynein along with the adaptor proteins synaptotagmin-like protein 1 and Ras-related in 
brain 27 (Rab27) which along with CRMP-2 forms a complex linking TrkB to dynein (Arimura et 
al., 2009a).  The sites of interaction of CRMP-2 with dynein (aa 100-150 and aa 348-440) are 
distinct from those found to bind KLC1.   
To serve as a trafficking protein a protein must interact with both motor proteins and 
endocytotic adapter proteins to facilitate trafficking of membrane proteins from the membrane to 
a different subcellular compartment.  CRMP-2 fits this role through its interactions with the 
endocytotic vesicle complex microtubule associated monoxygenase, calponin and LIM domain 
containing -like 1 (MICAL-L1) and the motor protein dynein thereby facilitating retrograde 
transport of vesicles bound to MICAL-L1 (Rahajeng et al., 2010).  While the majority of CRMP-
2’s characterized interactions make a clear link to its role in axon outgrowth, several other 
interactions hint at more diverse function.  For instance, CRMP-2 interacts in a Ca2+-dependen
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Table 1.2. CRMP-2 interacting proteins 
CRMP-2 
interaction 
partner 
Validation:  
biochemical 
Validation: 
functional Effect of interaction Reference(s) 
Abl N N ND (Varrin-Doyer et al., 2009) 
Actin Y Y CRMP-2 regulates actin dynamics (Arimura et al., 2000; Arimura et al., 2005; Yoneda et al., 2012) 
α-actinin N N  ND (Hensley et al., 2010) 
AP-2 Y Y Binding reduces endocytosis  (Nishimura et al., 2003)  
sAPP Y N  ND (Pawlik et al., 2007) 
BLK N N  ND (Varrin-Doyer et al., 2009) 
CaM Y Y Binding prevents CRMP-2 proteolysis and enhances process growth   (Zhang et al., 2009) 
α2-chimaerin Y Y Binding decreases axon growth and neuronal migration (Brown et al., 2004; Ip et al., 2012)  
CLN6 Y Y Mutations in CLN6 lead to reduced CRMP-2 expression  (Benedict et al., 2009) 
CRMP1 Y Y 
Over-expression of CRMP1 and CRMP-2 
opposes the effects of RhoA on neurite 
retraction 
(Leung et al., 2002) 
CRMP-5 Y Y 
CRMP-5 may block Sema3A-mediated 
growth cone collapse by inhibition of CRMP-
2 function; CRMP-5 acts a dominant negative 
in preventing neurite outgrowth promotion 
induced by CRMP-2 
(Brot et al., 2010) 
Intersectin N N ND (Varrin-Doyer et al., 2009) 
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CRMP-2 
interaction 
partner 
Validation:  
biochemical 
Validation: 
functional Effect of interaction Reference(s) 
Kinesin-1 Y Y Binding regulates Kinesin by linking it to cargo  
(Kawano et al., 2005; Kimura et al., 
2005) 
MICAL-L1 Y Y Links to intracellular Dynein motors  (Rahajeng et al., 2010)  
MBP N N ND (Hensley et al., 2010)  
NFL/NFM Y N ND (Hensley et al., 2010) 
Neurofibromin Y Y Changes in Neurofibromin expression alters CRMP-2 phosphorylation  (Patrakitkomjorn et al., 2008) 
Neuropilin 1 Y Y Couples Sema3A to CRMP-2 signaling  (Brown et al., 2004; Deo et al., 2004) 
Numb# Y Y Binding regulates endocytosis (Arimura et al., 2005; Nishimura et al., 2003) 
NMDARs Y Y CRMP-2 expression regulates surface expression of NR2B subunit  
(Al-Hallaq et al., 2007; Bretin et al., 
2006) 
PIPP Y Y Binding reduces neurite growth  (Astle et al., 2011) 
PI3Kβ N N ND (Zhang et al., 2009) 
PLCγ N N ND (Varrin-Doyer et al., 2009) 
PLD2 Y Y Binding inhibits PLD2 activity (Lee et al., 2002) 
Plexin-1 Y Y Couples Sema3A to CRMP-2 signaling  (Deo et al., 2004) 
PP2A Y Y Dephosphorylation of CRMP-2 enhances axon growth  (Zhu et al., 2010)  
ROCK II Y Y CRMP-2 prevents ROCK II from aiding in cell migration (Yoneda et al., 2012) 
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CRMP-2 
interaction 
partner 
Validation:  
biochemical 
Validation: 
functional Effect of interaction Reference(s) 
Slp1 Y Y Links TrkB to CRMP-2 for TrkB trafficking  (Arimura et al., 2009b) 
α- and/or β-
Spectrin N N  ND  (Hensley et al., 2010) 
Sra1 Y Y CRMP-2 links Sra1/WAVE complex to kinesin for trafficking  (Kawano et al., 2005) 
Tau Y N  ND (Takata et al., 2009)  
Thioredoxin Y Y Binding induces CRMP-2 phosphorylation causing growth cone collapse  (Morinaka et al., 2011) 
TrkB Y Y Links TrkB to Kinesin for anterograde trafficking  (Arimura et al., 2009b)  
α-/β-Tubulin# Y Y 
Binding enhances microtubule formation, in 
addition CRMP-2 regulates tubulin GTPase 
activity 
(Chae et al., 2009; Fukata et al., 
2002; Kimura et al., 2005) 
VAV1 N N ND (Varrin-Doyer et al., 2009) 
Vimentin Y Y CRMP-2 phosphorylation at Tyr-479 alters vimentin mobilization  
(Varrin-Doyer et al., 2009; Vincent 
et al., 2005)  
WAVE1 Y Y CRMP-2 links Sra1/WAVE complex to kinesin for trafficking  (Kawano et al., 2005) 
Abl, Abelson tyrosine kinase; AP2, Adaptor-related protein 2; sAPP, Amyloid precursor protein secreted form (sAPP) RERMS (328–332) 
neurotrophic domain; CaM, Calmodulin; CaV2.2, N-type voltage-gated calcium channel; aIN, alpha internexin intermediate filament 
protein, MICAL1, Molecule interacting with CasL; MBP, myelin basic protein; NFL/NFM, Neurofilament Light chain/Neurofilament middle 
chain; neurotrophin receptor tyrosine kinase; NMDARs, N-methyl-D-Aspartate receptors PI3Kβ, Phosphoinositide-3-kinase β; PIPP, Proline-
rich Inositol Polyphosphate 5-Phosphatase; PP2A, Protein phosphatase 2A; TrkB, neurotrophin receptor tyrosine kinase; VAV1, Vav proto-
oncogen; WAVE1, Wiskott–Aldrich syndrome protein family verprolin-homologous protein-1. 
#Interaction is decreased following phosphorylation of CRMP-2 by Cdk5/GSK3β/ROCK 
ND: not determined 
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fashion with the Ca2+-binding protein Calmodulin (CaM) (Zhang et al., 2009).  While it is well 
known that CaM is an important protein in Ca2+ signaling, it is unknown whether its interaction 
with CRMP-2 aids in this signaling.  Also although this study did observe changes in cell process 
length in response to CaM inhibition, their results did not assess if the interaction was responsible 
for this effect.  A comprehensive list of the many other proteins CRMP-2 has been found to 
interact with biochemically and functionally appears in Table 1.2.2.  Proteins which were 
observed in proteomic studies, but have not been verified by in vitro binding are included 
although they are marked as not having a verified biochemical interaction. 
 
1.2.6. Interaction and modulation of tubulin by CRMP-2 
It is fitting that the first characterized protein-protein interaction of CRMP-2 also appears 
to be one of its most functionally relevant and important interactions.  While it was known from 
the initial discovery of CRMP-2 that it functions to regulate axon growth dynamics, the identified 
interaction and modulation of tubulin by CRMP-2 revealed its aptitude for cytoskeletal 
rearrangement.  The first hint that CRMP-2 may regulate cytoskeleton as a means to modulating 
axon growth was through an observation in C. elegans.  A massive increase in the amount of 
microtubules was observed in animals with mutations in the Unc-33 sequence, representing the 
first reported link between the CRMP family of proteins and microtubule regulation (Hedgecock 
et al., 1985).  A study in 2000 further hinted that CRMP-2 may regulate microtubules (Gu and 
Ihara, 2000) although it was not until 2002 that a detailed study exclusively looked at this 
interaction (Fukata et al., 2002).  CRMP-2 was found to bind to both α- & β-tubulin in a screen 
using a CRMP-2 affinity column (Fukata et al., 2002).  This appears to not be a CRMP-2–specific 
interaction, however, as CRMPs -1, -3, and -4 also bound tubulin.  Interestingly, the well-known 
tubulin binding proteins Tau, MAP-1B, and 2 were not found to interact with CRMP-2.   
CRMP-2 leads to enhanced tubulin polymerization likely through binding tubulin 
heterodimers preferentially over longer chain polymerized tubulin.  Although both the long and 
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short splice variants of CRMP-2S/L interact with tubulin, it appears that only CRMP-2S enhances 
axon outgrowth, whereas CRMP-2L antagonizes this function of CRMP-2S – although this 
phenomenon has yet to be replicated (Yuasa-Kawada et al., 2003).  The CRMP-2 residues 
responsible for polymerization of tubulin were localized to amino acids 323-381.  The exact 
function of this sequence remains unclear, as a more recent study observed that residues 480-510 
of CRMP-2 regulate tubulin polymerization as well (Chae et al., 2009).  These latter residues 
enhance tubulin’s GTPase activity, which is an important determinant in polymerization, while 
the previously reported residues (323-381) had a minimal effect on GTPase activity.  In addition 
to the GTPase enhancer sequence (480-510), it was also found that an inhibitory domain (150-
299) antagonizes the activity of the former sequence.  Collectively, these studies suggest that 
CRMP-2 has a complex interaction with tubulin that is regulated by at least three different 
sequences.  Further supporting that the interaction between tubulin and CRMP-2 is important for 
neuritic growth, phosphorylation of CRMP-2 by either Cdk5 or ROCK leads to reduced binding 
to tubulin (Arimura et al., 2005; Uchida et al., 2005). 
 
1.2.7. CRMP-2 phosphorylation and function 
As it relates to CRMP-2, the term “activity” usually refers to its ability to enhance axon 
outgrowth.  Since phosphorylation of CRMP-2 is a negative determinant of axon growth, 
phosphorylated CRMP-2 is commonly referred to as inactive while the native unphosphorylated 
form is considered active.  The activity of CRMP-2 likely depends on the biochemical 
interactions engaged by these two CRMP-2 states.  Interestingly, phosphorylation at Thr-555 by 
ROCK (following LPA application) phenocopies (i.e. displays a similar phenotype) 
phosphorylation at Ser-509/Thr-514/Thr-518/Ser-522 by Cdk5/GSK3β (following Sema3A 
application) as it relates to axon growth and collapse.  The only observed biochemical reason for 
these observations currently is that phosphorylation by either the LPA or Sema3A pathway both 
lead to maintenance of CRMP-2’s interaction with actin while simultaneously disrupting the 
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interactions with tubulin and Numb (Arimura et al., 2005).  While CRMP-2 has many 
biochemical partners, the effect that phosphorylation has on these interactions is currently limited 
to those mentioned above.    
As there has yet to be a published report of a CRMP-2 knockout mouse, the whole animal 
effects of CRMP-2 are unknown.  The role of CRMP-2 in both the LPA and Sema3A growth 
cone collapse pathway links CRMP-2 to rapid alteration of the cytoskeleton.  CRMP-2 also 
regulates slow more subtle processes in the regulation of neuronal growth.  Over expression of 
CRMP-2 enhances the length of axons and leads to more axons per neuron (Inagaki et al., 2001).  
Conversely, knockdown of CRMP-2 using siRNA reduces axon outgrowth (Nishimura et al., 
2003; Yoshimura et al., 2005).  If these findings are grossly oversimplified and applied to a whole 
animal, the projected outcome would likely involve neuronal connection deficiencies likely 
resulting is devastating phenotype.  A recent study was published where a transgenic mouse was 
generated in which CRMP-2 was phospho-insensitive at Ser-522 (Yamashita et al., 2012).  In 
theory this mouse should be completely insensitive to Sema3A-induced growth cone collapse and 
is therefore predicted to display deficiencies in proper axon targeting.  This study also 
characterized the offspring from CRMP-2 522A and CRMP-1 knockout mouse (Su et al., 2007) 
to minimize possible effects of redundancy.  Surprisingly, the animals appeared to have no gross 
neuronal abnormality or cortical structure aberrations.  The only reported atypical finding in these 
mice was extreme curling of their cortical basal dendrites.  This finding phenocopies the Cdk5-/- 
mice that also showed basal dendrite abnormalities, which was not unexpected as Cdk5 is the 
primary kinase responsible for phosphorylating Ser-522 of CRMP-2 (Ohshima et al., 2007).  A 
caveat to this CRMP-2 transgenic animal is that the animal should likely show positive increases 
in axon growth rather than deficiencies and therefore a phospho-mimetic (S522D) or a knockout 
will likely result in more interesting results.  Furthermore, this study suggests that having an 
always active CRMP-2 does not lead to any deficiencies.   
 
 44 
 
1.2.8. CRMP-2 and neurological diseases 
The interest in CRMP-2 grew rapidly following the turn of the century likely due to 
several studies linking it to neurological disease.  The most prominent finding was that CRMP-2 
is present in neurofibrillary tangles (NFTs) – a histological hallmark of Alzheimer’s disease (AD) 
(Yoshida et al., 1998).  AD patients suffer from cognitive decline that is correlated with 
increasing neuronal death due to a still highly controversial mechanism.  The two pathological 
hallmarks of AD are the presence of extracellular β-amyloid plaques and intracellular NFTs 
(Hardy and Selkoe, 2002).  Given the importance of NFTs in AD, many studies have further 
investigated the link between CRMP-2 and AD.  Similar to tau that is hyperphosphorylated in 
NFTs, CRMP-2 present in NFTs was also found to be heavily phosphorylated (Gu et al., 2000).  
The phosphorylation of CRMP-2 appears to occur early on during the pathogenesis of AD (Cole 
et al., 2007).  The CRMP-2 phosphorylation sites present in NFTs were subsequently found to be 
the same sites as those involved in Sema3A signaling.  In addition, the NFTs were found to 
contain an enriched complex composed of other components of the Sema3A signaling pathway 
including Sema3A itself and its receptor dimer (Good et al., 2004).  CRMP-2 has also been 
implicated in β-amyloid processing and plagues, the other hallmark of AD pathology.  Incubation 
of a neuronal cell line with β-amyloid led to an increase in Thr-555 phosphorylation through 
upregulating ROCK activity (Petratos et al., 2008).  Phosphorylation at the GSK3β and Cdk5 
sites of CRMP-2 were also significantly increased in animals overexpressing the intracellular 
domain of β-amyloid precursor protein (Ryan and Pimplikar, 2005).  CRMP-2 expression is also 
down regulated in AD which might phenocopy the effect of phosphorylated CRMP-2 as both 
have negative effects on axon outgrowth (Lubec et al., 1999).        
CRMP-2 has also been linked to recurring seizures with studies reporting a decrease in 
full length CRMP-2 in epilepsy patients and animal models (Czech et al., 2004; Ryu et al., 2008).  
Interestingly, the anti-epilepsy medication lacosamide appears to bind to CRMP-2 leading to an 
as yet undetermined outcome on CRMP-2 function (Beyreuther et al., 2007; Park et al., 2009).  
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The link between CRMP-2 and neurofibromatosis type 1 (NF1) has also been made as CRMP-2 
interacts with neurofibromin (Lin and Hsueh, 2008; Patrakitkomjorn et al., 2008).  Mutations in 
the NF1 gene lead to subsequent truncation of the protein product neurofibromin, where loss of 
this protein’s function leads to NF1.  Similar to AD, alteration in phosphorylation of CRMP-2 
was observed when neurofibromin protein levels were decreased.  Despite the findings linking 
CRMP-2 to these diseases it is poorly understood whether CRMP-2 contributes to the pathology 
or if these alterations simply occur as a result of the pathology.        
 
1.2.9. CRMP-2 and neurotrauma 
Neurotrauma is a broad term referring to a nerve injury or injury to the nervous system.  
This encompasses both local injuries such as nerve lesions as well as insults to the CNS such as 
spinal cord injury and cerebral ischemia.  In general (plasticity not withstanding) axons grow 
during neurogenesis and insult-induced regeneration.  While the role of CRMP-2 in axon 
guidance during development is well characterized, CRMP-2 has also been implicated in injury-
induced regeneration.  Crushing of the sciatic nerve leads to peripheral axotomy and subsequent 
axonal regeneration (McQuarrie et al., 1977).  One of the first studies on CRMP-2 sought to 
identify the possible involvement of CRMP-2 in axonal regeneration given the initial findings of 
its regulation of axon outgrowth in c. elegans (Minturn et al., 1995a).  This hypothesis was 
confirmed when CRMP-2 was found to be upregulated in motor neurons of the ventral horn 
following sciatic nerve crush.  Similar results were also observed using a hypoglossal nerve 
injury model in rats, where it was found that CRMP-2 was upregulated following injury (Suzuki 
et al., 2003).  Interestingly, somewhat opposing results were found in regenerating chicken spinal 
cord, where CRMP-2 expression was minimally altered, but had an increase in phosphorylation 
(Gogel et al., 2010).   
CRMP-2 was first implicated in CNS neurotrauma by appearance of an atypical 
molecular weight isoform of CRMP-2 in rat brain tissue following middle carotid artery-
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occlusion (MCAO) (Chung et al., 2005).  Expression of CRMP-2 was also found to be up-
regulated following focal cerebral ischemia (Chen et al., 2007a).  The atypical isoform of CRMP-
2 was later found to be due to cleavage of CRMP-2 by the protease calpain leading to the 
observed shift of full length CRMP-2 from 62kD to ~55kD (Bretin et al., 2006; Hou et al., 2009; 
Jiang et al., 2007; Touma et al., 2007; Zhang et al., 2009; Zhang et al., 2007).  Calpain is a Ca2+-
activated protease that has been linked to neurotoxic signaling (Vosler et al., 2008).  Cleavage of 
CRMP-2 by calpain has been observed following ischemia (Jiang et al., 2007), neurotrauma 
(Zhang et al., 2007), excitotoxicity (Bretin et al., 2006), as well as nerve growth factor 
deprivation induced-neurite degeneration (Touma et al., 2007).  The cleavage of CRMP-2 by 
calpain occurs through activation of N-methyl-D-aspartate receptors (NMDARs) (Bretin et al., 
2006).  The role of NMDARs in neurotrauma will be explored extensively later (§1.3).  Cleavage 
is not specific to CRMP-2, however, as CRMPs 1, 3, 4, 5 also appear to be cleaved by calpain 
following neurotoxic insult (Hou et al., 2006; Jiang et al., 2007; Zhang et al., 2007).  Despite their 
high sequence identity, CRMP-1, -2, -4 are cleaved at a distinct location (C-terminus) compared 
to CRMP-3 (N-terminus) (Jiang et al., 2007; Liu et al., 2009).  Interestingly, expression of the 
calpain cleavage product of CRMP-2 is neuroprotective while the cleavage product of CRMP-3 is 
neurotoxic (Hou et al., 2006).  While it is unknown what affect acute cleavage of CRMP-2 by 
calpain has on neuronal survival, expression of a CRMP-2 construct mimicking calpain cleavage 
increases neuronal survival following excitotoxic challenge (Bretin et al., 2006).  The proposed 
mechanism for the neuroprotection conferred by expression of truncated CRMP-2 is reduced 
surface expression of NR2B containing NMDARs.  By reducing surface expression of NMDARs, 
the number of neurons exposed to toxic Ca2+ influx through NMDARs was reduced.  The likely 
mechanism for this neuroprotection is CRMP-2 regulates NMDAR surface expression through a 
biochemical interaction, which is supported by data showing a biochemical interaction between 
NMDARs and CRMP-2 (Al-Hallaq et al., 2007).  Al-Hallaq and colleagues found that CRMP-2 
interacts biochemically with both NR2A and 2B subunits of NMDARs. 
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Despite the extensive studies linking CRMP-2 phosphorylation to its signaling and role in 
growth cone collapse, there have been relatively few studies suggesting its phosphorylation in 
neurotrauma.  Using cortical neurons stimulated with glutamate (to mimic conditions of 
excitotoxicity), it was shown that phosphorylation of CRMP-2 at Thr-555 is upregulated 
following stimulation (Hou et al., 2009).  Notably, this phosphorylation was not due to ROCK, 
which is known to phosphorylate this site, but rather due to CaMKII.  It appears that 
phosphorylation Thr555 is not important for extent of injury, however, as a T555A mutant 
showed no neuroprotection.  Inhibition of CaMKII enhanced calpain cleavage of CRMP-2.  A 
more recent study found that hypoxic-ischemic brain injury decreased phosphorylation of CRMP-
2 at Thr-514 over a 72 hr period following insult (Xiong et al., 2012).  The exact ramifications of 
the changes in Thr-514 phosphorylation and their role in neuronal survival are unclear.  
Collectively, despite several reports linking CRMP-2 to neuronal survival, little is known about 
how CRMP-2 functions in neurons that are exposed to glutamate.  The only clear functional link 
is the observation that CRMP-2 is able to modulate NMDARs surface expression, suggesting an 
interaction between CRMP-2 and NMDAR may be important for neuronal death following 
neurotrauma.  In Chapter 4, I will describe my findings targeting CRMP-2 in NMDAR-mediated 
glutamate toxicity through the use of a CRMP-2 peptide.  In the following section of my 
dissertation, I will introduce the NMDAR and NMDAR-associated signaling involved in 
glutamate-mediated toxicity.
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1.3. NMDAR introduction 
At the time I began my dissertation research, there appeared two reports that seemed to 
tie CRMP-2 to potential regulation and activity of post-synaptic NMDARs.  As these proteins 
also allow Ca2+ influx, albeit on the post-synaptic side of the synapse, I was interested in 
determining whether this was indeed the case and with the tools that I had developed while 
studying CRMP-2 mediated regulation of CaV2.2 (see Chapter 3), I wanted to address signaling 
between the CRMP-2-NMDAR complex (Chapter 4). 
  
1.3.1. Structure and function of NMDARs 
 Composed of four subunits, the NMDAR is a non-selective, ligand-gated ion channel that 
is activated by glutamate (Figure 1.3) (Dingledine et al., 1999; Kohr, 2006).  NMDARs belong to 
a family of three classes of ligand-gated ion channels that respond to glutamate; NMDARs, 2-
amino-3-(3-hydroxy-5-methylisox-azol-4-yl) propionate receptors (AMPARs), and kainate 
receptors.  These receptors families can be isolated pharmacologically with specific agonists (e.g. 
NMDA or AMPA) as well as by specific antagonists (described in §1.3.2.).  While much 
controversy surrounds the subunit stoichiometry of NMDARs (Kohr, 2006), they are largely 
believed to be composed of two NMDAR subtype 1 (NR1) and two NR2 subunits, each with four 
transmembrane segments (Ishii et al., 1993; Moriyoshi et al., 1991).  To date, a single NR1 
subunit and four NR2 subunits (NR2A-D) have been identified (Dingledine et al., 1999).  These 
four subunits multimerize to form the functional pore that allows passage of Na+, K+ , and Ca2+ in 
response to engagement of extracellular ligand binding sites (Dingledine et al., 1999) (Figure 
1.3.1).  The rest of this section of the Introduction will focus on the NR2B subunit as this 1484 
amino acid long protein is the predominant NMDAR expressed in hippocampal and cortical 
neurons during the stages of cultures examined in my experiments (see Chapter 4).  NMDARs 
require both glutamate and the co-agonist glycine or D-serine to be activated (Johnson and 
Ascher, 1987; Kleckner and Dingledine, 1988).  The binding site for glycine is contained within 
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Figure 1.3 NMDARs: subunit composition and stoichiometry 
The NMDAR is a tetramer composed of two NR1 and two NR2 subunits.  These subunits 
have extracellular N-termini which are responsible for ligand binding and intracellular C-
termini responsible for forming biochemical complexes.  Also depicted in the schematic is 
pore-occlusion by Mg2+ under resting conditions and cation permeability assuming normal 
extra/intracellular cation concentrations. 
 
  
 
 50 
 
the extracellular portion of NR1 (amino acids 390, 392, and 466) (Kuryatov et al., 1994), while 
the glutamate site is present on the NR2 subunit (amino acids 387, 486, 493, and 488) (Laube et 
al., 1997).   
 
1.3.2. NMDAR agonists and antagonists 
 There are several inhibitors of NMDARs that have been developed for use in the research 
laboratory as well as for possible therapeutic potential.  Consistent with its function as a 
glutamate receptor, NMDARs are endogenously activated by L-glutamate and L-aspartate 
(Dingledine et al., 1999).  They are additionally activated by NMDA, which does not activate 
other ionotropic glutamate receptors.  Conversely, NMDARs are endogenously blocked at resting 
membrane potentials by Mg2+ (Nowak et al., 1984).  Interestingly, the tonic block by Mg2+ 
confers voltage-gated properties upon the NMDARs wherein a strong depolarization is required 
to dislodge Mg2+ and allow other cations to travel through the channel pore.  While several 
NMDAR inhibitors have been developed, (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] 
cyclohepten-5,10-imine maleate (MK-801)  and D-(-)-2-Amino-5-phosphonopentanoic acid (AP-
5) are the work horses for most laboratory research on these receptors.  MK-801 inhibits 
NMDARs by binding to and occluding the open pore of the NMDAR in an irreversible manner 
(Foster and Wong, 1987; Huettner and Bean, 1988) whereas AP5 reversibly binds to the 
glutamate site and competes with glutamate for NR2 subunit binding (Crunelli et al., 1983; 
Olverman et al., 1984).   
 
1.3.3. Post-synaptic interactions of NMDARs 
 Similar to CaV2.2 and the pre-synaptic Ca2+ channel complex, NMDARs function as part 
of a larger multimeric complex with a litany of proteins aiding in their post-synaptic responses 
(Sheng, 2001).  That the NMDAR NR2 subunits harbor a large cytosolic C-terminus (~650 amino 
acids) is suggestive of their involvement in complex protein interactions (Ishii et al., 1993; 
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Moriyoshi et al., 1991; Wo and Oswald, 1994).  Peter Seeburg’s laboratory sought to investigate 
possible C-terminal interactions by employing a two hybrid screen for potential binding partners 
of the C-termini of NR2 subunits (Kornau et al., 1995).  This screen found that the second PDZ 
domain of post-synaptic density 95 protein (PSD-95) bound to the last seven amino acids 
contained in the C-termini of the NR2 subunits (amino acids SSIEDV in NR2B).  Introduction of 
a SSIEDV peptide (commonly referred to as tSXV) dissociated NR2 subunits from PSD-95 and 
has hence been used extensively to study this interaction.  PSD-95 is a member of the membrane-
associated guanylate kinase (MAGUK) family.  Other members of the MAGUK family including 
synapse associated protein 102 (SAP-102) and post-synaptic density 93 (PSD-93) also binding to 
NMDARs (Kim et al., 1996; Sans et al., 2000).  It was subsequently determined that PSD-95 is 
able to concomitantly bind NMDARs and neuronal nitric oxide synthase (nNOS) (Christopherson 
et al., 1999).  Furthermore, a complex containing NMDARs, PSD-95, and nNOS was co-
precipitated from brain (Christopherson et al., 1999).  The existence of this complex answered a 
quandary in the field of neuroscience as to why NMDAR activation induces NO production while 
other Ca2+ influx pathways do not (Bredt and Snyder, 1990; Kiedrowski et al., 1992).  The reason 
for this selective activation is that the biochemical complex coupling nNOS to NMDARs is 
required for its activation.  Subsequent work supported this conclusion as treatment of cells with a 
PSD-95–NMDAR interaction disrupting peptide reduced nNOS activation following glutamate 
exposure (Aarts et al., 2002).  The post-synaptic complex containing NMDARs, MAGUKs and 
their associated proteins are commonly referred to as the NMDAR complex or MAGUK 
associated signaling complex (MASC) (Husi et al., 2000; Ryan et al., 2008).    
 NMDARs also interact and are regulated by various kinases (Ryan et al., 2008).  The first 
kinase found to regulate NMDARs was protein kinase C (PKC) (Chen and Huang, 1991).  
Activation of PKC leads to an increase in open probability which led to increased NMDAR 
currents (Lan et al., 2001; Liao et al., 2001).  Furthermore, PKC phosphorylation has also been 
shown to regulate NMDAR surface expression (discussed in §1.3.4).  NMDARs are also 
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phosphorylated by  protein kinase A (PKA) (Cerne et al., 1993).  Activation of PKA leads to 
enhanced NMDAR currents via an increase in the open probability.  PKA is also part of the 
MASC through complexation with A kinase anchoring proteins (AKAPs) 79/150 that bind to 
PSD-95 that brings together both the NMDAR and PKA (Klauck et al., 1996; Sanderson and 
Dell'Acqua, 2011).  In addition to PKA, AKAPs also aid in coupling the MASC to protein 
phosphatases (calcineurin and protein phosphatase 1) (Gomez et al., 2002; Klauck et al., 1996; 
Westphal et al., 1999).  By bringing these kinases and phosphatases in close spatial proximity to 
the NMDARs, AKAPs serve as a scaffold and allow for rapid phosphorylation/dephosphorylation 
of NMDARs to regulate their activity (Sanderson and Dell'Acqua, 2011). 
 Another kinase that has a well delineated interaction with NMDARs is CaMKII.  Early 
work by Mary Kennedy’s laboratory identified Ser1303 in NR2B as the phosphorylation site for 
CaMKII (Omkumar et al., 1996).  This site is also a target of PKC, so it is difficult to tease apart 
the precise contribution CaMKII phosphorylation of NR2B has on receptor function (Liao et al., 
2001).  Further complicating the matter is the finding that CaMKII binds to NR2B and this 
binding is enhanced by NMDAR activation (Strack and Colbran, 1998; Strack et al., 2000).  
Interestingly, phosphorylation of NR2B by CaMKII decreases the affinity of CaMKII for NR2B.  
This suggests an intricate series of events where CaMKII becomes active and binds to NR2B, but 
simultaneously reduces its ability to bind NR2B by phosphorylating Ser-1303.  The association 
between CaMKII and NMDARs has been fiercely studied as both are important players in 
memory and learning (Bear and Malenka, 1994; Malinow et al., 1989). 
 While the two previously discussed proteins that interact with NMDARs are both 
serine/threonine kinases, several Src family tyrosine kinases (SFKs) also interact and 
phosphorylate NMDARs (Chen and Roche, 2007; Salter, 1998).  One of the functions served by 
tyrosine phosphorylation of NMDARs is regulation of trafficking (discussed in detail in §1.3.5).  
In a seminal study by Michael Salter’s laboratory, it was observed that treatment of neurons with 
the SFK inhibitor genistein led to pronounced inhibition of NMDAR currents (Wang and Salter, 
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1994).  Conversely, addition of immunoprecipitated Src protein to the recording pipette led to a 
significant enhancement of currents.  SFKs functions extend beyond phosphorylating NMDARs 
to assembling biochemical complexes with MASC that enable a tight coupling between SFK 
activation and NMDAR phosphorylation (Yaka et al., 2002; Yu et al., 1997).  Phosphorylation of 
NMDARs by SFKs has also been proposed as a molecular mechanism for memory and learning 
(Grosshans et al., 2002).          
 As introduced in §1.2.9, Robert Wenthold’s group reported CRMP-2 as a putative 
NMDAR-interacting protein (Al-Hallaq et al., 2007).  Specifically, his group isolated CRMP-2 as 
an interacting protein through mass spectrometric analysis of enriched NR2A/B heteromeric 
NMDARs.  Furthermore, using sequential co-immunoprecipitation methodologies, they observed 
CRMP-2 in a biochemical complex with NR2A and NR2B.  This study was strictly biochemical 
and reported no functional impact of the interaction.  This section has introduced how NMDARs 
engage in signaling complexes which link their activation to downstream effectors (i.e. kinases).  
This is in stark contrast to CaV2.2, which interacts with the synaptic vesicle machinery to aid in 
tight coupling of Ca2+ channel activity with neurotransmitter release.  The common denominator, 
however, is that both CaV2.2 and NMDARs use biochemical complexes to link their activity with 
the next step in neurotransmission.  These biochemical complexes are hence vital to their 
function.             
 
1.3.4. Trafficking, localization, and quality control of NMDARs 
 Exploration into the molecular determinants of NMDAR trafficking identified the C-
terminus of the NR1/2 subunits as paramount in ensuring surface expression of the receptor 
(Wenthold et al., 2003).  This is not surprising as the C-terminus is over 600 amino acids and 
comprises the majority of intracellular region of the receptor and likewise encompasses the 
majority of protein interactions.  As previously described for CaV2.2, the NMDAR must also 
pass through ER and Golgi compartments prior to arriving at the membrane (Petralia et al., 2009; 
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Stephenson et al., 2008).  While CaV2.2 has auxiliary subunits and synaptic proteins that aid in 
proper trafficking, the NMDAR relies on the MASC and associated STKs interactions within the 
NR2 C-termini.  NMDARs must pass ER quality controls prior to exiting the ER which assures 
that only NMDARs containing NR1 and NR2 are exported from the ER (McIlhinney et al., 1998).  
Following exit from the ER, NMDARs are modified in the Golgi before reaching their final 
destination.   
NMDARs must hitch a ride with adapter proteins (e.g. MAGUKs) linking their transport 
out of the Golgi to endosomes and beyond.  The MAGUK SAP-102 links the NMDAR to the 
exocyst complex which is associated with transport out of the Golgi (Bowser et al., 1992), and 
appears to aid in transport of NMDARs from the Golgi to intracellular transport vesicles (Sans et 
al., 2003).  NMDARs are present in mobile clusters along dendritic processes which allow for 
rapid movement of receptors along dendrites (Washbourne et al., 2002).  The NMDAR is then 
transported to the membrane along microtubules (Washbourne et al., 2002) with the assistance of 
kinesin motor proteins (Guillaud et al., 2003; Setou et al., 2000).  To localize to the synapse, the 
NR2 subunit must bind to either PSD-95 or SAP-102 (Prybylowski et al., 2005; Sans et al., 
2003).  The translocation of the clustered receptors from intracellular compartments to the plasma 
membrane occurs through interaction with the post-synaptic SNAREs SNAP-23/25 (Lan et al., 
2001; Suh et al., 2010; Washbourne et al., 2004).  This transport from intracellular stores to the 
membrane can be initiated by PKC activation which leads to subsequent activation of SFKs 
(Huang et al., 2001; Lu et al., 1999).  The rapid insertion of NMDARs into the membrane 
requires both PKC and SFK activation and represents a mechanism whereby cells can add 
receptors to the membrane promptly following stimulation (Grosshans et al., 2002).  As discussed 
previously in §1.2.9, CRMP-2 has also been suggested to be involved in the trafficking of 
NMDARs (Bretin et al., 2006), although these findings have yet to be substantiated and are 
controversial.  The current consensus is that NMDARs are present in clusters along dendrites 
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where they can rapidly move in and around dendritic membranes to facilitate changes in NMDAR 
responses. 
Following trafficking of the NMDAR to the surface, there are multiple pathways that 
have been identified that can reduce surface expression of the receptor, most notably via receptor 
internalization.  Interestingly, unlike synaptic AMPARs which are recycled vigorously, 
NMDARs are rather stable in the post-synaptic terminal (Luscher et al., 1999).  Nevertheless, 
NMDARs still undergo internalization as was initially observed in experiments expressing 
NR1/NR2B in a heterologous cell line (Roche et al., 2001).  This internalization relied on a 
sequence (amino acids YEKL) just N-terminal to the PDZ binding peptide of NR2B.  
Internalization of NR2B occurs through dynamin-dependent endocytosis and appears to be 
developmentally regulated with immature (DIV 7) hippocampal neurons exhibiting significantly 
more internalized receptors than mature (DIV 18) neurons (Roche et al., 2001).  This 
internalization can be prevented by co-expression of PSD-95 (Lavezzari et al., 2003).  This is 
consistent with PSD-95 binding to the PDZ domain and stabilizing NMDARs while interfering 
with YEKL mediated-internalization (Roche et al., 2001).  Preventing AP-2 binding to NR2B 
reversed loss of synaptic receptors in response to mutation of the NR2B PSD-95 binding site, 
suggesting that synaptic internalization occurs via binding of the adaptin protein 2 (AP-2) 
complex which links NR2B to the clathrin-mediated internalization machinery (Lavezzari et al., 
2003; Prybylowski et al., 2005).  This finding further suggests that, under normal conditions, AP-
2 actively removes channels which are not associated with PSD-95 (Prybylowski et al., 2005).  
Additionally, phosphorylation of NR2B Tyr-1472 (YEKL) by the SFK Fyn leads to enhanced 
currents consistent with the observed reduction in AP-2 binding of NR2B following Tyr-1472 
phosphorylation.  Phosphorylation of Tyr-1472 can also be upregulated by inhibition or loss of 
Cdk5 activity (Zhang et al., 2008).  This occurs as phosphorylation of PSD-95 by Cdk5 reduces 
the affinity of SFKs for PSD-95 and therefore leads to reduced Tyr-1472 phosphorylation.  The 
net result of Cdk5 inhibition is an increase in surface expressed NR2B due to reduced NR2B–AP-
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2 interactions (Zhang et al., 2008).  NMDAR internalization can also be initiated by activation of 
CaMKII (Chung et al., 2004).  Following activation CaMKII phosphorylated and activated casein 
kinase 2 (CK2) which in turn phosphorylates Ser-1480.  This phosphorylation reduces NR2B-
PSD-95 interactions leading to NR2B internalization.  Finally, it has also been shown that GSK3β 
activity can regulate NR2B surface expression (Chen et al., 2007b).  While it was observed that 
Cdk5 inhibition leads to reduced NR2B internalization, the converse was found to be true for 
GSK3β.  The use of GSK3β inhibitors or siRNA led to a sharp decline in NMDAR currents 
(~30% of peak within 5 minutes).  This decline was dynamin dependent and accompanied by a 
decrease in NMDAR-PSD-95 interactions.  Collectively then, it appears that internalization of 
NR2B containing receptors is dependent upon the phosphorylated state of Tyr-1472 and Ser-
1480.  These phosphorylation sites in turn regulate interactions between NR2B and PSD-95/AP-2 
where PSD-95 favors membrane NR2B and AP-2 binding favors internalization of NR2B. 
 
1.3.5. Excitoxicity and role of NMDAR in glutamate-induced neuronal death  
The death of neurons due to toxic excitation is a phenomenon known as excitoxicity 
(Choi, 1992).  Excitotoxic death of neurons occurs due to excessive Ca2+ influx leading to 
activation of neurotoxic cascades (Choi, 1985).  Neuronal insults such as a stroke or traumatic 
brain injury induce localized cell death around the insult leading to dumping of glutamate from 
neuronal stores (Bullock et al., 1995; Katayama et al., 1990).  The excess of extracellular 
glutamate activates a variety of glutamate receptors including glutamate ligand-gated ion 
channels, which are the most commonly implicated receptors in glutamate toxicity (Sattler and 
Tymianski, 2001).  Ca2+ influx through NMDARs in particular is thought to be a key mediator of 
excitotoxicity as antagonists of these receptors are neuroprotective in animal models of traumatic 
brain injury and ischemia-induced excitotoxicity (Faden et al., 1989; Grotta et al., 1990; Park et 
al., 1988; Steinberg et al., 1989).  However, the majority of human trials using NMDAR 
antagonists did not replicate the effectiveness seen in animal models and alarmingly found 
 57 
 
NMDAR antagonists to be toxic (Ikonomidou et al., 2000; Ikonomidou and Turski, 2002; Muir, 
2006).  In contrast, the non-competitive NMDAR antagonist memantine has shown early promise 
in various models of excitotoxicity (Sonkusare et al., 2005; Volbracht et al., 2006) and appears to 
be clinically well-tolerated (Jain, 2000; Parsons et al., 1999).   
NMDAR activation causes a deregulation of Ca2+ homeostasis initiating a variety of 
pathways culminating in neuron cell death (Choi, 1985).  One such pathway that is activated 
during excitotoxicity is production of the free radical NO by nNOS (Dawson et al., 1991).  Not 
only is the Ca2+ influx through NMDARs responsible for nNOS activation, but the direct coupling 
of nNOS to NMDARs facilitates NO production (Aarts et al., 2002; Sattler et al., 1999).  The 
production of NO and other free radicals leads to modification of proteins, DNA, and lipids 
resulting in cell death (Sattler and Tymianski, 2000).  As previously mentioned, nNOS interacts 
with NMDARs by binding to PSD-95 and hence disruption of the NR2B–PSD-95 interaction 
displaces nNOS from the MASC.  Disruption of the NR2B-PSD-95 interaction using a peptide 
containing the last 9 amino acids of NR2B (NR2B9c) is therefore neuroprotective and has been 
used to prevent neuronal death following stroke (Aarts et al., 2002).  As many proteins interact 
with the NMDAR through PSD-95, it is difficult to attribute neuroprotection to a single protein 
and therefore the mechanism of NR2B9c remains enigmatic and controversial.   
NMDAR-mediated Ca2+ influx can also activate the Ca2+ activated protease calpain (del 
Cerro et al., 1994), which has been heavily linked to neurotoxic signaling (Vosler et al., 2008).  
Calpain is a cytosolic cysteine protease consisting of calpain I and II.  Inhibition of calpains has 
been shown to be neuroprotective prior to excitoxicity, suggesting that its activation aids in 
neuronal death (Bevers et al., 2009; Hong et al., 1994).  The prototypical calpain substrate is the 
cytoskeletal protein spectrin, where calpain activity is commonly monitored through the 
predictable cleavage pattern of spectrin (Czogalla and Sikorski, 2005).  Dozens of additional 
calpain substrates in the nervous system are known including cytosolic, mitochondrial, nuclear, 
and membrane bound proteins.  Pertinent to my dissertation, calpain cleaves both CRMP-2 
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(Bretin et al., 2006; Chung et al., 2005) and NR2B (Simpkins et al., 2003).  Another interesting 
substrate of calpain is p35 (activator of Cdk5), where cleavage of p35 to p25 occurs during 
neurotoxic stimulation and leads to activation of Cdk5 (Lee et al., 2000).  Cleavage of CRMP-2 
has previously been discussed in detail in § 1.2.9.  Stimulation of hippocampal neurons with 
NMDA for 5 min leads to a pronounced (~35%) decrease in NMDAR currents (Wu et al., 2005).  
Inhibition of calpain completely prevents the decrease, suggesting that cleavage reduces the 
amount of functional receptors.  Despite many prior studies showing calpain inhibition to be 
neuroprotective, a recent study found that neuroprotection by disrupting the NR2B–PSD-95 
interaction relied on calpain activation (Yuen et al., 2008).  This study suggests that by disrupting 
the NR2B–PSD-95 interaction, the NR2B subunit becomes susceptible to cleavage and therefore 
sparing the cells from NMDAR-mediated cell death.    
In addition to the negative signaling initiated by NMDAR activation, there is also pro-
survival signaling that occurs via NMDAR activation.  One theory behind the failure of NMDAR 
antagonists in clinical trials is that inhibition of NMDARs prevents both pro-survival as well as 
neurotoxic NMDAR signaling.  In other words, although the neurotoxic effects of NMDARs are 
blocked, neurons also lose the positive survival signaling that in turn leads to toxicity.  Work 
performed using both in vivo and in vitro models found that pre-incubation with low 
concentrations of NMDA reduced excitotoxicity (Jiang et al., 2005; Lee et al., 2005; Marini and 
Paul, 1992; Ogita et al., 2003).  This pro-survival signaling appears to be through a cyclic-AMP 
response element binding protein (CREB).  Following activation of NMDARs, CREB is rapidly 
phosphorylated which in turn induces release of the pro-survival brain-derived neurotrophic 
factor (Jiang et al., 2005).  While these results suggest that NMDARs possess the capability to be 
both pro-survival and neurotoxic, it is unknown what property of an NMDAR determines it role 
in neuronal survival.  Some studies have hypothesized that synaptic versus extrasynaptic 
NMDARs couple differently to these two distinct signaling pathways (Hardingham and Bading, 
2002; Hardingham et al., 2002).  The role of these receptors in cell viability has been linked to 
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CREB signaling, which is enhanced via synaptic NMDARs and reduced via extrasynaptic 
NMDARs (Hardingham et al., 2002).  These findings position NMDARs not only as a target for 
neuronal death but also for survival.  Recent findings suggest that the NMDAR interacting 
protein CRMP-2 may be neuroprotective by altering NMDAR receptor function (Al-Hallaq et al., 
2007; Bretin et al., 2006).  However, nothing is known about how the NMDAR-CRMP-2 
interaction is neuroprotective.  In Chapter 4, I will explore CRMP-2 and the role that a CRMP-2 
peptide plays in preventing NMDAR-mediated neuronal death.      
 
THESIS AIMS: 
1.  To determine if CRMP-2 interacts functionally and biochemically with CaV2.2. 
2.  To determine if phosphorylation of CRMP-2 by Cdk5 is an important determinant of CaV2.2 
modulation. 
3.  To determine if disruption of CaV2.2-CRMP-2 interaction prevents CRMP-2-mediated 
modulation of CaV2.2. 
4.  To determine if TAT-CBD3 is neuroprotective. 
5.  To determine the mechanism of TAT-CBD3 neuroprotection.
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CHAPTER 2.  MATERIALS AND METHODS 
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2.1.  Synaptosome isolation 
Synaptosomes are biochemically isolated preparations enriched with pre-synaptic 
structures and post-synaptic densities.  Synaptosomes were prepared as described (Carlin et al., 
1980; Huttner et al., 1983) with modifications.  Brains from PN1-2 Sprague Dawley rats (Harlan 
Labs) were dissected into 10 volumes ice-cold homogenization buffer A (see Table 2.1 for buffer 
compositions) and homogenized using 10-15 strokes of a glass Teflon hand-held homogenizer. 
The homogenate (H) was spun for 10 min at 1400x g 4°C and the supernatant was saved. The 
pellet (P1) from this spin was re-homogenized in buffer A and spun as before.  Both low-speed 
spin supernatants were combined and spun for 10 min at 13,800x g 4°C yielding a supernatant 
cytosolic fraction (S2) and a pellet consisting of a crude synaptosomal fraction (P2).  The P2 
fraction was homogenized in sucrose buffer B and layered onto a sequential gradient of 1M and 
1.4M sucrose (buffered with 0.5 mM HEPES/KOH pH 7.4) and centrifuged at 82,500x g (4°C) 
for 90 min in a swinging bucket rotor with slow acceleration and deceleration. The gradient 
interphase contained intact synaptosomes (P2’), which were used for depolarization experiments 
within 2 h of isolation or lysed in modified RIPA buffer; filtered through a 0.22 μm syringe filter 
and fractions stored at –80°C until use.  Protein concentrations were determined for all lysates 
using a BCA protein assay (Thermo Scientific). 
 
2.2.  Sucrose density gradient centrifugation 
To assess the sub-cellular distribution of CRMP-2 and CaV2.2 proteins, sucrose density 
gradients were prepared from PN1 rat brains.  Rat brains (~2 mg) were solubilized in 2 ml 1% 
Triton X-100 (Sigma) in MBS (2-morpholinoethanesulfonic acid (MES)-buffered saline).  
Following homogenization using 10-15 strokes of a glass Teflon hand-held homogenizer, the 
homogenates were adjusted to 45% with sucrose and overlaid with 4 ml of 30% sucrose in MBS 
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Table 2.1. Buffers used in this thesis 
Buffer Name Contents 
(protease inhibitors) 1 µg/ml  pepstatin, 1 µg/ml leupeptin, 2 µg/ml aprotinin, 1 mM PMSF (Sigma) together with Protecease 
inhibitor cocktail 
DEAE buffer 25 mM sodium phosphate (pH 7.8) containing 10 mM 2-mercaptoethanol and 1 mM phenylmethylsulfonyl 
fluoride  
Excitatory Tyrode’s buffer 32 mM NaCl, 90 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 25 mM HEPES pH 7.5, 30 mM Glucose 
Extracellular solution 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, pH 7.4, 10 mM glucose 
GST lysis buffer 20 mM Tris pH 7.5, 200 mM NaCl, 0.1 mM EDTA, 1 mM DTT, and protease inhibitors 
HA buffer 10 mM potassium phosphate (pH 7.0) containing 10 mM 2-mercaptoethanol 
HBS-EP buffer 10 mM HEPES, pH 7.4, 10 mM M NaCl, 3 mM EDTA, and 0.005% surfactant P20 
Heparin extraction buffer 5% SDS, 20 mM DTT, 125 mM Tris-HCl, pH 6.8, 10% sucrose, 20 mM EDTA 
His elution buffer 50 mM HEPES pH 7.4, 150 mM NaCl, 100 mM Imidazole 
His lysis buffer 50 mM HEPES pH 7.4, 150 mM NaCl 
His storage buffer 10 mM HEPES, pH 7.4, 100 mM M NaCl, and 20 mM CaCl2 
His wash buffer 50 mM HEPES pH 7.4, 150 mM NaCl, 10 mM Imidazole 
Homogenization buffer A 0.32 M sucrose, 10 mM HEPES pH 7.4, 2 mM EDTA, with protease inhibitors 
Kinase assay buffer 100 mM HEPES pH 7.2, 20 mM MgCl2, 2 mM MgATP, 2 mM DTT  
MBS 25 mM MES pH 6.5, 150 mM NaCl 
Mild lysis buffer 20 mM HEPES pH 7.2, 150 mM NaCl, 2 mM MgCl2, 1 mM DTT, 0.5% (v/v) Triton X-100, 
PBS 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4  
Protein binding buffer 20 mM HEPES pH 7.2, 1 mM EDTA, 150 mM NaCl, 5 mM MgCl2, 0.1 % NP-40 with protease inhibitors 
RIPA #1 50 mM Tris-HCl, pH 8, 1% NP-40, 150 mM NaCl, 0.5% Na deoxycholate, and 1 mM EDTA with protease 
inhibitors 
S buffer 25 mM sodium phosphate (pH 6.0) containing 10 mM 2-mercaptoethanol 
Standard bath solution 139 mM NaCl, 3 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 10 mM NaHEPES, pH 7.4, 5 mM glucose 
Sucrose buffer B 0.32 M sucrose, 0.5 mM HEPES/KOH pH 7.4 and protease inhibitors 
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Sucrose homogenization 
buffer 
320 mM Sucrose, 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA pH 7.5 and protease inhibitors 
TAE buffer 40 mM Tris Acetate, 1 mM EDTA 
TBST 25 mM Tris-Cl, pH 8.0, 125 mM NaCl, 0.1% to 2% Polyoxyethylene Sorbitan Monolaurate (Tween-20) 
TE SDS buffer 1% SDS, 100 mM Tris-HCl pH 7.5, 10 mM EDTA 
Triton X100 extraction 
buffer 
Sucrose homogenization buffer with 0.5 % Triton X100 
Tyrode's buffer 119 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 25 mM HEPES pH 7.5, 30 mM Glucose 
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and 4 ml of 5% sucrose in MBS.  The sucrose gradient was formed by centrifuging at 200,000x g 
for 18 h at 4°C using a Beckman SW41 rotor (Beckman Coulter).  Twelve 1 ml aliquots were 
removed, beginning at the top.  The high density membrane fractions (9–12) at the bottom of the 
gradient contain proteins like the Na+/K+ ATPase and voltage-gated ion channels(Wong et al., 
2002), fractions 5 and 6 are rich in cholesterol and sphingolipids, confirming the ability of this 
centrifugation method in separating membrane and cellular components. 
 
2.3.  Preparation of synaptic and extrasynaptic brain fractions 
Protocol was modified from a previously published study (Goebel-Goody et al., 2009).  
Freshly removed E19 rat cortices were homogenized in sucrose homogenization buffer.  
Homogenates were then spun for 10 min at 1000 x g to remove insoluble debris and the nuclear 
fraction (P1).  The supernatant (S1) was then spun at 10,000 x g for 10 min producing a crude 
synaptosomal pellet (P2) and a cytosolic fraction (S2).  S2 was then further spun at 100,000 x g 
for 60 min producing an intracellular membrane fraction (LP1) and a nonmembrane cytosolic 
fraction (LP1).  P2 was then resuspended in Triton X100 extraction buffer and agitated gently by 
continual rotation at 4°C for 30 min.  The resuspended pellet was then centrifuged at 32,000 x g 
for 30 min producing a pellet containing an enriched synaptic fraction (TxP) and a supernatant 
containing an enriched extrasynaptic fraction (TxS).  TxP and LP1 fractions were resuspended in 
SDS TE buffer along with sonication and boiling.  All samples were quantified for total protein 
and equal protein from each fraction was separated by SDS-PAGE before immunoblotting was 
performed. 
 
2.4.  Co-immunoprecipitations and western blotting 
Rat brain synaptosomes were pre-cleared by a 1 h incubation with 20 μl of a 50% slurry 
of protein A/G beads (Pierce).  The cleared lysate was then incubated overnight with various 
primary antibodies (see Table 2.2) or rabbit or mouse isotype-specific IgGs (Sigma or Jackson
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Table 2.2. Antibodies used in this thesis 
Protein Dilution Species Source Epitope Applications Company Cat # 
Akt 1:500 Mouse Rabbit C-terminal peptide WB Cell Signaling C67E7 
CaV2.2 1:500 Rat Rabbit 851-867 WB, IP Calbiochem 681505 
CaV2.2 1:500 Human Rabbit 2013-2169 WB Origene TA308673 
CRMP-1 1:750 human Rabbit unknown WB Sigma AV41932 
CRMP-2 1:1000 Human Rabbit unknown IC, WB, IP Cell Signaling 9393 
CRMP-2 1:1000 Rat Rabbit unknown IC, WB, IP Chemicon AB9218 
CRMP-2 1:1000 Human Mouse C-terminal peptide WB Abcam AB62539 
CRMP-2 1:1000 Human Rabbit 476-493 WB Sigma C2933 
CRMP-2 (C4G) 1:1000 Human Mouse C-terminus WB, IP Immuno-Biological Laboratories 11096 
CRMP-2 (p522) 1:1000 Human Rabbit Phospho-peptide WB ECM Biosciences CP2191 
CRMP-3 1:500 Human Mouse unknown WB Abcam AB36217 
CRMP-4 1:500 Human Rabbit 499-511 WB Chemicon AB5454 
CRMP-5 1:500 Human Rat whole protein WB Chemicon MAB5442 
Kv2.1 1:500 Rat Mouse 837-853 WB NeuroMab K89/34 
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Protein Dilution Species Source Epitope Applications Company Cat # 
GFP 1:20,000 Jellyfish Mouse whole protein WB Clontech 632375 
Glu Tag 1:500 peptide Mouse Glu peptide WB, IP Dr. Clark Well's (IUSM) N/A 
GluR2 1:250 Rat Mouse 834-883 WB NeuroMab L21/32 
Munc18 1:500 Rat Mouse 381-567 WB BD Biosciences 610336 
NR2B 1:1000 Rat Mouse 892-1051 WB ,IP BD Biosciences 610417 
NR2B 1:1000 Mouse Rabbit 1437-1456 WB, IP Millipore 06-600 
NR2B 1:200 Rat Mouse 20-271 IP NeuroMab N59/20 
PSD-95 1:1000 Human Mouse 77-299 WB Neuromab K28/43 
Tubulin (βIII) 1:2000 Human Mouse 373-378 WB Promega G7121 
WB: western blot, IP: immunoprecipitation, IC: Immunocytochemistry 
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Immunoresearch) as controls.  The antibody-captured complexes were recovered with fresh 
protein A (for rabbit polyclonal antibodies) or protein A/G (for mouse monoclonal antibodies) 
agarose beads (15-30 µl original bead slurry per sample) by incubation with lysate-antibody 
mixture at 4°C for 2 h.  The beads were then washed three times with lysis buffer.  Prior to 
electrophoresis on SDS polyacrylamide gels, protein samples were boiled in Laemmli sample 
buffer for 5 minutes.  Proteins were fractionated on 5%, 7.5%, 10% or 4-15% separating gels with 
4% stacking gels.  Apparent molecular weights were determined using broad range standards 
(Fermentas).  Following electrophoresis, proteins were transferred to PVDF membranes 
(Invitrogen) for immunoblotting and stained with Amido black or ponceau (BioRad) to monitor 
transfer efficiency.  The membranes were blocked for 1 h in 5% skim milk powder in TBST at 
RT. Primary antibody incubations were for 2 h at RT or overnight at 4°C.  Following incubations 
with primary antibody and secondary antibody (goat anti-rabbit or anti-mouse IgG horseradish 
peroxidase (1:10,000 or 1:20,000; Stressgen)), blots were washed extensively in TBST and 
probed with Enhanced Chemiluminescence Western blotting substrate (Thermo Scientific) before 
exposure to photographic film.  Blots were exposed for a range of durations to ensure the 
generation of a print in which the film is not saturated.  Films were then scanned, digitized and 
quantified using Un-Scan-It gel V6.1 scanning software (Silk Scientific Inc., Orem), limiting our 
analysis to the linear range. 
 
2.5.  Isolation and culture of hippocampal or cortical neurons 
Rat hippocampal and cortical neuron cultures were prepared from hippocampi or cortices 
dissected from PN1 or embryonic day 19  (E19) rats respectively as described(Goslin and Banker, 
1989).  Briefly, rat hippocampi were dissected out of PN1 rats, and cells were dissociated 
enzymatically and mechanically (trituration through Pasteur pipette) in a Papain solution (12 
U/ml; Worthington) containing Leibovitz’s L-15 medium (Invitrogen), 0.42 mg/ml cysteine 
(Sigma), 250 U/ml DNase 1 (type IV; Sigma), 25 mM NaHCO3, penicillin (50 
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U/ml)/streptomycin (50 µg/ml), 1 mM sodium pyruvate, and 1 mg/ml glucose (Invitrogen).  After 
dissociation, the cells were gently washed by sequential centrifugation in Neurobasal medium 
containing either 2 mg/ml or 20 mg/ml BSA and Pen/Strep, glucose, pyruvate, and DNase1 (as 
above) and then plated on poly-D-lysine-coated Aclar coverslips at high density (~2000 
cells/mm2).  Growth media (1 ml/well) consisted of Neurobasal medium continaing 2% NuSerum, 
2% B27 or NS21 (Chen et al., 2008), supplemented with penicillin/streptomycin (100 U/ml; 50 
µg/ml), 0.1 mM L-Glutamine and 0.4 mM L-glutamax (Invitrogen).  Cytosine β-D-
arabinofuranoside (5 µM; Sigma) was added 24 h after plating to reduce the number of non-
neuronal cells.  After 4 d in culture and 2× each week thereon, half of the growth medium was 
replaced with medium without cytosine β-D-arabinofuranoside.  
 
2.6.  Immunocytochemistry, confocal microscopy and iterative deconvolution deblurring 
DIV 10 hippocampal cultures were fixed with 4% paraformaldehyde (diluted in 0.1 mM 
PBS) for 10 min at room temperature, permeabilized with 0.2% Triton X-100 for 10 min, and 
then washed three times with 0.1 mM PBS.  Neurons were then pre-incubated with 10% bovine 
serum albumin (diluted in 0.1 mM PBS) for 1 h at RT to block nonspecific binding with the 
primary antibody.  Primary antibodies for monoclonal CRMP-2 (Abcam) and rabbit polyclonal 
N-type/CaV2.2 (Calbiochem) were diluted 1:100 (in 0.1 mM PBS) and applied to the cells.  After 
incubation at 4°C overnight, the neurons were washed again with PBS and secondary antibodies 
(goat anti-mouse Alexa 488 or anti-rabbit Alexa 594, 1:1000; Molecular Probes, Eugene, OR) 
were incubated in blocking solution for 45 min at RT.  Coverslips were mounted in Prolong Gold 
Antifade mounting media (Molecular Probes).  The hippocampal neurons were imaged on a 
Nikon Ti swept-field confocal microscope using a 60X, 1.4 NA lens and standard FITC/Texas red 
fluorescence cubes with a cooled Cascade 512B digital camera (Photometrics, Tucson, AZ).  Z 
stack image pairs were captured at an inter-plane distance of 200 nm through the sample.  Images 
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were deblurred off line by an iterative deconvolution protocol (Nikon Elements v3.0) using a 
theoretical point-spread function and pseudocolored for presentation. 
 
2.7.  Intensity correlation analysis (ICA)/Intensity correlation quotient (ICQ) 
Developed by Dr. E. F. Stanley (Toronto Western Research Institute, Toronto, Canada), 
this analysis was completed as previously described with modifications (Khanna et al., 2006b).  
ICA/ICQ analysis was carried out by means of an automated graphic plugin (Khanna et al., 
2006b) for the public domain image analysis software ImageJ (Wayne Rasband; National 
Institutes of Health, Bethesda MD).  For the intensity correlation analysis (ICA) the function was 
calculated (Ai–a)(Bi–b), where a and b are the means of each pixel staining pair intensity values 
Ai and Bi.  Ai or Bi was graphed in separate scatter plots against their respective (Ai–a)(Bi–b) 
value.  Distributions that skew to the right reflect dependent staining patterns (where the two 
pixel staining intensity values vary in synchrony); distributions that are symmetrical about the 0 
axis indicate random staining, while those that skew to the left reflect independent staining 
patterns, where the pixel staining intensity values vary inversely.  Analysis for each stain was 
performed separately so that a dependence of stain A on B but a lack of dependence of B on A can 
be identified and, further, that the plots permit detection of complex or mixed staining relations.  
The intensity correlation quotient (ICQ) reflects the ratio of the number of positive (Ai–a)(Bi–b) 
values to the total number of pixels in the ROI, corrected to a -0.5 (independent staining) to +0.5 
(dependent staining) range by subtracting 0.5.  The ICQ provides a single value parameter that is 
used for statistical comparisons.  Typically, with N>6 ROIs, a mean ICQ value of -.05 to +.05 
indicates random staining, +.05 to +.10, indicates a moderate covariance and >.1 a strong 
covariance.  Images shown in Figure 3.3C were enhanced using the smart sharpen mask filter, 
high pass, and brightness-contrast adjustment functions in Adobe Photoshop.  Images were 
processed with Nikon Elements v3.0 and all figures were constructed in Adobe Illustrator CS5 
(Adobe Systems). 
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2.8.  Cloning CRMPs and CaV2.2 channel fragments into pGEX-Glu vectors 
Constructs containing full length and truncated CRMP-2 in the pGEX-5X-3 vector were 
generously provided by Dr. Akihiro Kuramasa (Tahimic et al., 2006).  The intracellular loops of 
CaV2.2 were cloned into the dual-tagged pGEX3X-GST-Glu (a kind gift of Dr. Andy Hudmon) 
vector for expression of recombinant proteins.  Using Vector NTI (v. 11; Invitrogen) or GENtle 
software, primers were designed to amplify regions corresponding to intracellular loops of rat 
CaV2.2 cDNA from P3 rat brain cDNA. The primers (Table 2.3) harbored restriction sites 
(BamHI or BglII (5’) and EcoRI or MfeI (3’)) to facilitate cloning into the plasmid. In addition to 
the GST-tag, this vector contains the Glu tag, a sequence of six amino acids (EYMPME).   
 
2.9.  Polymerase chain reaction (PCR) 
A vector containing full length CaV2.2 cDNA was used as a template for amplification of 
the CaV2.2 cytosolic regions by PCR.  PCR reactions consisted of 0.4 mM dNTPs, 0.4 mM of 
each primer, 1-5 units of Taq polymerase, and 50-100 ng of template.  The reaction was run using 
a standard heated lid thermocycler (Eppendorf, Hamburg, Germany).  Samples were heated to 
95°C for 2 min to denature the cDNA and primers before cooling to 55°C to allow for annealing 
of the primers to the cDNA.  Samples were then warmed to 72°C for 1 min/kb of desired product 
to promote elongation of the product by Taq polymerase.  The samples were then cycled between 
denaturing, annealing, and elongation (using only a 30 sec denaturing) for a total of 30 cycles 
before a 10 min long elongation period to finish elongation on any incomplete strands.  The 
thermocycler was then cooled to 4°C until the samples were removed. 
 
2.10.  Restriction digestion, gel purification, and ligation.   
Correctly-amplified PCR products and parent pGex-3x-Glu vector were digested in the 
appropriate buffer for the selected restriction enzymes (as indicated by the provider of the 
enzyme) by incubating at 37°C for 4-6 hours.  The digested DNA was then separated on a 1% 
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agarose gel in TAE buffer and visualized using SybrSafeTM (Invitrogen).  DNA bands at the 
predicted sizes were excised using a scalpel and the DNA was extracted using the GeneJET™ 
Gel Extraction Kit (Fermentas, Vilnius, Lithuania).  The extracted DNAs were quantified 
(Nanodrop 1000, Thermo Scientific), and ligations were performed using 6:1 and 3:1 insert to 
vector molar ratios.  The ligations were transformed into XL-10 or DH5α Escherichia Coli (E. 
Coli) and colonies were screened using colony PCR.  Those colonies with the correct-sized 
inserts were further verified by dideoxy sequencing (Cogenics, Houston, PA).  
 
2.11.  Recombinant GST protein production 
DNA encoding verified pGex-CaV2.2-Glu-type channel fragments, GST-Glu, Munc18-1-
GST, CRMP-2-GST, p25-GST, Cdk5-GST, and GSK3β-GST constructs were transformed into 
the BL21 (DE3) E. Coli for protein expression.  CRMP-2-GST fusion constructs were generously 
provided by Dr. Akihiro Kurimasa (Tottori, Japan) (Tahimic et al., 2006) and a Munc18-1-GST 
fusion vector was provided by Dr. Debbie Thurmond (IUSM).  Expression of fusion proteins was 
induced with 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG).  For purification, following 
overnight growth at 16°C, transformed bacteria were pelleted at 5,000 x g for 20 min at 4°C and 
lysed in GST lysis buffer using a M-110L Microfluidizer (Microfluidics Corp., Newton, MA). 
The microfluidized lysate was adjusted with Triton-X100 (1% final for CaV2.2 constructs only) 
and the cells were incubated on ice for 30 min followed by centrifugation at 30,000 x g for 45' at 
4°C. The high-speed supernatant was then incubated with either Glutathione-cellulouse beads or 
protein G agarose beads (for GST-Glu proteins) conjugated with mouse monoclonal Glu primary 
antibody (gift from Dr. Clark Wells, IUSM).  Alternatively proteins were loaded on a glutathione-
cellulouse column, washed extensively with GST lysis buffer, and eluted with glutathione using a 
stepwise gradient from 0 to 100 mM glutathione.  Purified protein concentration was determined 
using a bovine serum albumin curve on a SDS-PAGE stained by comassie.  The Coomassie 
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Table 2.3. Primers used to generate GST-CaV2.2-Glu fusion constructs 
Construct Nucleotides Primer Sequence 5'  3' Restriction site 
N-terminus    
(Nt) 46-330 
TAG GAT CCT TAT GGT CCG CTT CGG 
GGA CGA GCT A 
BamHI 
TAT GAA TTC GGC CAT TCG GTG ATG 
CGC TTA 
EcoRI 
I-II loop (L1) 1111-1494 
TAG GAT CCC ATC AGG AGA GTT TGC 
CAA AGA G 
BamHI 
TAT GAA TTC CCG CTC TGT GCT TTC 
ACC ATA CGA 
EcoRI 
II-III loop 
proximal region 
(L2-p) 
2176-3000 
CTA GAT CTT GGA AGA GGC AGC CAA 
TCA GAA GC 
BglII 
TAT GAA TTC CCT GCA CGG TGC CTG 
CGT GTG  
EcoRI 
II-III loop distal 
region (L2-d) 2914-3471 
TAC TAG ATC TTG GGC GAG CGT CGC 
GCA AGA CAT 
BglII 
TAT GAA TTC CCG TAA TGG CAG AAG 
CGA CGG AG 
EcoRI 
III-IV loop  
(L3) 4276-4467 
TGG GAT CCC CTT GAT CAT CAT CAC 
CTT CCA G 
BamHI 
CCG GAA TTC CCA ATG AAG TAC TCA 
AAG GGT GG 
EcoRI 
C terminus 
proximal (Ct-p) 5116-5793 
TGG GAT CCT CTG TTC CTT TCT GAT 
GCT GAA 
BamHI 
TGA CCG CAA TTG GAA GTT GCA CTC 
TTT TGT C 
MfeI 
Ct-medial    
(Ct-m) 5683-6429 
TAG GAT CCA GAT GGG TCC TGT TTC 
CCT GTT 
BamHI 
CTG GAA TTC CCA AAG CGG TCA CAG 
GAA TA 
EcoRI 
Ct-distal (Ct-d) 6400-7044 
TGG GAT CCA GCG CTT CTA TTC CTG 
TGA C 
BamHI 
TTA TCC CAA TTG CAC CAG TGA TCC 
TGG TCT 
MfeI 
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stained gels were then scanned and bands were quantified by UN-SCAN-IT gel (Silk Scientific 
Inc, Orem, Utah).    
 
2.12.  Endogenous CRMP-2 purification 
This was performed as described previously with slight modifications (Wang and 
Strittmatter, 1997).  Adult rat brains (~10g) were homogenized in 3 volumes of DEAE buffer 
with a Teflon/glass homogenizer.  The homogenate was centrifuged at 200,000 g for 40 min at 
4°C and the supernatant was applied to a 1 mI DEAE-Sephacel column (Sigma) equilibrated with 
DEAE buffer.  The column was washed thoroughly with DEAE buffer, and bound proteins were 
eluted with 100, 200, and 300 mM NaCI step gradients in DEAE buffer.  Two ml fractions were 
collected at each salt concentration.  Peak CRMP-2-containing fractions (as monitored by 
Western blot with a polyclonal CRMP-2 antibody) in the 200 mM NaCI elution was diluted 10-
fold with S buffer, and applied to a 2 ml S-Sepharose (GE Healthcare/ Amersham) column 
equilibrated with S buffer.  After washing, proteins were eluted in 150 mM NaCI in S buffer. One 
3 ml fraction was collected, diluted fivefold with HA buffer.  The diluted sample was applied to a 
1 ml hydroxyapatite column (Bio-gel HTP; Bio-Rad) and eluted with 100 mM potassium 
phosphate (pH 7.0) containing 10 mM 2-mercaptoethanol.  Six fractions of 0.5 ml each were 
collected. At this step, Coomassie Blue staining and Western blot analysis was performed to 
verify CRMP-2 purification at the predicted molecular mass of 65 kDa.  An identical procedure 
was used to purify CRMP from rat brains at several ages.  
 
2.13.  In vitro protein-binding assay 
For binding studies, the cytoplasmic loops of CaV2.2 and full-length (as well as 
truncated) CRMP-2 proteins were purified as GST or GST-Glu-tagged proteins, respectively.  
Binding reactions were performed in protein binding buffer.  Monoclonal Glu antibody-saturated 
Protein G beads (GE Healthcare) carrying various CaV2.2 cytoplasmic loop constructs or GST-
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Glu were incubated with rat brain purified CRMP-2 protein in a total reaction volume of 100 μl.  
For binding assays using synaptosomes the purified proteins were added to synaptosomes.  
Reactions were incubated end-over-end for 4 h at 4°C, washed three times with a 10-fold excess 
of binding buffer, and the proteins were eluted in 60 µl of SDS gel buffer and boiled for 5 min, 
after which 20 µl of each assay was run on SDS-PAGE and analyzed by immunoblotting with 
CRMP-2.  To determine binding affinity (Kd), experiments were performed using a fixed amount 
of rat brain purified CRMP-2 protein and increasing CaV2.2-GST-Glu fusion proteins.  
 
2.14.  Transfection/Infection of Hippocampal neurons 
Adherent hippocampal cultures were transfected with cDNAs using Lipofectamine 2000 
(Invitrogen) as per the manufacturer’s instructions or infected with lentivirus expressing CRMP-2 
or scrambled shRNAs.  I routinely achieve about 10–15% transfection efficiencies in 
hippocampal neurons transfected with this method.  With lentiviral infections, I have observed up 
to 95% infection in ≤7 days.  Typically, cultured neurons were transfected with equal amounts of 
different cDNA constructs at 10-12 DIV, and electrophysiology experiments performed two days 
later. 
 
2.15.  Construction of pLL3.7-CRMP-2 shRNA, pLL3.7 CaV2.2 shRNA, and control shRNA 
lentiviral shuttle vectors 
Primers were designed containing the published target sequence against rat CRMP-2 [5′-
GTAAACTCCTTCCTCGTGT-3′] (Uchida et al., 2005) or the novel CRMP-2 target sequence 
  
 
75 
Table 2.4 Primers used to generate shRNA constructs and CRMP-2 mutants 
Primer 
name 
Sequence (5’3’) Restriction Enzyme 
CRMP-2 
shRNA 1 
 
TGTAAACTCCTTCCTCGTGTTTCAAGAGAACACGAGGAAGGAGTTTACTTTTTTC 
Hpa I and Xho I 
TCGAGAAAAAAGTAAACTCCTTCCTCGTGTTCTCTTGAAACACGAGGAAGGAGTTTACA 
CRMP-2 
shRNA 2 
TGCCTATTGGCAGCCTTTGATTCAAGAGATCAAAGGCTGCCAATAGGCTTTTTTC 
Hpa I and Xho I 
TCGAGAAAAAAGCCTATTGGCAGCCTTTGATCTCTTGAATCAAAGGCTGCCAATAGGCA 
Scramble 
shRNA 
TGACTTCGATCCTCGTACTTTTCAAGAGAAAGTACGAGGATCGAAGTCTTTTTTC 
Hpa I and Xho I 
TCGAGAAAAAAGACTTCGATCCTCGTACTTTCTCTTGAAAAGTACGAGGATCGAAGTCA 
CRMP-2 
KDR 
CCACGGGGTAAATAGCTTCCTCGTGTAC 
NA 
GTACACGAGGAAGCTATTTACCCCGTGG 
CRMP-2 
S522A 
CATCAGCTAAGACAGCCCCTGCCAAGCAG 
NA 
CTGCTTGGCAGGGGCTGTCTTAGCTGATG 
CRMP-2 
S522D 
CATCAGCTAAGACAGACCCTGCCAAGCAG 
NA 
CTGCTTGGCAGGGTCTGTCTTAGCTGATG 
CRMP-2 
T555A 
CCCGCCGCACCGCCCAGCGCATC 
NA 
GATGCGCTGGGCGGTGCGGCGGG 
CRMP-2 
T555E CCCGCCGCACCGAACAGCGCATC NA 
GATGCGCTGTTCGGTGCGGCGGG 
For shRNA sequences: blue = target/scramble sequence, green = loop sequence, red = poly A terminator, black = restriction site mimic 
NA = not applicable for the sequence (i.e. mutagenic primer) 
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[5’-GCCTATTGGCAGCCTTTGA-3’] and harboring Hpa I and Xho I restriction sites.  Primers 
(sense and antisense) were annealed, by heating to 90°C then slowly cooling to RT, and then 
ligated into the previously digested pLentilox3.7 (pLL3.7; generous gift of our collaborator, Dr. 
Michael R. Vasko, IUSM) to create the pLL3.7-CRMP-2-v1 and pLL3.7-CRMP-2-v2 expression 
vectors.  Scrambled shRNA sequences with the same percentage of GC but no sequence 
homology were used to create control lentiviral vectors.  Primers are shown in Table 2.3.  
 
2.16.  Recombinant lentivirus production 
Self-inactivating LV vectors were packaged as described (Zufferey, 2002). Human 
embryonic kidney (HEK) 293T cells were transfected with a 4-plasmid vector system, i.e., the 
shuttle plasmid (LV-CRMP-2 shRNA-v1-CMV-EGFP, LV-CRMP-2 shRNA-v2-CMV-EGFP or 
LV-Scrambled shRNA-CMV-EGFP) and the packaging plasmids pMDMg/pRRE, pRSV-Rev, 
and pCMV-VSV-G, to provide the VSV-G envelope.  Two days post-transfection, the virus-
containing medium was collected, and debris removed by centrifugation.  Virus was concentrated 
by ultracentrifugation, and the viral pellet was suspended in DMEM supplemented with 10% 
FBS, passed through a 0.45 μm filter and frozen at -80°C.  The viral titer, as determined by 
analysis of the virus-associated p24 core protein (QuickTiter Lentivirus Quantification Kit (Cell 
Biolabs)), was above 2×108 TU/ml for all viruses used in this thesis.  Virus particles were 
produced in the SNRI’s Viral Production Core Facility staff.  
 
2.17.  Electrophysiological recordings of whole cell Ca2+ currents from hippocampal neurons 
Whole-cell calcium currents were isolated using the following solutions: external (bath) 
medium (in mM): NaCl 128, KCl 5, MgCl2 1, BaCl2 10, D-glucose 10, HEPES-Na 10, and 
tetraethylammonium-Cl 10; with an osmolarity of 300 mosm/l and pH 7.3; patch electrode 
intracellular solution: CsCl2 110, EGTA 10, MgSO4 1, HEPES(Cs) 25, ATP 2, and GTP 0.2; 
osmolarity 305 mosm/l, pH 7.4. Tetrodotoxin (1 µM; Alomone Laboratories) and nifedipine (1 
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µM; Calbiochem, La Jolla, CA) were added in the bath solution to block Na+ and L-type Ca2+ 
channels. Under these conditions, the primary Ca2+ current component should be of N- and P/Q-
type with some R-type Ca2+ current (Zhang et al., 1993).  Cells were held at a holding potential of 
–80 mV.  Current to voltage relations were assessed using a standard, incrementing 10 mV step 
depolarizing pulses at 1 sec intervals. Leak currents were subtracted on line using a -P/5 
procedure. Data was acquired using an EPC-10 amplifier (HEKA Electronics) and analyzed using 
Pulsefit (v8.5, HEKA) and Origin 7.0 software (Microcal, Northampton, Mass., USA).  All 
experiments were performed by Drs. Cummins, Wang, and Piekarz. 
 
2.18.  Cell surface biotinylation of hippocampal and cortical neurons 
Hippocampal neurons grown for 10 DIV were transfected with EGFP or CRMP-2–EGFP 
for 2 days and then processed for biotinylation experiments.  Cortical neurons were grown for 7 
DIV before being exposed to TAT peptides +/- glutamate/ glycine stimulation.  Live cells were 
incubated with sulfosuccinimidyl 2-(Biotinamido) Ethyl-1,3’Dithiopropionate (EZ-link Sulfo 
NHS-SS-biotin; 1 mg/mg protein, Pierce) for 30 min at 4°C in cold PBS, pH 8.0. Excess biotin 
was quenched with PBS containing 100 mM glycine, washed 3× with ice-cold PBS and the pellet 
was resuspended in RIPA lysis buffer.  The resuspended pellet was triturated 10× (25-gauge 
needle) and centrifuged at 100,000 x g for 20 min.  The biotinylated proteins were separated from 
clear solubilizate by adsorption onto Streptavidin agarose beads (Novagen) for 2–4 h at 4°C.  
Beads were washed 3–5× with RIPA buffer, and bound biotinylated proteins were gently eluted 
off the beads with RIPA buffer containing 2% Triton X-100 and 650 mM NaCl by end-over-end 
incubation for 1 h at 30°C.  The biotinylated fraction was subjected to immunoblotting with 
CRMP-2 and CaV2.2 antibodies.  To ensure that the cells remained intact throughout the surface 
labeling, biotinylation of β-tubulin, a cytosolic protein, was analyzed by immunoblotting. 
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2.19.  glutamate release assay – HPLC 
glutamate released into the cytosol in CRMP-2-overexpressing or ablated hippocampal 
neurons was measured by HPLC separation and electrochemical detection of the o-
phthaldialdehyde-mercaptoethanol derivative using modifications of the methods of Donzanti & 
Yamamoto (Donzanti and Yamamoto, 1988).  Using this method, the minimal detectable amount 
of glutamate is ~2.5 pmol.  Following a series of washes in phosphate buffered saline, and a 1 h 
incubation in normal Tyrode’s buffer, 400 μl samples were sequentially collected every 10 min 
from the cytosol: (1) bathed in Tyrode’s buffer, (2) bathed in Tyrode’s buffer in the absence or 
presence of drug, (3) in high K+ Tyrode’s, and (4) re-bathed in Tyrode’s buffer.  These samples 
were collected on ice, filtered with 0.22 μm filters (Millipore), and processed for HPLC analyses.  
The resulting four values represent basal 1, +drug, stimulated, and basal end for each sample. 
Samples were processed in triplicate and averaged to yield a single value.  
Several measures were used to ensure that comparable numbers of viable cells were 
present in all wells within a dish.  The average basal releases of neurotransmitter from each 
treatment group (in the absence of drug) in an experiment were within 20% of each other.  The 
cells exhibited robust KCl-stimulated neurotransmitter release at least three-fold over the basal 
levels.  Post-treatment basal release (in the absence of drug) was measured in some glutamate 
assays and was not more than 50% higher than initial basal levels indicating that the release assay 
did not damage the cells or induce cell lysis.  These observations when taken together indicate 
that similar numbers of neurotransmitter releasing cells were present in all wells within an 
experiment. 
 
2.20.  Culturing Catecholamine A Differentiated (CAD) cells 
CAD cells were grown at 37°C and in 5% CO2 (Sarstedt) in Ham's F12/EMEM medium 
(GIBCO), supplemented with 8% fetal bovineserum (FBS; Sigma) and 1% 
penicillin/streptomycin (100% stocks, 10,000U/ml penicillin G sodium and 10,000 µg/ml 
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streptomycin sulfate) (Wang and Oxford, 2000).  Cells were passaged every 6-7 days at a 1:25 
dilution. 
 
2.21.  Generation of CRMP-2 DsRed and CRMP-2 mutants 
Mouse CRMP-2 cDNA (mus musculus accession # NM_009955.3) was cloned into 
pDsRed2-N1 using PCR amplification followed by restriction digest and ligation.  All mutations 
were made as previously described using Quikchange II XL (Agilent Technologies, Santa Clara, 
CA) using primers as listed in Table 2.3 and verified by DNA sequencing. 
 
2.22.  Knock-down of gene expression by siRNA 
Validated siRNAs against the rat CRMP-2 [5′-ACTCCTTCCTCGTGTACAT-3′] 
sequence and controls (scrambled sequence with approximately the same percentage of GC but 
no sequence homology) were used for CRMP-2 knockdown (Invitrogen, Carlsbad, CA). Cells 
were incubated for 2-4 days with vector-siRNA or scrambled siRNA (50-1000 nM optimized for 
each condition) and assessment of knock-down was performed by western blot.  
 
2.23.  Treatment of hippocampal neurons with kinase inhibitors 
P2 hippocampal neurons DIV 9 were treated with either vehicle (0.1% Methyl-2-
pyrrolidone; MPL), 10 μM Purvalanol A, or 10 μM Y27632.  Purvalanol A is a Cdk5 specific 
inhibitor where a dose of 10 μM has been previously shown to reduce phosphorylation of CRMP-
2 in culture (Cole et al., 2006; Gray et al., 1999; Patrakitkomjorn et al., 2008).  Y27632 is a 
ROCK specific inhibitor with an IC50 = 0.7 μM, which was used at 10 μM to ensure complete 
inhibition (Uehata et al., 1997).  Neurons were treated for 1, 2, or 18 hours with the drugs before 
being washed in PBS and removed from the culture dishes using a cell scrapper.  Cells were then 
lightly spun at 10,000x g for 2 min to pellet the cells, which were subsequently resuspended in 
mild lysis buffer by gentle pipetting before incubating at 4°C for 10 min with continual agitation.  
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Lysates were then spun at 10,000x g for 20 min to remove and insoluble material.  The 
supernatant was saved and used in subsequent immunoblotting analysis. 
 
2.24.  Fura-2 Ca2+imaging of transfected cortical neurons 
E18 cortical neurons were plates on poly D-Lysine coated glass bottom 35 mm dishes 
(World Precision Instruments).  At 7-8 DIV cells were co-transfected with pDsRed-CRMP-2 
KDR constructs (WT, S522A, S522D, T555A, T555E) and/or 200 nM CRMP-2 siRNA using 
Lipofectamine 2000 (Invitrogen).  Two days following transfection Ca2+ imaging experiments 
were performed.  Neurons were loaded with 3 μM Fura-2AM (Invitrogen) in Tyrode’s buffer 
(119 NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2, 25 HEPES pH 7.5, 30 Glucose, concentrations in mM) for 
25 min at RT in the dark.  Neurons were then washed 3x with Tyrode’s buffer and transferred to 
the imaging stage.  Changes in intracellular calcium was measured by digital video 
microfluorometry with an intensified CCD camera coupled to a microscope and monitored using 
Nikon Elements Software (Nikon Instruments Inc., Melville, NY).  Cells were illuminated with a 
Lamda DG-4 175 W xenon lamp, and the excitation wavelengths of the fura-2 (340/380 nm) were 
selected by a filter changer.  Cells were observed using DIC prior to beginning experiments to 
verify cells were healthy and intact.  Fura-2AM fluorescence (F340/F380) was measured every 10 
seconds in order to minimize photo-bleaching.  After a baseline of at least 6 images was obtained, 
neurons were stimulated by addition of Excitatory Tyrode’s buffer to a final concentration of 
46.25 mM KCl.  Neurons were then imaged for an additional 7 minutes following stimulation.  
Cells which had either F340 or F380 drop below that of background (an area without any cells 
present) were disregarded from the analysis.   
  
2.25.  Purification of CRMP-2-6xHis 
The vector pET28B containing CRMP-2-His, a kind gift from Dr. Rihe Liu (University 
of North Carolina) was used to express CRMP-2-6xHis in bacteria.  CRMP-2-His protein was 
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grown as previously described for GST-fusion proteins except the bacterial pellet was 
resuspended in His lysis buffer.  The resuspended pellet was then lysed using the microfluidizer 
and clarified by spinning at 30,000 x g for 45’ at 4°C.  The supernatant was then filtered through 
a 0.45 μm syringe filter.  The filtered supernatant was loaded onto a TalonTM metal affinity resin 
(Clontech, Mountain View, CA) column pre-equilibrated with His wash buffer.  Column was 
washed with 2x column volumes of His wash buffer and the eluted with His elution buffer.  
Elution fractions were separated by SDS-PAGE and fractions containing CRMP-2 were 
combined.  The combined elution fractions were then dialyzed against protein storage buffer.  
Purified protein concentration was determined using a bovine serum albumin curve on a SDS-
PAGE stained by comassie and protein identity was verified by immunoblotting. 
 
2.26.  In vitro phosphorylation of CRMP-2-His by Cdk5/GSK3β   
CRMP-2-6xHiswas phosphorylated in vitro as previously described with minor 
modifications.  Purified Cdk5-GST (1 μM) and its cofactor, p25-GST (1 μM) were incubated at 
room temperature for 2 hours to activate the kinase.  CRMP-2-6xHis was then incubated in 
Kinase assay buffer (100 mM HEPES pH 7.2, 20 mM MgCl2, 2 mM MgATP, 2 mM DTT) along 
with 200 nM activated Cdk5/p25 and/or 200 nM GSK3β for 1 h at 30°C.   
 
2.27.  Co-immunoprecipitation and western blotting using phosphorylated CRMP-2-6xHis 
Rat brain lysates were generated by homogenization and gentle sonication in a detergent 
free modified RIPA buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, and 1 mM EDTA with 
protease inhibitors).  Lysates were incubated with CRMP-2-6xHis, following phosphorylation, 
and immunoprecipitated with a 6x-His ab (UC Davis/NIH NeuroMab Facility, clone N144/14) 
O/N at 4°C with gentle rotation.  Samples were then incubated with Protein G-agarose for 2 hr at 
4°C before being processed by immunoblotting for CaV2.2 (Origene). 
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2.28.  Purification/enrichment of Ca2+ channels from synaptosomes 
To prepare a rich source of CaV2.2 for the far-Western analyses (see below), 
synaptosomes from P1 neonatal rat brains were solubilized with digitonin and enriched by 
chromatography on WGA-Sepharose as described previously (Westenbroek et al., 1992; 
Westenbroek et al., 1995).  Briefly, 30 PN1 neonatal rat brains were homogenized in 180 ml of 
320 mM sucrose with a glass-Teflon homogenizer.  After a short centrifugation (5000 rpm, 2 
min), the supernatant (SN) was centrifuged (42,000 rpm, 60 min).  The membranes were 
solubilized with 1.2% digitonin, 80 mM sodium phosphate buffer, pH 7.4 for 20 min. 
Unsolubilized material was removed by the centrifugation as before, and the supernatant (S3) was 
poured over a 40 ml WGA-Sepharose column (50 ml/h).  After incubation for 1 hr at 4°C, the 
column was washed with 10 column volumes of WGA-column buffer at a flow rate of 50 ml/hr.  
The glycoproteins bound to the WGA-Sepharose column were eluted with 100 mM N-acetyl-D-
glucosamine (Sigma, St. Louis, MO) in the same buffer at a flow rate of 50 ml/hr.  Three 
milliliter fractions were collected and the protein concentration of each fraction was determined 
by BCA protein assay kit (Thermo Fisher Scientific, Shelbyville, IN).  To further enrich for Ca2+ 
channels, WGA-column fractions were incubated for 4 hr on ice with 200 μl of heparin-agarose 
85.  The resin was washed four times with 0.2% CHAPS, 10 mM Tris-HCl, pH 7.4, and once 
with 10 mM Tris-HCl, pH 7.4. Ca2+ channels were gently extracted for 30 min at 50°C with100 
µl of Heparin extraction buffer. 
 
2.29.  Peptide spots arrays and Far Westerns 
Peptide arrays (10-15 mers) spanning the entire length of rat CRMP-2 were constructed 
using the SPOTS-synthesis method (Edmondson and Roth, 2001; Hall, 2004; Schechtman et al., 
2003; Wu et al., 2007).  Standard 9-fluorenylmethoxy carbonyl (Fmoc) chemistry was used to 
synthesis the peptides on cellulose membranes prederivatized with a polyethylene glycerol spacer 
(Intavis AG).  Fmoc protected and activated amino acids (Intavis) were spotted in 20-30 arrays on 
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150 mm by 100 mm membranes using the Intavis MultiPep robot.  Membranes were probed in a 
far-Western manner with an antibody against CaV2.2 (Calbiochem Inc, La Jolla, CA).  Briefly, 
Peptides (10-15–mers) were immobilized to nitrocellulose membrane which was then soaked in 
10 mM CAPS pH 11.0 and 20% methanol for 30 min, washed once with TBST, and then blocked 
for 1 h at RT with gentle shaking in TBST containing 5% non-fat milk and finally incubated with 
a purified synaptosome fraction enriched in Ca2+ channels for 1 h at RT with gentle shaking.  
Next, the membrane was incubated in primary antibody for CaV2.2 for 2 h at RT with gentle 
shaking, followed by washing with TBST.  Finally, the membrane was incubated in secondary 
antibody (horseradish peroxidase-conjugated goat anti-rabbit; 1:10,000) for 45 min, washed for 
30 min in TBST and developed using enhanced chemiluminescence.   
 
2.30.  Peptides 
TAT-Control (YGRKKRRQRRRWEAKEMLYFEALVIE (TAT sequence denoted in 
underlined text); a random sequence with no homology to any known sequence) TAT-CBD3 
(YGRKKRRQRRRARSRLAELRGVPRGL) were synthesized by Antagene Inc. (Sunnyvale, 
CA). 
 
2.31.  Surface plasmon resonance (SPR) 
Binding analyses between TAT-CBD3 or TAT-Control peptides and CaV2.2 L1- or 
Ctdis-GST fusion proteins was determined by surface plasmon resonance using a BIAcore3000 
instrument (Biacore AB, Uppsala, Sweden)(Richman et al., 2005).  Briefly, binding assays were 
performed using HBS-EP buffer as the running buffer.  The CaV2.2 L1- and Ct-dis GST fusion 
proteins were diluted in HBS-EP buffer and injected at a 10 μl/min flow rate over four flow cell 
surfaces simultaneously using the KINJECT command.  Surface regeneration was performed by 
10-μl injections of 0.05% SDS in HBS-EP buffer at a 20 μl/min flow rate.  Background binding 
to a negative control peptide surface (control) was subtracted from all binding curves using 
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BIAevaluation software version 3.0 (BIAcore Inc.) and plotted using GraphPad Prism version 4.0 
(Graph-Pad Software Inc.). 
 
2.32.  Isolation and maintenance of sensory neurons for electrophysiology 
DRG from young adult rats (~150g) were dissociated and cultured as described 
previously (Koplas et al., 1997).  Spinal cords were rapidly removed from rats before DRGs were 
visually identified and isolated, and then dissociated by a combination treatment with a 
dispase/collagenase cocktail and mechanical disruption through a series of fire-polished glass 
pipettes with a decreasing inner tip diameter.  The resulting suspension of single cells was plated 
on poly-D-lysine-coated coverslips and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Hyclone) and 
100 units/ml penicillin and  100 μg/ml streptomycin for 12-16 hours at 37°C under 5% CO2. 
 
2.33.  Whole-cell patch-clamp recordings from sensory neurons 
Whole-cell voltage recordings were performed at room temperature on primary sensory 
neurons using an EPC 10 Amplifier (HEKA Electronics, Germany).  Electrodes were pulled from 
thin-walled borosilicate glass capillaries (Warner Instruments, Hamden, CT) with a P-97 
electrode puller (Sutter Instrument, Novato, CA) such that final electrode resistances were 2–3 
MΩ when filled with internal solutions.  The internal solution for recording Ca2+ currents 
contained (in mM): 150 CsCl2, 10 HEPES, 5 Mg-ATP, and 5 BAPTA (pH 7.2 with KOH).  The 
external solution contained (in mM); 110 N-methyl glucamine (NMG), 2 CaCl2, 30 TEA-Cl, 10 
HEPES, and 10 glucose; 1 µM TTX and 1 µM Nifedipine were added just before use to block 
voltage-gated Na+ and L-type Ca2+ channels, respectively.  Whole-cell capacitance and series 
resistance were compensated with the amplifier.  Series resistances compensation (70–80%) was 
routinely applied.  Cells were considered only when the seal resistance was more than 1G Ω and 
the series resistance was less than 10 MΩ.  Linear leak currents were digitally subtracted by P/4.  
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Signals were filtered at 10 kHz and digitized at 10-20 kHz. Analysis was performed using 
Fitmaster and origin8.1 (OriginLab Corporation, MA, USA).  For activation curves, conductance 
(G) through ion (Ca2+) channels was calculated using the equation G= I/(Vm −Vrev), where Vrev 
is the reversal potential, Vm is the membrane potential at which the current was recorded and I is 
the peak current.  Activation and inactivation curves were fitted to a Boltzmann function G/Gmax 
= 1/{1+exp[(V–V50)/k]}, where G is the peak conductance, Gmax is the fitted maximal G, V50 is 
the half-activation voltage, and k is the slope factor.  All experiments were performed by Drs. 
Zhu and Wang. 
 
2.34.  Release of iCGRP from rat spinal cord slices 
The release of iCGRP from spinal cord slices was performedby Dr. Duarte using a 
modification of the technique previously described (Chen et al., 1996).  Briefly, rats were 
sacrificed using CO2 asphyxiation and decapitation and the spinal cord from each animal was 
removed and a 2 cm section of the lumbar enlargement was weighed and chopped parasagitally 
and transversely into 300 μm cross-sections using a McIllwain Tissue Chopper.  The sections 
from each spinal cord were placed into individual chambers and perfused at a flow rate of 
0.5ml/min with a HEPES buffer, consisting of HEPES 25 mM, NaCl 135 mM, KCl 3.5 mM, 
MgCl2 1 mM, CaCl2 2.5 mM, dextrose 3.3 mM, bovine serum albumin 1%, ascorbic acid 200 
μM, phe-ala 100 μM, phenylmethanesulfonyl fluoride (PMSF) 10 µM and bacitracin 20 µM, 
aerated with 95% O2–5% CO2, pH 7.4–7.5, and maintained at  36–37°C.  After 30 min, 1.5 ml 
samples were collected into test tubes containing 75 μl of 1 M MES buffer (pH 6.7–6.9) every 3 
min.  Basal release was established by first perfusing the tissue with HEPES buffer for 9 min and 
then with HEPES buffer containing 10 or 20 µM of the TAT-Control peptide or TAT-CBD3 for 9 
min.  To evoke iCGRP release, tissue was then perfused for an additional 9 min with HEPES 
buffer containing 500 nM capsaicin with 10 or 20 µM of the TAT-Control or TAT-CBD3.  To 
demonstrate a return to basal release after stimulation, the tissue was perfused with HEPES buffer 
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alone for another 15 min.  Evoked release is determined by subtracting the values obtained for 
stimulated release from those obtained for basal release.  After the release protocol was complete, 
the spinal cord tissue was recovered and homogenized in 4 ml 0.1 N HCl.  The homogenate was 
centrifuged at 3000 x g for 20 min at 4°C and the supernatant was serially diluted with HEPES 
buffer and assayed for iCGRP by RIA, as previously described (Chen et al., 1996).  The total 
peptide content was the amount of iCGRP released during the perfusion and the amount 
remaining in the tissues.  This value was used to determine the amount of release as % of total 
content. 
 
2.35.  ddC model of peripheral neuropathy   
Hyperalgesia and allodynia were established by a single injection (25 mg/kg) of the 
antiretroviral drug 2′,3′ -dideoxycytidine (ddC, Sigma) given i.p.  A single administration of ddC 
produced a significant bilateral decrease in paw withdrawal threshold to von Frey hair stimulation 
from post-injection day (PID) 3 through the last day of testing at PID42 58.  The von Frey test 
was performed on the area of the hind paws as previously described (LaMotte et al., 1998; Ma et 
al., 2003; Song et al., 1999; Zhang et al., 1999).  Briefly, the rat was placed on a metal mesh floor 
and covered with a transparent plastic dome where the animal rested quietly after an initial few 
minutes of exploration.  Animals were habituated to this testing apparatus for 15 minutes a day, 
two days prior to pre-injection behavioral testing.  Following acclimation, each filament was 
applied to six spots spaced across the glabrous side of the hind paw; two distinct spots for the 
distribution of each nerve branch (saphenous, tibial and sural).  Mechanical stimuli were applied 
with seven filaments, each differing in the bending force delivered (10, 20, 40, 60, 80, 100, and 
120 mN), but each fitted a flat tip and a fixed diameter of 0.2 mm.  The force equivalence of mN 
to grams is: 100 mN=10.197 grams.  The filaments were tested in order of ascending force, with 
each filament delivered for 1 second in sequence from the 1st to the 6th spot alternately from one 
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paw to the other.  The interstimulus interval was 10-15 seconds.  A cutoff value of 120 mN was 
used; animals that did not respond at 120 mN were assigned that value.  
Measurements were taken on 3 successive days before rats were subjected to either TAT-
Control or TAT-CBD3.  Stimuli were applied randomly to left and right hind paws to determine 
the stimulus intensity threshold stiffness required to elicit a paw withdrawal response.  The 
incidence of foot withdrawal was expressed as a percentage of six applications of each filament 
as a function of force.  A Hill equation was fitted to the function (Origin version 6.0, Microcal 
Software) relating the percentage of indentations eliciting a withdrawal to the force of 
indentation.  From this equation, the threshold force was obtained and defined as the force 
corresponding to a 50% withdrawal rate.  A threshold that exhibits at least a -20 mN difference 
from the baseline threshold of testing in a given animal is representative of neuropathic pain.  
Threshold values were statistically analyzed for each foot separately and the significance of 
differences between the average of at least two pre-injection tests and the mean obtained for each 
post-injection test.  In all tests, baseline data were obtained for the ddC-treated and sham-treated 
groups before drug or vehicle administration.  Within each treatment group, post-administration 
means were compared with the baseline values by repeated measures analyses of variance 
(RMANOVA) followed by post hoc pairwise comparisons (Student-Newman-Keuls Method).  A 
probability level of p <0.05 indicates significance.  These experiments were performed by Matt 
Ripsch. 
 
2.36.  Rotarod test for motor coordination   
The rotarod test was performed as described previously (Nakamura et al., 1999; 
Onyszchuk et al., 2008) with slight modifications.  The latency to fall off a rotating rod was 
measured at two different rotational accelerations (fast and slow).  The rotarod device (IITC Life 
Science, Inc., Woodland Hills, CA, USA) consists of a metal rod with hard plastic drums 
(diameter: 1.25 in) in each of five individual lanes.  For slow acceleration, the device was 
 88 
 
accelerated from 1 rpm to 18 rpm over 90 seconds, with each trial lasting a maximum of 120 
seconds.  For fast acceleration, the device was accelerated from 1 rpm to 30 rpm over 90 seconds, 
with each trial lasting a maximum of 120 seconds.  The trials ended when the mouse (C57BL6) 
either fell off the rod or clung to the rod as it made one complete rotation.  The rotarod tests were 
performed before the injection to score the baseline latencies for each animal.  These trials also 
served to acclimate the animals to the test paradigm.  Four trials each of the fast and slow 
acceleration paradigms were performed, and the average of the two middle latencies was taken as 
the baseline.  Following intraperitoneal (i.p.) injection of vehicle or peptides (10mg/kg or 
50mg/kg), the mice were tested with three trials each of fast and slow acceleration.  All 
experiments and analyses were done in a double-blind manner by Dr. Liu.    
 
2.37.  Morris water maze test of spatial/reference memory 
The Morris water maze test was used to test spatial memory(D'Hooge and De Deyn, 
2001).  The maze consisted of a plastic pool (100 cm in diameter and 60 cm in depth) filled with 
water to a depth of 26.5 cm, with a clear Plexiglas stand (10 cm in diameter and 26 cm in height 
[i.e., 0.5 cm below the water’s surface]) used as the hidden goal platform.  The mice were trained 
prior to the injection for 4 consecutive days (4 trials/day).  For each daily block of four trials, the 
mice were placed in the pool facing the wall.  Trials were initiated from each of the four possible 
start locations (north, east, south, west) in a randomized manner.  A maximum of 60 sec was 
allowed for each mouse to find the hidden platform.  If the mouse failed to find the platform 
within the allotted time, it was placed on the platform by the experimenter where it remained for 
30 sec before being placed in a heated incubator between trials (4-min inter-trial interval).  Mice 
were excluded from the study if their average latency to locate the platform on day 4 of the trials 
was greater than 50 sec.  As a control for nonspecific deficits such as visual processing and 
motivation, additional trials were performed with the hidden platform positioned below a ball, 
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which served as a marker.  All experiments and analyses were done in a double-blind manner by 
Dr. Liu. 
 
2.38.  Excitotoxic stimulation by glutamate + glycine/D-serine  
E18-19 cortical neurons (7-8 DIV) grown in 96, 12, or 6 plates were stimulated for 30 
minutes in serum free media in a final volume of 100, 1000, or 2000 μL respectively.  The 
excitotoxic insult was achieved by addition of 200 μM L-glutamate and 20 μM glycine or 100 μM 
D-serine (an NMDAR co-agonist (Mothet et al., 2000)).  Following stimulation, all media was 
removed from neurons and replaced with fresh complete media.  For biochemical experiments 
cells were harvested at the time point indicated.  For cell viability experiments cells were grown 
for 24 hours under normal growth conditions before cell viability was measured.  The cell 
viability of cultured neurons was quantified using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) from Promega.  Following the 24 hour growth period MTS reagent 
was added to each well and incubated for 1 hour at 37°C.  MTS is a tetrazolium analog that is 
converted to the water-soluble blue absorbing formazan by the endogenous reductases of living 
cells (Hansen et al., 1989).  The formation of formazan following incubation with MTS reagent 
was then measured (Viktor3v, Perkin Elmer) by recording the absorbance at 490 nm.  Control 
wells containing media only (no cells) were used to subtract the background absorbance from the 
neuronal culture media.     
  
2.39.  In vitro calpain cleavage 
Lysates were freshly prepared from E18-19 brains using a mild lysis buffer.  Rat brains 
were homogenized then allowed to lyse for 30 minutes before clarifying by centrifugation at 
15,000 x g for 20 minutes.  The soluble protein fraction was removed and used the same day for 
cleavage experiments.  Lysates were incubated with TAT-CBD3 or MDL28170 for 10 minutes 
prior to addition of 20 mM CaCl2.  Lysates were then incubated at RT for 30 minutes to allow for 
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proteolytic cleavage.  Reactions were stopped by addition of SDS loading buffer and then 
processed for immunoblotting.  
 
2.40.  In vitro measurement of calpain activity 
Lysates were prepared as described above and incubated for 10 minutes with vehicle 
(0.2% DMSO), TAT-CBD3 (10 μM) or MDL-28170 (50 μM) prior to addition of 20 mM CaCl2.  
The fluorogenic calpain substrate t-Boc-Leu-Met-CMAC (t-Boc, 10 μM) was then added to the 
lysates.  Samples were then transferred to a 96 well plate and incubated for 30 minutes at 37°C.  
Cleavage of t-Boc was assayed by measuring fluorescence using a plate reader (Viktor3v, Perkin 
Elmer, Covina, CA) with a 355 nm excitation filter and a 460 nm emission filter (Kennett et al., 
2004).  Wells containing t-Boc alone were used to subtract background fluorescence.  
Background subtracted values were then normalized to vehicle treated samples. 
 
2.41.  Calcium imaging of glutamate and NMDA evoked Ca2+-fluxes 
Cortical neurons were loaded at 37°C with 2.6 µM Fura-2FF-AM (Kd=25 μM, λex 340, 
380 nm/λemi 512 nm) or Fura-2-AM (Kd=224 nM) to follow changes in [Ca2+]c in standard bath 
solution.  Fluorescence imaging was performed with an inverted microscope, Nikon Eclipse 
TE2000-U, using objective Nikon Super Fluor 20× 0.75 NA and a Photometrics cooled CCD 
camera CoolSNAPHQ (Roper Scientific, Tucson, AZ) controlled by MetaFluor 6.3 software 
(Molecular Devices, Downingtown, PA).  The excitation light was delivered by a Lambda-LS 
system (Sutter Instruments, Novato, CA).  The excitation filters (340±5 and 380±7) were 
controlled by a Lambda 10-2 optical filter change (Sutter Instruments, Novato, CA).  The 
excitation filters (340±5 and 380±7) were controlled by a Lambda 10-2 optical filter change 
(Sutter Instruments, Novato, CA).  Fluorescence was recorded through a 505 nm dichroic mirror 
at 535±25 nm.  To minimize photobleaching and phototoxicity, the images were taken every 15 
seconds during the time-course of the experiment using the minimal exposure time that provided 
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acceptable image quality.  The changes in [Ca2+]c were monitored by following a ratio of 
F340/F380, calculated after subtracting the background from both channels.  [Ca2+]c was 
calculated using the Grynkiewicz equation using KD= 25 µM for Fura-2FF and KD= 224 nM for 
Fura-2 (Grynkiewicz et al., 1985).  All of these experiments were performed by Tatiana 
Brustovetsky. 
 
2.42.  SEP fluorescent microscopy 
E18-19 cortical neurons, transfected with NR2B-SEP DNA using lipofectamine 2000, 
were imaged on a Nikon Ti swept-field confocal microscope using a 60x, 1.4 numerical aperture 
lens and a standard fluorescein isothiocyanate cube with a cooled Cascade 512B digital camera 
(Photometrics, Tucson, AZ).  Neuronal somatic fluorescence was measured by digital video 
microfluorometry with an intensified CCD camera coupled to a microscope and Nikon Elements 
Software (Nikon Instruments Inc., Melville, NY).  Cells were bathed and all drugs were diluted in 
extracellular solution.  Experiments were completed at room temperature and images were taken 
every 15 (spines) or 10 (soma) seconds to prevent photo-bleaching.  After completing each 
imaging experiment SEP fluorescence was quenched by the addition of acetic acid (final pH 5.5).  
Finally cellular integrity was verified by differential image contrast microscopy. 
 
2.43.  Hippocampal neuron whole cell voltage-clamp electrophysiology of NMDA Ca2+-currents 
Whole-cell voltage-clamp recordings were performed on rat hippocampal neurons 
(DIV7-11) days in culture (Khosravani et al., 2008), at room temperature using an Axopatch 
200B amplifier (Axon Instruments, Union City, CA), with a holding potential of -60 mV.  The 
NMDAR external solution contained (in mM): 140 NaCl, 5 KCl, 1 CaCl2, 25 HEPES and 33 D-
glucose, pH adjusted to 7.4 with NaOH.  The external solution was supplemented with 0.5 μM 
TTX (Tocris Bioscience, UK), 100 μM picrotoxin, 100 μM glycine.  The internal pipette solution 
was composed of (in mM): 120 CsCl, 35 CsOH, 11 EGTA, 1 CaCl2, 2 MgCl2 and 10 HEPES, 4 
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ATP (tris salt) and 20 phosphocreatine (tris salt) and creatine phosphokinase 50 U/ml, pH 
adjusted to 7.3 with CsOH. 
Drug delivery was controlled by a Valvelink8.2 perfusion system (Automate Scientific 
Inc., Berkeley, CA) with a pressurized superfusion device to achieve fast switching of solution. 
NMDA current was evoked by application of NMDA (50 μM, Tocris Bioscience) for 2 s every 30 
s.  During experiments, control NMDA current was stabilized for 5 mins (10 traces, with peak 
current fluctuation within 5%) before TAT-CBD3 application.  Data were analyzed using 
Clampfit (Axon Instruments), Origin 7 (OriginLab) and Prism 5 (GraphPad Software Inc.).  All 
of these experiments were performed by Dr. Haitou You.  
 
2.44.  Co-immunoprecipitations with CRMP-2 and NR2B 
Co-immunoprecipitations were performed on freshly prepared or flash frozen lysates.  
For co-immunoprecipitations in the presence of TAT peptides, lysates were incubated with 100 
µM TAT-Control or TAT-CBD3 or an equal volume of vehicle (DMSO) for 1 hour at 37°C prior 
to addition of the primary antibody.  Lysates were incubated with the primary antibody of interest 
under gentle agitation for 2 hours or overnight at 4°C.  Samples were then clarified to remove any 
additional precipitate and incubated with Protein A/G Plus for rabbit primary antibodies or 
Protein G Plus agarose for mouse primary antibodies (Santa Cruz Biotechnology) for 2 hours at 
4°C.  The immune-captured complexes were then washed three times with lysis buffer before 
being boiled in equal volumes of SDS loading dye (Invitrogen).  Samples were then processed by 
immunoblotting. 
 
2.45.  P2 membrane preparation from Rat brains 
Enrichment for the plasma membrane fraction of rat brains was performed as previously 
described (Aarts et al., 2002).  Approximately 10 PN2 rat brains were homogenized in Sucrose 
homogenization buffer with 2 mM NaOV4.  The homogenate was spun at 800x g for 10 min to 
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remove any insoluble homogenate.  The supernatant was then spun at 11,000x g for 20 min 
producing a pellet consisting of enriched plasma membranes.  The pellet was resuspended in 
Sucrose homogenization buffer and quantified.  The resuspended pellet was then diluted and 200 
μg/90 μl at a final concentration of 1% sodium deoxycholate and 0.1 % Triton X-100 before 
incubating at 37°C for 30 min.  The lysates was then spun at 100,000x g for 10 min to clarify the 
lysates.  Aliquots of 200 μl were then flash frozen on dry ice and stored at -80°C. 
 
2.46.  Statistical Analyses  
Differences between means were compared by either paired or unpaired two-tailed 
Student’s t–tests or an analysis of variance (ANOVA) when comparing multiple groups. With the 
ANOVA, if a significant difference is determined, then either Tukey’s or Dunnett’s post-hoc was 
performed unless otherwise noted. Data is expressed as mean±S.E.M, with p < 0.05 considered as 
the level of significance. Imaging (ICA/ICQ) values were either tested for two means between 
conditions (P) or for one mean for a difference from 0 (P=0).  Each hippocampal ICQ value 
reflects the mean of two determinations from image planes at least 400 nm apart (two z axis 
increments). The normal approximation to the sign test was used for statistical tests of ICQ values 
for single experiments. 
 
2.47.  Accession numbers 
Accession numbers for the clones used in this thesis are: NM_147141 for α1B (CaV2.2), 
NM_009955.2 for CRMP-2, AB012697.2 for Munc18-1, and NM_012574 for NR2B. 
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CHAPTER 3.  REGULATION OF CaV2.2 BY CRMP-2 
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3.1. Introduction 
The role of CRMP-2 in synaptic regulation has yet to be properly explored.  It is known 
that CRMP-2 is important for axon path finding and neuronal polarity (Arimura et al., 2004; 
Schmidt and Strittmatter, 2007).  By inference then, it is possible that CRMP-2 may be important 
for proper synapse formation given that neurons must polarize and send their axons to the proper 
dendritic fields to form intended synaptic connections.  In Chapter 4, I will focus on CRMP-2 and 
the post-synaptic NMDAR which has been proposed to be modulated by CRMP-2 (Al-Hallaq et 
al., 2007; Bretin et al., 2006), which, at the time I began my dissertation work, was the only 
report that provided a potential link between CRMP-2 and modulation of synaptic function.  One 
additional study reported the presence of a closely related CRMP-4L (long isoform) homolog 
in synaptic vesicles (Quinn et al., 2003).  Thus, a goal of my thesis work was to focus on the 
potential role of CRMP-2 in synaptic biology.   
Proteomic studies conducted by Dr. Khanna’s laboratory and others had identified 
CRMP-2 as a putative interacting partner of CaV2.2 (Khanna et al., 2007c; Muller et al., 
2010).  Enriched at functional release sites, CaV2.2 forms part of a large macromolecular 
complex, which facilitates efficient neurotransmitter release.  Identification and analyses of a 
litany of protein-protein interactions within the nerve terminal have demonstrated a functional 
coupling between presynaptic Ca2+ channels and the transmitter release machinery (Catterall and 
Few, 2008; Davies and Zamponi, 2008; Kisilevsky and Zamponi, 2008b; Stanley, 1997). 
 Although neurotransmission was not affected in CRMP-1 knockout mice (Su et al., 2007), long-
term potentiation, spatial learning and memory were affected in both CRMP-1 and CRMP-3 
knockout mice (Quach et al., 2008; Su et al., 2007), suggesting a role for CRMPs in 
neurotransmission as well as synaptogenesis.  As potential binding partners, CRMPs could affect 
neurotransmission by either a physical interaction with the synaptic machinery or CaV2.2 itself. 
 Therefore, in this Chapter I sought out to confirm that CRMP-2 was indeed a bona fide binding 
partner of CaV2.2, determine the functional consequence of this interaction, determine how 
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signaling between the two proteins occurred and if it affected release of neurotransmitter.  Given 
the unequivocal ties between CaV2.2 and chronic pain treatments (see §1.1.10), I also sought to 
target the interaction between CRMP-2 and CaV2.2 with the idea that disruption of this 
interaction could be an alternative approach to discovering useful tools for pharmacological 
investigations of calcium channels as well as potential pharmacotherapeutics for management of 
chronic pain.  Part of the work in this Chapter has been previously presented in several 
publications (Brittain et al., 2011b; Brittain et al., 2009; Brittain et al., 2012b).  
 
3.2.  Subcellular and synaptic localization of CRMP-2 and CaV2.2 
CRMP-2 is extensively expressed in neurons, although the exact subcellular localization 
as it relates to the synapse has not been described (Wang and Strittmatter, 1996; Wang and 
Strittmatter, 1997).  Therefore, in order to determine if CRMP-2 is able to interact with CaV2.2 I 
first sought to determine if it is present in the proper subcellular domains.  Synaptic structures can 
be enriched from brain tissue using differential centrifugation and a discontinuous sucrose 
gradient yielding a so-called “synaptosome” (Huttner et al., 1983; Takamori et al., 2006).  As 
expected the synaptosome fraction (P2’) isolated from neonatal PN1 rat brain contained synaptic 
proteins including CaV2.2, the AMPAR subunit GluR2, and Munc18 (Figure 3.1A).  All five 
CRMP proteins were present in synaptosomes, with CRMP-2 being relatively more abundant 
than the other CRMPs.  This finding shows that CRMP-2 is present in the synaptosome and 
therefore in the same subcellular compartment as CaV2.2.  Next, sucrose density gradient 
fractionation of PN1 rat brains revealed co-sedimentation of CRMP-2 and CaV2.2 in both 
cholesterol rich/cytosolic (lanes 5–8, Figure 3.1B, C) and membrane fractions (lanes 9–12, Figure 
3.1B, C), consistent with cytosolic and membrane distribution of both proteins.   
Now having shown that CRMP-2 is present in some of the same subcellular fractions as 
CaV2.2 I wanted to further delve into its localization within the synapse.  In order to study this I 
employed a technique to separate the synaptic and extrasynaptic regions of the synaptosome.  
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Figure 3.1.  Neuronal subcellular localization of CRMP-2 
(A) Western blots of CaV2.2, CRMPs 1-5 and synaptic proteins Munc18 and the glutamate 
receptor 2 subunit (GluR2) in homogenate (H), pellet (P1), supernatant (S2) and synaptosomes 
(P2’) of PN1 rats. (B, C) CRMP-2 and CaV2.2 are present in both cytosolic (lanes 5–8) and 
membrane (lanes 9–12) fractions in sucrose density gradients from PN1 rat brain 
synaptosomes. Summary of fractionation data represents mean ± SEM of four experiments.  
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Figure 3.2.  Synaptic and Extrasynaptic localization of CRMP-2 
(A) Synaptic and extrasynaptic fractions of PN1 rat brains were isolated using differential 
centrifugation along with the Triton-X100 insolubility property of synaptic PSD-95. (B) 
Immunoblots display protein localization to the various neuronal fractions.  An equal amount 
of protein from each fraction was loaded to compare the relative amount of protein present in 
the various fractions.  Fractions and percent loaded are as follows: LP1 (~0.8%): intracellular 
membranes, LS1 (~0.1%): cytosol non-membrane, P2 (~0.3%): Synaptosome, TxP (~1.2%): 
synaptic fraction, TxS (~0.4%): extrasynaptic, kDa: kilo-Daltons. 
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Using differential centrifugation and detergent selective sedimentation the PSD-95 associated 
synaptic fraction can be isolated.  PSD-95 is known to be insoluble in Triton-X100 that can be 
used to isolate the extrasynaptic fraction from the synaptic (Cotman and Taylor, 1972; Matus and 
Taff-Jones, 1978).  This method was verified by the selective presence of PSD-95 in the Triton 
X100 insoluble pellet (TxP) otherwise known as the synaptic fraction (Figure 3.2).  The NR2B 
subunit of the NMDAR was also found primarily in the synaptic fraction.  As would be expected 
given its role in synaptic transmission, CaV2.2 was found in the synaptic fraction.  Both of these 
Ca2+ channels were not present in the cytosolic light soluble fraction (LS1), but were in the light 
pellet fraction (LP1) that is composed of intracellular membranes.  Interestingly, CRMP-2 was 
present, in varying degress, in all fractions including the membrane and cytosolic fractions as 
well as the synaptic and extrasynaptic fractions although at much lower quantities.  
 
3.3.  Biochemical complex containing CaV2.2 and CRMP-2 
Finally, to confirm that CRMP-2 has a bona fide interaction with CaV2.2, standard co-
immunoprecipitations and immunoblotting were performed. Precipitation of CaV2.2 with a 
polyclonal CaV2.2 antibody or a polyclonal CRMP-2 antibody from PN1 rat brain synaptosomes 
reliably precipitated the associated protein (Figure 3.3A).  No proteins were observed in control 
immunoprecipitations using rabbit isotype-specific IgG antibodies.  The interaction of CaV2.2 
and CRMP-2 was also observed in hippocampal neurons cultured for 14 DIV (Figure 3.3B).  
Thus, biochemical evidence clearly shows that CRMP-2 and CaV2.2 co-exist in a complex.    
Immunocytochemistry on PN1 rat hippocampal neurons revealed the presence of CRMP-
2 in soma, dendrites, neurite shafts, as well as in punctate structures. An overlap was observed in 
the staining patterns for CRMP-2 and CaV2.2 in the soma as well as in presynaptic varicosities 
(Figure 3.3C). ICA was used to quantitatively assess the colocalization (Khanna et al., 2007a; 
Khanna et al., 2007b; Khanna et al., 2006a).  This method tests if staining for two proteins co-
vary, as they should if the two proteins are part of the same complex.  This test generates an ICQ, 
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Figure 3.3.  CRMP-2 is in the same biochemical complex as CaV2.2 
(A)  CRMP-2 and CaV2.2 co-immunoprecipitate reciprocally from purified synaptosomes.  
(B)  Immunoblot with CaV2.2 antibody showing that CRMP-2 and CaV2.2 co-
immunoprecipitate from purified hippocampal neurons grown for 14 days in vitro (DIV).  The 
bottom blot, probed with CRMP-2 antibody, represents 10% of the lysates used in the IPs.  
(C)  Double labeling of endogenous CRMP-2 (green) and CaV2.2 (red) in cultured 
hippocampal neurons.  Enlarged regions show co-localization of both proteins at the cell 
surface of the soma and in punctate structures along neurites (i, ii).  (D)  Merged and black 
and white confocal images of region ii from a. Quantitative co-localization analysis shows a 
moderate to strong skew in the intensity correlation analysis (ICA) plots for CaV2.2 and 
CRMP-2, indicative of staining pairs that vary in synchrony.  The intensity correlation 
quotient (ICQ) of the region in ii was 0.178.  Rbt IgG, isotype-specific rabbit IgG (control) 
antibody. 
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which ranges from –0.5 to +0.5 and can be used for statistical comparison.  ICA plots of CaV2.2 
and CRMP-2 staining of the soma cell surface, in the axons, and in boutons/dendritic spines (see 
examples in Figure 3.3 C, D) exhibited varying degrees of positive skews, suggesting strong to 
moderate levels of covariance. The mean ICQ values were 0.078±0.017 (axons, n=12, P=0 
<0.001), 0.038±0.052 (surface of soma, n=7, P=0 <0.001), and 0.245±0.073 (boutons/dendritic 
spines, n=9, P=0 <0.001). 
 
3.4.  CaV2.2 and CRMP-2 regions responsible for CaV2.2-CRMP-2 complex 
To identify regions of CRMP-2 and CaV2.2 that are responsible for the interaction 
between CRMP-2 and CaV2.2, in vitro pull down assays were performed to assess binding.  First, 
I purified bacterially expressed GST-fusion proteins of full length CRMP-2 or fragments and 
incubated them with PN1 rat synaptosomes.  To ensure that the synaptosomes contained a 
sufficient amount of CaV2.2, the channels were partially purified with wheat-germ agglutinin as 
described by Catterall and colleagues (Westenbroek et al., 1992) followed by enrichment with 
heparin-agarose.  The in vitro complexes were recovered by incubation with glutathione 
sepharose beads, washed extensively and immunoblotted with a CaV2.2 antibody.  CaV2.2 bound 
to full-length CRMP-2 (Figure 3.4A, B).  Within CRMP-2, three regions of interactions were 
determined: a region in the CRMP-2 N-terminus (residues 94-166), a region in the middle of the 
protein (residues 212–297), and one near the C-terminus of the CRMP-2 protein (residues 479-
500), proximal to the microtubule binding domain ( (Figure 3.4B).  These regions, designated 
CaV binding domains (CBDs) 1–3 are identified in the crystal structure of CRMP-2 tetramer 
(RCSB databank PDB code: 2GSE; Figure 3.4C) (Deo et al., 2004); for clarity, the CBDs are 
identified only on monomer 1. Interestingly, the CBD3 interaction lies near the oligomerization 
domain of the tetrameric CRMP-2 protein (Figure 3.4C). A large portion of CBD2 appears to be 
buried within the CRMP-2 tetrameric structure and may interfere with binding of the other CBDs 
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Figure 3.4.  Mapping binding sites between CRMP-2 and CaV2.2 
(A)  Binding experiments pulling down CaV2.2 from synaptosomes using CRMP-2 GST 
truncation mutants.  Bound proteins were analyzed by Western blotting with an antibody for 
CaV2.2 and CRMP-2 GST mutants visualized by coomassie staining.  (B)  Three CaV binding 
domains (CBDs) on CRMP-2 were observed – residues 94-166, designated CBD1; yellow, 
residues 212-297, CBD2; orange, residues 479-500, CBD3; red).  (C)  These regions (CBD1, 
CBD2, and CDB3) are identified in the crystal structure of CRMP-2, regions present in 
monomer 1 only (RCSB databank PDB code: 2GSE).  Images were rendered using PyMol (v. 
0.99). 
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Figure 3.5.  Details of the boundaries for the intracellular regions of CaV2.2  
(A)  Diagram depicting the protein sequence of CaV2.2 as it relates to the transmembrane and 
intracellular regions and the nomenclature used for these regions.  (B)  Table displaying the 
specific nucleotides and amino acids of the intracellular regions and the subdivisions used for 
cloning of these intracellular regions.  Nucleotides are from the rat cDNA sequence accession 
#NM_147141. 
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by an as yet unclear mechanism. This is consistent with the demonstration of large segments of 
the CRMP protein being involved in oligomerization (Wang and Strittmatter, 1997). 
The alpha subunit of CaV2.2 is 2399 amino acids long and has 4 domains with each of 
domains containing 6 transmembrane regions (Figure 3.5A).  The majority of biochemical 
interactions with CaV2.2 occur not within these regions but rather with the intracellular regions 
where the majority of cytosolic proteins have access (Sheng et al., 1994; Sheng et al., 1997; 
Vance et al., 1999; Zamponi, 2003).  I therefore worked under the assumption that CRMP-2 
interacted with CaV2.2 in an intracellular region.  In order to determine which intracellular 
region(s) are responsible for the interaction with CRMP-2 bacterially expressed constructs of 
these regions were generated (Figure 3.5B).  These regions were cloned using a PCR-based 
approach.  Primers were made so that each region could be cloned into the bacterial expression 
vector pGex3x-Glu.  This vector was used as it would produce proteins with two protein tags; 
glutathione S-transferase (GST) and Glu (amino acids EYMPME) (Figure 3.6A).  The primer 
sequence and restriction enzymes used for the cloning are included in Table 2.3.  The CaV2.2 
region of interest for each construct was amplified from rat CaV2.2 cDNA before being digested 
using the listed restriction enzymes (Figure 3.6B).  The digested PCR product was then ligated 
into the Gex3x-Glu vector that had previously been digested with EcoRI and BamHI.  Ligations 
were screened by colony PCR and positive clones were grown up in E-coli and DNA was 
subsequently isolated (Figure 3.6C).  The potential constructs were then verified by DNA 
sequencing.  Properly sequenced constructs were transformed into BL21(DE3)pLysE for 
expression.  Proteins were grown in large 1 L cultures and then lysed and purified using 
glutathione cellulose (Figure 3.7).  The purified proteins were visualized by comassie-stained 
SDS-PAGE.  In addition to verifying proper purification by SDS-PAGE the CaV2.2 constructs 
were tested by immunoblotting using an anti-Glu antibody (Figure 3.8A).  This was used 
specifically as the Glu tag is on the C-terminal end of the protein and therefore will only detect 
full-length proteins.   
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Figure 3.6.  Cloning of CaV2.2 intracellular regions into pGex-3x-Glu 
The intracellular regions of CaV2.2 were cloned into pGex-5x-Glu using standard molecular 
biology techniques.  (A)  Vector map of pGex-5x-Glu displaying the 5’- GST protein flanked 
by a 3’- Glu tag.  All CaV2.2 constructs were inserted using restrictions site located between 
these protein coding sequences.  (B)  DNA gel stained with SYBR® Safe of CaV2.2 L2 
amplified from full length CaV2.2 DNA using PCR.  The PCR product was then gel purified 
before being digested with BamHI and EcoRI and gel purified again.  The digested PCR 
product was then ligated into a previously digested pGex-5x-Glu vector and transformed.  (C)  
Transformed colonies were screened for insertion using colony PCR along with a positive 
control of a PCR product amplified from CaV2.2 DNA.  Positive colonies were then grown 
and the subsequently isolated DNA was verified by sequencing. 
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Figure 3.7.  Purification of CaV2.2 intracellular regions fusion proteins 
(A)  The cloned CaV2.2 intracellular regions constructs were transformed into E-coli and the 
subsequent protein was purified using glutathione cellulose and eluted using glutathione.  
Proteins were identified based upon identifying the protein by comassie stained SDS-PAGE as 
shown.  The box highlights the GST-L1-Glu protein at approximately the predicted size.  
(B,C,D)  Additional example comassie stained SDS-PAGE showing purification with a box 
highlighting the protein at the predicted size. 
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Figure 3.8.  CRMP-2 binds to two cytoplasmic regions within CaV2.2  
(A)  Western blot with Glu antibody of GST- and Glu-tagged calcium channel fragments used 
in the binding experiments. Pulldown assays with GST-Glu fusion CaV2.2 constructs from 
synaptosomes (B) or brain purified CRMP-2 (C).  Bound proteins were analyzed by 
immunoblotting with CRMP-2 antibody.  GST-Glu-L1 (D) or GST-Glu-Ct-d (E) proteins at 
increasing concentrations, incubated with CRMP-2 (~500 nM), were captured by protein A 
Sepharose beads.  Captured CRMP-2 proteins were identified by immunoblotting with 
CRMP-2 antibodies.  Quantitative densitometry was performed on the bands shown in panels 
D and E.  (F)  Data representing the normalized average band intensity ± SEM (n=3) were 
subjected to a Sigmoidal curve-fitting method to evaluate the apparent dissociation constant 
(Kd).  The CaV2.2–CRMP-2 Kds were: L1 ~24.1 ± 7.1 μM; Ct-d ~0.31 ± 0.09 μM.  
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Synaptosomes or CRMP-2 protein purified from rat brains using a three-step affinity 
chromatography method (Wang and Strittmatter, 1997) were used for binding assays.  
Synaptosomes were incubated with equimolar amounts of glutathione beads saturated with GST-
CaV2.2-Glu fusion proteins or GST-Glu protein alone for 2h at 4°C with gentle agitation.  After 
washing, the in vitro complexes were eluted from the beads, resolved by SDS-PAGE and 
immunoblotted for CRMP-2 protein. CRMP-2 bound two regions on CaV2.2: loop 1 (L1) and the 
distal part of the C-terminus (Ct-d).  Next, the strength of the binding of the CaV2.2 L1 and Ct-d 
regions was measured using an in vitro binding assay (Figure 3.8B, C).  A fixed amount of 
CRMP-2 protein was incubated overnight at 4°C with increasing amounts of protein G beads 
saturated with L1 or Ct-d fusion proteins.  The bound complexes were washed, resolved by SDS-
PAGE and subjected to immunoblotting with CRMP-2 antibody as above (Figure 3.8D,E) . The 
intensities of the CRMP-2 band were quantified, normalized to the maximum intensity within an 
experiment (n=3) and plotted against the concentration of the fusion protein.  The CaV2.2–
CRMP-2 binding affinity (Kd) values were: L1= 24.1 ± 7.1 μM (n=3) and Ct-d = 0.31 ± 0.09 μM 
(n=3) (Figure 3.8F).  As a control, the Kd of interaction between the presynaptic protein Munc 18 
(Chan et al., 2007) and Loop 2 (L2-p) of CaV2.2 was found to be ~32 ± 8.5 nM (n=3; data not 
shown), consistent with the value of ~13.8 ± 4 nM as previously reported (Chan et al., 2007).  
Thus, CRMP-2 binds directly to CaV2.2 via a moderate affinity (Ct-d) and a low affinity (L1) 
binding site. 
 
3.5.  Activity and Ca2+ dependence of CRMP-2-CaV2.2 interaction 
Having established that CRMP-2 binds to CaV2.2 and that CRMP-2 is present in synaptic 
fractions, I next asked if changes in synaptic activity could affect the interaction.  To address if 
the CRMP-2–CaV2.2 interaction was dynamic, neonatal synaptosomes were used.  These were 
chosen since a majority of the Ca2+ uptake in neonatal synaptosomes is dependent on CaV2.2 
activity (Yamaguchi et al., 1998); this differs dramatically from adult synaptosomes in which 
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Figure 3.9.  Activity-dependent regulation of CRMP-2–CaV2.2 interaction  
(A)  Intact synaptosomes were depolarized with 90 mM KCl for 5 or 10 min, then lysed and 
immunoprecipitated with CRMP-2 or CaV2.2 antibodies.  (B)  Experiments as completed in B 
were performed with the addition of: ω-CTX; ω-Agatoxin (ω-Aga); and the Ca2+ chelator 
BAPTA-AM. Following lysis, the synaptosomes were IP’ed with CRMP-2 antibody and 
immunoblotted with CaV2.2.  Fraction left denotes the density of the CaV2.2 protein relative 
to control.  (C)  Synaptosomes were incubated with increasing amount of Ca2+ and IP’ed with 
CRMP-2 antibody followed by immunoblotting with CaV2.2.  Representative blots from two 
to four experiments are shown. 
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CaV2.2 blockade has little to no effect on uptake.  In order to study how synaptic activity may 
affect the interaction between CaV2.2 and CRMP-2, freshly prepared, unsolubilized 
synaptosomes were depolarized with 90 mM KCl for 5 or 10 min, and then lysed in RIPA buffer 
and immunoprecipitated with CRMP-2 or CaV2.2 antibodies and immunoblotted with either 
antibody.  The interaction between CRMP-2 and CaV2.2 was increased upon depolarization 
(Figure 3.9A).  Interestingly, there was relatively more CaV2.2 and CRMP-2 in the depolarized 
versus non-depolarized immunoprecipitations (Figure 3.9A, compare lanes 3 to 1 and 6 to 4). 
This result suggests that depolarization may cause changes in the conformations of the interacting 
proteins which could lead to unmasking of the antigenic sites for either antibody, thereby 
facilitating greater recovery in the immunoprecipitations and thus greater association.  This 
increase in CRMP-2–CaV2.2 interaction was dependent on Ca2+ influx via CaV2.2 as incubation 
of synaptosomes with ω-CTX for 15 min prior to depolarization decreased the association (Figure 
3.9B, compare lanes 2 or 3 to 1). Incubation of the synaptosomes with the CaV2.1 blocker ω-
Agatoxin IVA also partially affected the CRMP-2–CaV2.2 interaction (Figure 3.9B).  Incubation 
with increasing amounts of the membrane-permeable Ca2+ chelator BAPTA-AM (Nichols and 
Suplick, 1996) caused a dose-dependent decrease in CRMP-2–CaV2.2 association (Figure 3.9B, 
lanes 6-8).  The interaction exhibited maximal binding at around 100 µM added Ca2+ and 
declined at higher concentrations (Figure 3.9C).  Collectively, these results suggest an activity-
dependent regulation of the interaction between CRMP-2 and CaV2.2. 
 
3.6.  Effect of altering CRMP-2 expression on CaV2.2 function 
 The biochemical interaction between CRMP-2 and CaV2.2 appear to be both direct and 
activity dependent which is interesting in its own right.  These findings importantly lead to 
perhaps a more interesting question regarding the relationship between CRMP-2 and functional 
effects on CaV2.2.  In order to test if CRMP-2 regulates CaV2.2 activity I wanted to develop a 
method to reduce expression of CRMP-2, already having a CRMP-2 overexpression vector that 
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Figure 3.10.  Construction and validation of lentiviral CRMP-2 shRNA 
(A)  Lentiviral shRNA vectors were made using the pLL3.7 vector.  I used an oligo-cloning 
approach to insert the shRNA sequences into the vector.  Following verification of proper 
insertion of the shRNA sequences into the pLL3.7 vector, lentiviral particles were generated 
and purified by expressing the vector along with viral packaging plasmids (pMDMg/pRRE, 
pRSV-Rev, and pCMV-VSV-G) in HEK293T cells.  (B)  Hippocampal neurons grown in 
culture for 5 days were treated with equal infectious titers (determined by infection of 
HEK293 cells) of scrambled or CRMP-2 shRNA lentiviral particles.  Western blot analysis 
with a CRMP-2 monoclonal antibody showing successful (>90%) knockdown of CRMP-2 
protein in neurons treated with CRMP-2 shRNA or scrambled shRNA lentiviruses for 7 days. 
Under the same conditions, expression of the neuronal protein β-III-tubulin was unchanged. 
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could be used to enhance expression.  I decided to develop a lentiviral short hairpin RNA 
(shRNA) construct to mediate CRMP-2 knockdown.  Another requirement would be that the 
infected cells would express a fluorescent protein to identify cells that were successfully infected.  
This is particularly important for electrophysiology experiments.  The pLL3.7 vector (a generous 
gift from Dr. Michael Vasko) meets these requirements as it contains a U6 promoter t to drive 
expression of shRNA and a cytomegalovirus (CMV) promoter driving expression of enhaced 
green fluorescent protein (EGFP) (Figure 3.10A).  The desired shRNA sequences (Table 2.4) 
were inserted in the pLL3.7 vector using direct ligation of the annealed shRNA oligonucleotides 
into pLL3.7 previously digested with XhoI and HpaI.  Lentiviral particles were then grown up 
after the vector was verified by DNA sequencing.  Treatment of cultured neurons with CRMP-2 
shRNA lentiviral particles led to a ~90% reduction in CRMP-2 proteins levels compared to 
scramble shRNA (Figure 3.10B). 
 In collaboration with Dr. Theodore Cummins’ laboratory and using whole cell voltage-
clamp electrophysiology, the potential modulation by CRMP-2 on Ca2+ currents was examined in 
primary hippocampal neurons.  Drs. Cummins, Yuying Wang (Khanna Laboratory), and Andrew 
Piekarz recorded whole cell Ca2+ currents from EGFP- and CRMP-2-EGFP-overexpressing cells.  
Whole-cell Ca2+ currents were elicited from a holding potential of –80 mV to depolarizing test 
potentials (ranging from –80 to +70 mV) for 200 ms using Ba2+ as the charge carrier (for 
simplicity, these currents are referred to as Ca2+ currents).  Figure 3.11A shows representative 
voltage-dependent inward currents (IBa) from an EGFP- and a CRMP-2-EGFP expressing neuron. 
Nifedipine (1 μM) was included in the bath solution to block CaV1 (i.e. L-type) channels.  Forty-
eight hours after transfection, the Ca2+ current density was significantly higher in CRMP-
2-EGFP-transfected neurons than in EGFP neurons (Figure 3.11).  On average, the Ca2+ current 
density was increased by about 60%, from 12.8 ± 2.2 (n=15) to 20.4 ± 2.5 (n=24) pA pF-1 (Vt= 0 
mV, p <0.001, One-way ANOVA), consistent with the values of 14.6 ± 1.0 pA pF-reported 
previously for control hippocampal neurons (Lai et al., 2005).  Expression of CRMP-2-EGFP did 
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Figure 3.11.  CRMP-2 regulates Ca2+ current density in hippocampal neurons   
(A)  Exemplar current traces obtained from a cell transfected with EGFP and CRMP-2–EGFP 
recored using the voltage protocol displayed above the traces.  Lines labeled 0 indicate the 
zero current level.  (B)  I-V relationships for the currents shown in A.  Peak currents were 
normalized to the cell capacitance.  (C)  Peak current density (pA/pF) measured at + 10 mV 
for EGFP, CRMP-2–EGFP transfected neurons and CRMP-2 shRNA and scrambled shRNA 
infected neurons. Numbers in parentheses represent numbers of cells tested, */# indicated 
p<0.05 versus all other conditions (One-way ANOVA).  Electrophysiology experiments were 
performed by Drs. Theodore Cummins, Andrew Piekarz, Yuying Wang.  
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not alter the size of the transfected neurons’ cell bodies, as the cell capacitance was identical in 
CRMP-2–EGFP (21.8 ± 1.8 pF, n=24) and EGFP (20.2 ± 1.7 pF, n=17, p >0.56) transfected 
neurons. This result rules out changes in cell size as a potential contributing factor for the 
increased Ca2+ current density.  
To further confirm that CRMP-2 manipulation affected Ca2+ current density, I asked if 
CRMP-2 knockdown using lentiviral-mediated delivery of CRMP-2 shRNA would decrease Ca2+ 
current density.  Interestingly, infection of 12 DIV hippocampal neurons with CRMP-2 shRNA 
lentivirus for seven days reduced Ca2+ currents to 2.9 ± 0.4 pA/pF (n=9); an ~80% reduction 
compared to CRMP-2–EGFP over-expressing neurons (Figure 3.11C).  Scramble shRNA 
lentivirus did not affect Ca2+ currents; currents were 11.7 ± 1.5 pA/pF (n=8; Figure 3.11C).   
 
3.7.  Effect of CRMP-2 expression on CaV2.2 expression 
The observed modulation of CaV2.2 current can occur by a change in channel present on 
the membrane or by differences in open probability.  While it is possible that CRMP-2 alters open 
probability of CaV2.2, direct testing of this would require technically difficult single channel 
recordings.  In addition previous reports linking CRMP-2 to kinesin mediated transport of 
proteins down axons suggests that CRMP-2 could be an important determinant of CaV2.2 surface 
trafficking  (Kawano et al., 2005; Kimura et al., 2005).  Therefore I choose to examine if surface 
trafficking could account for observed increasd in Ca2+ currents.  To test if there is a change in 
surface CaV2.2 following manipulation of CRMP-2 levels, cell surface biotinylation of 
hippocampal neurons was performed.  Immunoblotting with CaV2.2 for streptavidin-enriched 
complexes from biotinylated neurons showed increased CaV2.2 surface expression in CRMP-2-
EGFP expressing neurons compared to EGFP neurons (Figure 3.12Ai, biotinylated (B) fractions).  
The surface levels of an unrelated membrane protein, the voltage-gated Na+ channel, were not 
affected by CRMP-2 overexpression (Figure 12Aii, compare lane 3 to 5).  As a control for the 
biotinylation assay, no surface proteins were detected in samples in which the biotinylation 
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Figure 3.12.  CRMP-2 enhances surface expression of CaV2.2 
Cell–surface expression of CaV2.2 and CRMP-2 was monitored using a biotinylation assay. 
Hippocampal neurons expressing EGFP or CRMP-2–EGFP were biotinylated, the cell-surface 
proteins were harvested from the cell lysates, and the precipitates were analyzed by 
immunoblotting with CaV2.2 (i), Na+ channel (ii) and CRMP-2 (iii) antibodies.  Equal 
amounts of samples were used for the precipitation of biotinylated proteins.  Of these samples, 
the entire biotinylated fraction (B) and 10% of the non-biotinylated (U) fraction were loaded. 
CRMP-2-EGFP overexpression increased the amount of CaV2.2 at the cell surface compared 
to EGFP transfected cells.  Representative blots from three experiments are shown.  
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reagent was omitted prior to the streptavidin precipitation (Figure 3.12Ai, ii, lane 1).  Thus, these 
results suggest that the increased Ca2+ current density in CRMP-2 overexpressing neurons likely 
occurs via increased cell surface trafficking of CaV2.2.   
 
3.8.  Effect of CRMP-2 expression on glutamate release 
At this point I have observed that CRMP-2 can bind directly to the CaV2.2 channel and 
can enhance Ca2+ current density in hippocampal neurons, but do these events translate into an 
increase in transmitter release?  This question is particularly important as CaV2.2 regulates 
neurotransmitter release (Wheeler et al., 1994; Wu et al., 1999).  To answer this question, 
glutamate release was measured from hippocampal neurons over-expressing EGFP or CRMP-
2-EGFP using high pressure liquid chromatography.  At 10 DIV, hippocampal neurons were 
transfected with EGFP or CRMP-2-EGFP and release experiments were performed 48 h later.  
Representative chromatographs are shown in Figure 3.13A, B with a typical retention time of 
glutamate at about 3 min.  Exposing hippocampal neurons transfected with EGFP to 30 mM KCl 
stimulated glutamate release by about 3.5-fold from a basal level of 3.8 ± 1.0 μM/well/10 min to 
13.3 ± 0.9 μM/well/10 min.  In CRMP-2-EGFP over-expressing neurons, 30 mM KCl stimulated 
glutamate release by about 8-fold from a basal level of 3.7 ± 0.9 μM/well/10 min to 29.5 ± 1.9 
(p<0.001 vs. EGFP).  This shows that CRMP-2 can augment glutamate release by 2.3-fold over 
control EGFP-transfected cells. Although the CRMP-2-mediated glutamate release is smaller than 
the 2.7- to 12-fold increase in glutamate release that is predicted based on a ~65% increase in 
Ca2+ current density, it is important to note that not every neuron overexpresses CRMP-2 due to 
incomplete transfection efficiency (<5-15%). 
Importantly, the addition of 1 μM ω-CTX, the CaV2.2 blocker, decreased the magnitude 
of the potassium-stimulated glutamate release from CRMP-2-EGFP expressing neurons by ~77% 
(to 8.9 ± 1.9 μM/well/10 min) compared to potassium-stimulated glutamate release in the absence 
of blocker (Figure 3.13C, p < 0.05). Block of Ca2+ channels did not affect the basal release of 
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Figure 3.13.  CRMP-2 enhances hippocampal glutamate release 
Representative HPLC chromatographs of glutamate from hippocampal neurons transfected 
with EGFP (A) or CRMP-2–EGFP (B) in response to a depolarizing (30 mM KCl) stimulus. 
The neurons were incubated with HEPES buffer at 37°C for 1 h and then exposed to 
successive 10 min incubations for basal 1, pretreatment, stimulated (KCl), and basal end.  (C)  
CRMP-2 overexpressing neurons vs. controls (EGFP; p < 0.05, Student’s t-test; n=9).  The 
addition of 1 µM ω-conotoxin GVIA, the CaV2.2 blocker, completely attenuates the CRMP-2 
mediated increase in glutamate release. 
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glutamate. These results suggest that, in hippocampal neurons at 12 DIV, CaV2.2 supports most, 
if not all, of the CRMP-2 enhanced, depolarization-associated glutamate release. 
 
3.9.  Effect of Cdk5-mediated phosphorylation of CRMP-2 on CaV2.2 function 
Phosphorylation of CRMP-2 in the C-terminus regulates its axon growth activity.  When 
CRMP-2 is phosphorylated specifically by Cdk5 or ROCK this leads to a cascade of still 
unknown signaling leading to halting of neuritic growth (Arimura et al., 2000; Arimura et al., 
2005; Brown et al., 2004; Cole et al., 2006).  Based upon the important role of phosphorylation in 
modulating CRMP-2’s activity I hypothesized that phosphorylation may also modulate its 
regulation of CaV2.2.  This is likely as well given that the CBD3 region of CRMP-2 is located in 
the C-terminus near these phosphorylation sites.  While there are many kinases involved in 
modulating CRMP-2 activity Cdk5’s phosphorylation of Ser-522 is perhaps the most important 
due to its role in sema3A-induced growth cone collapse and as a priming kinase for subsequent 
phosphorylation of CRMP-2 by GSK3β.  I first verified that Cdk5 was active in my P2 
hippocampal neuron cultures by treating neurons with the Cdk5 inhibitor purvalanol A (10 µM) 
(Villerbu et al., 2002).  As a negative control I also treated neurons with the ROCK inhibitor Y-
27632 (10 µM) which should not affect phosphorylation of CRMP-2 at Ser-522.  A time-
dependent decrease in phosphorylation of CRMP-2 at Ser-522 was detected using a Ser-522 
phospho-specific antibody (Figure 3.14).  As expected, treatment with Y-27632 did not lead to a 
significant change in the phosphorylated state of Ser-522.  This series of experiments 
demonstrates that my neuronal cultures have a basal level of Cdk5 activity and supports 
investigation into the role that phosphorylation of CRMP-2 by Cdk5 plays in its interaction and 
regulation of CaV2.2.   
Despite the effectiveness of purvalanol A in reducing CRMP-2 Ser-522 phosphorylation, 
the use of a Cdk5 inhibitor to study CaV2.2 function may show complicating factors as other 
Cdk5 substrates in addition to CRMP-2, including CaV2.2 itself, can regulate CaV2.2 funnction 
 119 
 
 
Figure 3.14.  Phosphorylation of CRMP-2 in cortical neurons by Cdk5 
(A)  Lysates from neurons exposed to Cdk5 inhibitor Purvalanol, the ROCK inhibitor Y-
27632, or vehicle (0.1% DMSO) for the indicated times were immunoblotted with the 
indicated antibodies.  (B)  Summary data of ratio CRMP-2 p522 to total CRMP-2 and then 
normalized to vehicle-treated neurons (n= 5-6 from two separate experiments, *, p<0.05, one-
way ANOVA with Dunnett’s post-hoc compared to vehicle).   
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Figure 3.15.  Generation of knockdown resistant CRMP-2 and expression of CRMP-2 
mutants    
(A)  Alignment of the protein (top) and nucleotide sequences (bottom) within a validated 
siRNA region targeting CRMP-2 (mouse, GenBank Accession # NM_009955.3 ) highlighting 
the silent mutations (underlined nucleotides) used to generate a knockdown resistant (KDR) 
CRMP-2.  (B)  Lysates from CAD neuronal cells co-transfected with wildtype (WT) CRMP-
2-DsRed and scramble or CRMP-2 siRNAs or KDR CRMP-2-DsRed and scramble or CRMP-
2 siRNAs.  (C)  Phospho–mimetic or –null mutations engineered into the CRMP-2-KDR-
DsRed construct express robustly. 
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(Samuels et al., 2007a; Su et al., 2012).  Based upon this I chose to use a direct approach to 
investigate the role of CRMP-2 phosphorylation in regulation of CaV2.2.  This was accomplished 
first by generating a CRMP-2 construct that was resistant to knockdown (KDR) by siRNA 
through site-directed mutagenesis of the siRNA target sequence (Figure 3.15A).  Mutation of 
three nucleotides within the siRNA target sequence, without alteration of the amino acid 
sequence, prevented knockdown by CRMP-2 targeted siRNA when co-transfected with CRMP-2-
KDR in CAD cells, a neuronal cell line (Figure 3.15B).  The CRMP-2 KDR construct was then 
used for subsequent generation of Ser-522 and Thr-555 phosphorylation mutants.  The phospho-
mimetic mutants (S522D & T555E) and phospho-null mutants (S522A & T555A) along with 
CRMP-2 wildtype (WT) displayed equal expression when transfected into CAD cells suggesting 
that the mutations did not alter expression of CRMP-2 (Figure 3.15C).  The constructs were then 
transfected into DIV 7-8 P1 hippocampal neurons along with 200 nM CRMP-2 siRNA.  Two 
days following transfection, Ca2+-channel function was measured by monitoring KCl 
depolarization-induced Ca2+-influx with the Ca2+-sensitive dye Fura-2.  Transfected cells were 
visualized using DsRed, which is fused to the CRMP-2 constructs.  The microscope was then 
switched to visualize Fura-2 (F340 nm /F380 nm) and stimulated with KCl.  Stimulation with 
KCl led a sharp increase in the Fura-2 ratio which is indicative of an increase in [Ca2+]i (Figure 
3.16A).  The peak change in the ratio was then compared between the various conditions.  The 
dotted line represents the average value obtained for neurons transfected with CRMP-2 siRNA 
alone (Figure 3.16B).  While the phospho-mimetic and phospho-null mutants for Thr-555 were 
not significantly different from WT, mutation of the Cdk5 site of CRMP-2 caused a significant 
decrease in Ca2+-influx.  Interestingly both phospho-mutants of Ser-522 led to a decrease 
suggesting that both the phosphorylated and unphosphorylated form of CRMP-2 is required to 
enhance Ca2+-channel function.  Alternatively it is possible that CRMP-2 S522D does not 
function as a phospho-mimetic.  Furthermore the regulation of CRMP-2’s interaction with 
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Figure 3.16.  Phosphorylation of CRMP-2 at Ser-522 is an important determinant for 
modulation of Ca2+ influx 
Cortical neurons (DIV 10-12) were co-transfected with KDR CRMP-2-DsRed constructs and 
CRMP-2 siRNA and Ca2+ influx was monitored 2 days later with Fura-2AM.  (A)  Time 
course illustrating that a brief stimulation of neurons with 46.5 mM KCl led to a sharp 
increase in the 340nm/380nm ratio that diminished over the course of the 5 min of the 
experiments.  (B)  Summary of average peak change ± SEM in Ca2+ influx from neurons 
transfected with CRMP-2-KDR-DsRed constructs as indicated.  The dotted line represents 
mean peak response for neurons transfected with CRMP-2 siRNA only.  Number in 
parentheses represent numbers of cells per condition (#, p < 0.05 one-way ANOVA with 
Dunnett’s post-hoc test compared to CRMP-2-WT-KDR).      
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CaV2.2 is specific to Ser-522 phosphorylation as the Thr-555 sites showed no change in Ca2+-
influx. 
 
3.10.  Effect of Cdk5-mediated phosphorylation of CRMP-2 on CRMP-2-CaV2.2 interactions 
As the basis for regulation of CaV2.2 by CRMP-2 appears to be through a biochemical 
interaction, I next sought to determine if phosphorylation of CRMP-2 regulated this interaction.  
To investigate this interaction I wanted to obtain a highly pure source of CRMP-2 that could be 
phosphorylated in vitro and used for binding assays.  A CRMP-2 fused to a 6 histidines (CRMP-
2-6xHis) was used for this purpose.  CRMP-2-6xHis (using the vector pET28B- CRMP-2-6xHis) 
was purified from BL21(DE3) E-coli using a TalonTM metal affinity resin column and eluted by 
100 mM Imidazole which was collected over eight fractions (Figure 3.17A).  The fractions with 
the highest concentration of CRMP-2-6xHis were pooled and then dialyzed O/N into His storage 
buffer.  The final dialyzed protein was quantified by SDS-PAGE by comparing to a bovine serum 
albumin protein standard curve (Figure 3.17B).  The final concentration of CRMP-2-6xHis was 
found to be ~30 µM.  I then purified the necessary kinases and accessory proteins to 
phosphorylate CRMP-2 in vitro.  Cdk5-, p25-, and GSK3β-GST were purified as previously 
described in this thesis for other GST fusion proteins (Figure 3.18).  Cdk5 is not natively active 
and therefore must be activated by co-incubation with its activator p25 (Patrick et al., 1999).  
Purified CRMP-2-6xHis was incubated with Cdk5/p25 and/or GSK3β in vitro and 
phosphorylation was monitored by probing with anti-CRMP-2 p522 (Figure 3.19A).  The in vitro 
phosphorylated CRMP-2 was then incubated with P2 synaptosomes and immunoprecipitated with 
anti-CaV2.2.  Immunoprecipitations were then immunoblotted for CRMP-2 and CaV2.2 (Figure 
3.19B, n = 5).  Interestingly it appears that phosphorylation of CRMP-2 leads to a significant 
increase in the amount of CaV2.2 bound to the immunoprecipitated CRMP-2 (Figure 3.19C).  
This finding is consistent with the Ca2+-imaging results supporting phosphorylation of Ser-522 as 
an important determinant of CRMP-2’s modulation of CaV2.2 function.  
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Figure 3.17.  Purification of CRMP-2-6xHis 
(A)  CRMP-2-6xHis was purified from E-coli using Nickel-agarose and eluted by a grade flow 
of increasing concentration of Imidazole.  The proteins samples were then run on a SDS-
PAGE which was subsequently comassie stained to visualize proteins.  Elution fractions 2-5 
were pooled and then dialyzed into an Imidazole-free buffer.  The dialyzed fraction was then 
concentrated using centrifugation concentrating filters with a cut-off of 30 kDa.  (B)  
Comassie stained SDS-PAGE showing final concentrated CRMP-2-6xHis and comparing it to 
the pre-concentrated protein.    
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Figure 3.18.  Purification of GST-Cdk5, GST-p25, and GST-GSK3β 
(A)  GST-Cdk5 was grown up in E-coli and purified using a glutathione cellulose column 
before elution with glutathione.  (B, C)  GST-p25 and GST-GSK3β were purified using the 
same protocol as Cdk5.  Elutions 3-5 were pooled for each protein and then dialyzed against a 
buffer without glutathione before being concentrated using a centrifugation concentrator.   
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Figure 3.19.  Phosphorylation of CRMP-2 by Cdk5 enhances its interaction with CaV2.2 
(A)  Purified CRMP-2-6xHis was phosphorylated in vitro by incubation with Cdk5/p25 and/or 
GSK3β.  (B)  Cdk5-phosphorylated CRMP-2-6xHis was incubated with E19 cortical neuron 
lysates and then immunoprecipitated for CaV2.2–CRMP-2 protein complexes with an anti-
6xHis antibody.  The amido black stain demonstrates equal amounts of protein across all 
lanes.  In the example shown, the increases in CaV2.2 recovered by CdK5 + GSK3β- or 
GSK3β-phosphorylated CRMP-2, compared to without added Cdk5, were atypically greater 
than the average.  (C)  Graph bar depiction of CaV2.2 bound to immunoprecipitated CRMP-2 
normalized to rxn buffer condition (no added kinases).  Asterisk indicates p < 0.05 by 
Student’s t-test where n = 5. 
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3.11.  Discovery and characterization of CaV2.2 binding domain 3 (CBD3) 
While it has been observed that changes in CRMP-2 expression or phosphorylation lead 
to correlative changes in CaV2.2 activity and downstream effectors it is unknown whether a 
direct interaction is responsible for these occurrences.  Answering this question may also lead to a 
way to disrupt the interaction for applications where reduction of CaV2.2 activity may be 
favorable.  To develop a reagent to disrupt the interaction of CRMP-2 with the CaV2.2 complex 
in vivo, a series of overlapping 15-amino-acid peptides were synthesized covering the entire 
length of CRMP-2 using a robotic peptide spotter (Figure 3.20A).  The peptides synthesized 
included the three CaV2.2 binding domains (CBDs1–3) identified in vitro as crucial for the 
CRMP-2–CaV2.2 interaction (Figure 3.4).  The peptides were spotted onto a membrane which 
was then overlaid with synaptosomes enriched for Ca2+-channels.  Following this incubation the 
membrane was probed for CaV2.2 using a far western approach (Edmondson and Roth, 2001; 
Hall, 2004).  The binding of CaV2.2 to the peptides was quantified by densitometry of the spots 
and is depicted as CaV2.2 binding to CRMP-2 normalized to max.  The peptide found to have the 
highest binding potential for CaV2.2 was a 15 amino acid portion of the previously identified 
CBD3 sequence (Figure 3.20B).  This sequence is mildly conserved amongst CRMPs1-5 with 
CRMP-3 showing highest homology with 12 out of 15 residues being identical (Figure 3.20C).  
Interestingly the CBD3 peptide sequence is completely conserved from Humans all the way to 
Zebrafish (Figure 3.20D).  This conservation further supports the physiological importance of this 
sequence. 
I next wanted to validate the binding of the CBD3 peptide to CaV2.2 using a different 
approach.  In order to facilitate the penetrance of the CBD3 peptide inside of cell for future 
studies the CBD3 peptide along with a control peptide having no homology to CBD3 were fused 
to the transduction domain of the HIV protein TAT (Schwarze et al., 1999).  This yielded the cell 
penetrating peptides TAT-Control and TAT-CBD3.  Surface plasmon resonance (SPR) was 
performed using a BIAcore3000 instrument to observe binding between the TAT-peptides and 
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Figure 3.20.  CRMP-2 peptides with binding affinity to CaV2.2 
(A)  Diagram describing method for peptide spotting, 15 amino acid long peptides comprising 
the entire CRMP-2 sequence with 5 amino acids overlapping between peptides were spotted 
onto a membrane.  The membrane was subsequently incubated with synaptosomes enriched 
for CaV2.2 before being probed for CaV2.2 by immunoblotting.  (B)  Bar graph depicting 
binding of CRMP-2 peptides to CaV2.2 normalized to max.  Small strip shows region of 
immunoblot containing peptide with the max binding, this peptide was designated Ca2+-
channel binding domain 3 (CBD3).  (C) Alignment of CBD3 peptide between rattus 
norvegicus CRMPs1-5.  Alignment was performed using ClustalX 2.1.  (D)  Alignment of 
CBD3 peptide in CRMP-2 across species.  Spots blots were made by Dr. Andy Hudmon.  
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Figure 3.21.  TAT-CBD3 binds to both CaV2.2 L1 and Ct-Dis 
(A)  Surface plasmon resonance was used to detect binding of TAT peptides to CaV2.2 
regions by adhering the CaV2.2 regions to a sensor chip and then flowing the TAT peptides 
over the chip.  An increase in the observed resonance units (RU) of the light diffracted through 
the prism and angled at the sensor chip is indicative of association between the proteins on the 
chip and the peptides.  (B)  Sensorgram displaying binding of TAT-CBD3 to CaV2.2 L1, 
below shows sensorgrams of TAT-Control in response to interacting with CaV2.2 L1.  (B)  
Sensorgram of TAT-CBD3 binding to CaV2.2 Ct-dis, below shows TAT-Control in same 
experiment.  Red traces: 5 µM, Black traces: 3 µM, Purple traces: 1 µM.  Traces represent 
typical result of what was observed from 3 separate runs.  SPR traces were generated by Dr. 
May Khanna from my experimental data collection.  
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Figure 3.22.  TAT-CBD3 disrupts the interaction between CRMP-2 and CaV2.2 
(A)  Immunoprecipitation with recombinant CRMP-2-6xHis in the presence of TAT-CBD3 or 
TAT-Control, immunoblots are shown for both CaV2.2 and β-tubulin.  (B)  Similar 
experiments were completed using recombinant CaV2.2 L1-GST and Ct-dis-GST with TAT-
CBD3 and TAT-Control with blots for CRMP-2 shown. 
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CaV2.2 L1 and CaV2.2 Ct-d proteins (Figure 3.21).  An upward deflection in the 
resonance is indicative of binding between the bound protein (CaV2.2 fragments) and the ligand 
being tested (TAT-peptides).  Binding of TAT-CBD3 peptide to both CaV2.2 fragments was 
observed while no binding was observed for TAT-Control.  This result supports CBD3 as a 
binding partner of CaV2.2 and further shows that attachment of the TAT sequence does not 
prevent this binding. 
Now that the interaction between CBD3 and CaV2.2 has been established I sought to 
determine if CBD3 was able to disrupt the interaction between CRMP-2 and CaV2.2.  Lysates 
(either E19 brains or PN1 synaptosomes) were pre-cleared with protein-A agarose beads prior to 
incubation with 10 µM of TAT-CBD3 or TAT-Control for 15 min at 4°C.  Lysate were then 
incubated with a CRMP-2 antibody at 4°C O/N with gentle agitation.  Samples were then 
incubated with protein-A agarose beads for 2 hr before washing three times in RIPA buffer.  The 
samples were then separated by SDS-PAGE and probed by immunoblotting for CaV2.2 and the 
known CRMP-2 interacting protein β-Tubulin (Figure 3.22A).  The addition of TAT-CBD3 
reduced the interaction between CRMP-2 and CaV2.2 without affecting the interaction with β-
Tubulin.  I additionally wanted to test the interaction using specific pieces of CaV2.2.  Using a 
similar protocol lysates were pre-cleared with glutathione-cellulose beads and then incubated 
with TAT-peptides prior to addition of CaV2.2 L1- or Ct-d-GST-glu fusion proteins.  As I 
previously observed both L1 and Ct-d interact with CRMP-2 and the addition of TAT-CBD3 
prevents the pulldown of CRMP-2 by either of these cytoplasmic regions of CaV2.2 (Figure 
3.22B).  These results show that TAT-CBD3 disrupts the interaction between CaV2.2 and 
CRMP-2 and can therefore be used to study how disruption of this interaction affects CaV2.2 
function. 
 132 
 
3.12.  Effects of CBD3 on CaV2.2 currents 
To determine if CBD3 is able to prevent CRMP-2-mediated enhancement of CaV2.2 
function hippocampal neurons were transfected with vector, CRMP-2, or CRMP-2 +CBD3 and 
whole Ca2+ currents were recorded by Dr. Wang 2-3 days following transfection (Figure 3.23A).  
As observed previously CRMP-2 overexpression cause a significant increase in peak current 
density compared to vector alone.  Co-expression of CBD3 completely abrogated the increase in 
current density due to over-expression of CRMP-2 (Figure 3.23B).  This finding indicates that 
CBD3 is able to prevent CRMP-2’s upregulation of current and therefore suggests that disrupt of 
the interaction between CRMP-2 and CaV2.2 is responsible for this enhancement of current 
density.  Having shown that co-expression of CBD3 prevents CRMP-2-mediated increased in 
current density I sought to determine if TAT-CBD3 could be used to reduce current density.  The 
long-term goal of developing TAT-CBD3 was to use it to treat CaV2.2-related pathology.  
Therefore, the ability of TAT-CBD3 to reduce currents was tested in sensory neurons as CaV2.2 
function in sensory neurons has been heavily implicated in pain (Bowersox et al., 1996; 
Malmberg and Yaksh, 1994; Nebe et al., 1998; Neugebauer et al., 1996).  The cell penetrating 
ability of TAT-CBD3 was verified by using a TAT-CBD3 fused to fluorescein isothiocyanate 
(FITC) generating TAT-CBD3-FITC.  Primary sensory neurons isolated from rat DRG were 
incubated with TAT-CBD3-FITC for 10 minutes and then fixed in a DAPI containing fixative.  
TAT-CBD3 showed robust penetrance in neurons within this short time (Figure 3.24A).  Next 
whole cell Ca2+-currents were measured by Drs. Wang and Weiguo Zhu (in collaboration with 
Dr. Gerry Oxford’s laboratory) from sensory neurons after a 15 min application of TAT-CBD3.  
This application led a ~60% reduction in peak current density compared to TAT-Control treated 
neurons (Figure 3.24B-D).  Current density was not significantly reduced by the addition of the 
CaV2.2 specific inhibitor ω-CTX suggesting that TAT-CBD3 attenuated the majority of CaV2.2-
mediated current. 
 
 133 
 
 
 
Figure 3.23.  CBD3 reverses CRMP-2-mediated enhancement of Ca2+-currents 
(A)  Top displays the voltage protocol used to elicit Ca2+ channel currents, bottom displays 
exemplar traces from hippocampal neurons transfected with vector (EGFP), CRMP-2-EGFP 
alone, or CRMP-2-EGFP along with CBD3.  (B)  Bar graph depicting the peak current density 
(pA/pF) at +10 mV for the various transfection conditions.  Electrophysiology experiments 
were performed by Dr. Yuying Wang. 
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Figure 3.24.  TAT-CBD3 reduces Ca2+-currents in primary sensory neurons 
(A)  Representative differential interference contrast/fluorescence images showing robust 
penetration of FITC-TAT-CBD3 into DRGs (arrowheads) but not other cells (arrows).  Nuclei 
are stained with Hoechst dye in the bottom image. Scale bars, 10 µm.  (B)  Representative 
current traces from a DRG incubated for 15 min with TAT-Control (10 µM; green) or TAT-
CBD3 (10 µM; purple) in response to the voltage steps illustrated at the top.  (C)  Current- 
voltage relationships for the currents shown in B fitted to a b-spline line. Peak currents were 
normalized to the cell capacitance.  (D)  Peak current density measured at -10 mV for DRGs 
incubated with TAT-Control, TAT-CBD3 or   TAT-CBD3 + 1 µM ω-conotoxin (CTX).  The 
numbers in parentheses represent numbers of cells tested.  *P < 0.05 versus TAT-Control.  
Electrophysiology experiments performed by Dr. Weiguo Zhu and Dr. Yuying Wang. 
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3.13.  TAT-CBD3’s effect on CGRP release 
As the physiological function of CaV2.2 is to facilitate neurotransmitter release the next 
logical step was to determine if TAT-CBD3 could prevent neurotransmitter release in sensory 
neurons.  This would further support TAT-CBD3 as a functionally relevant modulator of CaV2.2.  
CaV2.2 has been shown to regulate release of many different neurotransmitters in sensory 
neurons, one of particular interest to pain research is calcitonin gene related peptide (CGRP) 
(Evans et al., 1996; Maggi et al., 1990b).  CGRP is a potent neuropeptide that induces 
vasodilatation and has been linked to pain and inflammation likely due to this action (Brain et al., 
1985; Schaible, 1996; Sun et al., 2003).  Capsaicin-induced release of CGRP was measured by 
Dr. Djane Duarte (in collaboration with Dr. Michael Vasko’s laboratory) from rat spinal cord 
slices following a 10 min incubation with either 20 μM TAT-Control or TAT-CBD3 (Figure 
3.25).  CGRP was measured using a radio-immuno assay to detect immunoreactive CGRP 
(iCGRP).  Slices incubated with TAT-Control displayed a ~9 fold increase in iCGRP in response 
to Capsaicin exposure whereas those incubated with TAT-CBD3 displayed less than a 3 fold 
increase compared to basal iCGRP levels.  These findings strongly support that inhibition of 
CaV2.2 by TAT-CBD3 results in a functionally relevant decrease in stimulated release of CGRP.  
An important note is that TAT-CBD3 incubation did not alter the total content of iCGRP. 
 
3.14.  Systemic administration of TAT-CBD3 for the treatment of neuropathic pain 
The results to this point strongly support TAT-CBD3 as a novel antagonist to CaV2.2 
function as seen by decreases in current density and CGRP release.  Based upon these findings 
and the previous link between CaV2.2 and pain I next asked if TAT-CBD3 could reduce pain 
using an in vivo model of hypersensitivity.  Through a collaboration with the laboratory of Dr. 
Fletcher White and performed by Matthew Ripsch the in vivo efficacy of TAT-CBD3 was tested.  
We utilized a neuropathic pain model in which animals are treated with the anti-retroviral drug 
dideoxycytidine (ddC) (Bhangoo et al., 2009; Joseph et al., 2004).  Nucleoside reverse 
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Figure 3.25.  TAT-CBD3 attenuates CGRP release from spinal cord slices 
(A–D)  iCGRP release was measured in three 3-min exposures to HEPES buffer alone (white 
bars), to HEPES buffer with peptides (white), to HEPES buffer containing 500 nM capsaicin 
(Cap) with peptides (yellow), then to HEPES alone to re-establish baseline (white).  Each 
column represents the mean ± s.e.m. of iCGRP levels in each 3-min perfusate sample, 
expressed as percentage of total peptide content in the tissues per minute (n = 7 rats).  TAT-
Control (A) or TAT-CBD3 (B) was included as indicated by the horizontal bars, *p < 0.05 
versus basal iCGRP release in the absence of capsaicin (analysis of variance (ANOVA), 
Dunnett's post hoc test). Neither peptide altered basal iCGRP release (not significant, NS). (C) 
Basal release is the amount of iCGRP released in the three fractions exposed to HEPES plus 
peptides. Stimulated release is the amount of iCGRP released in the three fractions exposed to 
500 nM capsaicin + peptides.  The evoked release was obtained by subtracting iCGRP release 
during three basal fractions (12–18 min) from that during the three capsaicin-stimulated 
fractions (21–27 min) and expressed as percentage of total iCGRP content in each group. *P < 
0.05 versus the respective TAT-Control using a Student's t-test.  (D)  Total content of iCGRP 
(in fmol mg−1) is the sum of CGRP released during perfusion and from spinal cord tissue 
measured at the end of the release experiments.  CGRP release experiments were performed 
by Dr. Djane Duarte. 
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transcriptase inhibitors such as ddC, which are commonly used to treat AIDS, produce side 
effects that include painful neuropathies.  To induce hypersensitivity using this in vivo model, rats 
are inject once with 25 mg/kg ddc intraperitoneally (i.p.) and 7 days post injection (7 PID) 
mechanical hypersensitivity is observed by measuring paw withdrawal threshold (PWT) (Figure 
3.26).  The hypersensitivity is seen as a predictable decrease in PWT.  Animals were then treated 
i.p. with TAT-peptides and PWT was measured 1 h following injection.  A significant increase in 
PWT was seen with injection of TAT-CBD3 at 0.1 mg/kg and complete reversal of 
hypersensitivity was accomplished by 1 mg/kg.  No additional increase in PWT was observed 
when TAT-CBD3 was increased to 10 mg/kg, suggesting that TAT-CBD3 is targeting 
hypersensitivity rather than sensitivity in general.  TAT-Control did not significantly affect PWT 
when injected at 1 mg/kg.  These results extend the in vitro work that was completed using TAT-
CBD3 showing that it is effective in treating in vivo neuropathy. 
Having shown that TAT-CBD3 is effective in vivo, I next sought to determine the safety 
of TAT-CBD3 as it relates to memory and motor function.  These two cognitive functions were 
used in this preliminary safety test for a gauge of any possible side effects that TAT-CBD3 may 
have.  These tests were completed in collaboration with Dr. Xiao-ming Xu’s laboratory by Dr. 
Naikui Liu.  The rotarod test was performed to measure for any possible effects on locomotor 
function, motor coordination, or sedation (Hedgecock et al., 1985).  Mice were injected with 
vehicle, TAT-Control, or TAT-CBD3 and tested using the rotarod using either a fast (left panel) 
or slow (right panel) acceleration profile (Figure 3.27A).  TAT-CBD3, at doses as high as 50 
mg/kg, showed no effect on the animals’ ability to stay upright on the rotating rod at 1 h or up to 
7 days later.  This suggests that TAT-CBD3 does not cause severe sedation or observable deficits 
in locomotor function and coordination.  It is, however, important to note that injection of 50 
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Figure 3.26.  Systemic administration of TAT-CBD3 reduces neuropathic hyperalgesia 
Adult Sprague dawley rats were given a single injection of ddc and then treated 7 days 
following injection (PID7) with TAT-CBD3 or TAT-Control.  This single injection of ddc 
induces neuropathic hypersensitivity as observed by a decrease in paw withdrawal threshold 
(PWT).  Reversal of this decrease in PWT is indicative of a reduction in the hypersensitivity 
associated with neuropathic pain.  Response of ddC alone at PID7 is shown in the brown bar. 
*p < 0.05 versus ddC or TAT-Control (ANOVA with Student-Newman-Keuls post hoc test, n 
= 7).  Animal measurements of hypersensitivity were performed by Matthew Ripsch. 
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Figure 3.27.  TAT-CBD3 does not alter gross motor coordination or memory retrieval  
(A)  Motor coordination of animals treated with either TAT-CBD3 or TAT-Control was 
assessed using the rotarod test.  Latency to fall off a slow (left) or fast (right) rotating rod was 
recorded for animals treated with the TAT-peptides.  There were no significant differences in 
rotarod performances between groups (ANOVA with Dunnett's post hoc test).  (B)  Memory 
retrieval ability in mice was measured using the Morris water maze.  Latency for mice to find 
the hidden platform during the test was not different between groups.  (C)  Time spent in 
target quadrant. There were no significant differences in percentage time spent in target 
quadrant or path length between groups (Student's t-test).  Experiments performed by Dr. 
Naikui Liu. 
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mg/kg caused a single transient (< 1 min) motor dysfunction as observed by tail kinking and body 
contortion.  It is unknown the cause of this although there appeared to be no long term effects.  
Next I sought to determine if TAT-CBD3 led to deficits in memory using the Morris water maze, 
again in collaboration with Dr. Xu and completed by Dr. Liu.  Mice were trained in the Morris 
water maze for 4 days prior to treatment with TAT-peptides.  Following injection animals were 
tested in the morris water maze at 3 h, 1, 2, and 3days (Figure 3.27B, C).  Animals showed no 
significant deficit in latency to reach the platform at any of these time points.  This suggests that 
TAT-CBD3 does not affect memory retrieval.  However, as TAT-CBD3 was only tested after 
training it is unknown if it affects memory acquisition.   
 
3.15.  Conclusions 
Prior to the beginning of my research into the interaction between CRMP-2 and CaV2.2 
it was unknown if CRMP-2 regulated synaptic transmission.  Through the results contained in 
this Chapter I have shown that by modulating CaV2.2 function CRMP-2 is able to alter 
neurotransmitter release.  CRMP-2 directly interacts with CaV2.2 through a small peptide 
sequence (CBD3) which interacts with the CaV2.2 cytosolic regions L1 and Ct-d.  This 
interaction is dynamically regulated as depolarization leads to enhanced CaV2.2-CRMP-2 
interactions.  Importantly CaV2.2 function correlates with CRMP-2 expression, which is likely 
through an observed regulation of CaV2.2 surface expression by CRMP-2.  Collectively the 
regulation of CaV2.2 by CRMP-2 culminates with enhancement of neurotransmitter release.  
Furthermore phosphorylation of CRMP-2 by Cdk5 enhances the interaction between CRMP-2 
and CaV2.2.  This is also supported by the finding that Cdk5 phosphorylation site mutants of 
CRMP-2 do not enhance CaV2.2 function.  The biochemical basis of CRMP-2’s regulation of 
CaV2.2 is supported by the ability of CBD3 to both disrupt the CRMP-2-CaV2.2 complex as well 
as antagonized CRMP-2-mediated enhancement of CaV2.2 function.  Finally the CRMP-2-
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CaV2.2 complex is validated as a therapeutic target for neuropathic pain by the observed reversal 
of pain behavior in animals following systemic administration of the cell penetrant TAT-CBD3.   
CaV2.2 functions as both a gate keeper for the requisite Ca2+ influx for neurotransmitter 
release as well as a hub for synaptic proteins in the active zone.  The interaction between CRMP-
2 and CaV2.2 leads to enhanced surface expression of CaV2.2 culminating in enhanced 
neurotransmitter release, and therefore identifies CRMP-2 as an important regulator of the pre-
synaptic Ca2+ channel complex.  While this supports CRMP-2 as a functionally relevant 
modulator of CaV2.2 function it is unknown if CRMP-2 also serves as a scaffold for additional 
proteins to interact with CaV2.2.  CRMP-2 has previously been shown to traffick the TrkB 
receptor via a multiprotein complex (Arimura et al., 2009b).  The trafficking of CaV2.2 by 
CRMP-2 may employ a similar complex of several proteins all of which are required for 
mobilization of CaV2.2. 
Interestingly I observed that Cdk5-, but not ROCK-, mediated phosphorylation of CRMP 
is responsible for enhancement of CaV2.2-mediated Ca2+ influx.  This is particularly intriguing as 
the Sema3A and LPA pathways induce growth cone collapse via phosphorylation of CRMP-2 by 
Cdk5 or ROCK, respectively.  This suggests that conformational changes in CRMP-2 responsible 
for growth cone collapse are distinct from that required for regulating CaV2.2.  Furthermore this 
allows cells to select whether a neuron wants to retract and enhance CaV2.2 (Sema3A) or retract 
without enhancing CaV2.2 (LPA).  A neuron’s ability to select between these two outcomes may  
be a vital step in axons deciding what synaptic connections to make.  The signaling with regards 
to CaV2.2 and Cdk5 becomes murky, however, as a recent study found that Cdk5 directly 
phosphorylates CaV2.2 enhancing its synaptic localization through enhancing RIM’s association 
with CaV2.2 (Su et al., 2012).  This finding along with a previous report showing that 
phosphorylation of CASK by Cdk5 leads to enhanced CaV2.2 synaptic targeting suggests 
multiple signaling pathways are able to utilize Cdk5 to enhance synaptic transmission via 
modulating CaV2.2 (Samuels et al., 2007b).  It is unknown, however, if Sema3A application for 
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example will specifically engage Cdk5 phosphorylation of CRMP-2 or if other Cdk5-mediated 
pathways will also be employed.  Additional studies into the selectivity of the pathways of 
Sema3A, LPA, and growth factors are needed to determine how modulation of CaV2.2 by 
CRMP-2 may be involved.  In addition the observed enhancement of the CRMP-2-CaV2.2 
interaction in depolarized synaptosomes may be due in part to Cdk5 activation and subsequent 
phosphorylation of CRMP-2. 
 Structural and biochemical studies have demonstrated that CRMPs exist as tetramers 
(Wang and Strittmatter, 1997).  Tetramer formation is stabilized by the presence of divalent 
cations, whereas in the presence of cation chelating agents almost half of CRMP-2 exists in a 
monomeric state (Majava et al., 2008).  While I have not directly tested whether Cav2.2 binds to 
a tetrameric or monomeric form of CRMP-2, the latter is a more likely possibility given the 
presence of chelators in my binding assay buffers.  If, however, CRMP tetramers bind Cav2.2, 
then the subunit composition of the tetramer will be an important determinant of its effect on 
Cav2.2.  The composition of CRMP tetramers will vary due to the differential spatial and 
developmental patterns of CRMPs expression within the nervous system (Wang and Strittmatter, 
1996).  Thus, CRMPs, by virtue of their ability to heteromultimerize in multiple combinations, 
may help in ‘fine tuning’ the effects on Ca2+ channel density, thereby adding another level of 
complexity in transmitter release regulation. This oligomeric assembly of CRMPs may also serve 
as the building blocks upon which presynaptic signaling complexes are erected. 
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CHAPTER 4. NEUROPROTECTION BY TAT-CBD3 THROUGH INHIBITION OF 
NMDARS
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4.1. Introduction 
The results from Chapter 3 positioned CRMP-2 as a novel modulator of pre-synaptic 
function through interaction and modulation of CaV2.2.  Prior to the start of my thesis work, two 
studies potentially linking CRMP-2 to NMDARs  suggested that CRMP-2’s regulation of Ca2+ 
channels may extend beyond the pre-synaptic space to the post-synaptic zone as well (Al-Hallaq 
et al., 2007; Bretin et al., 2006).  The first study, by Bretin and colleagues, found that CRMP-2 
cleavage occurs due to NMDAR activation.  These authors also found that CRMP-2 expression 
increased glutamate toxicity.  As CRMP-2 is cleaved following glutamate exposure, they next 
asked if expression of a cleaved form of CRMP-2 affected neurotoxicity.  Notably, they observed 
that neurons expressing the calpain cleaved form of CRMP-2 had reduced NMDAR responses 
and decreased neurotoxicity.  As overexpression of CRMP-2 was neurotoxic, it appeared 
then that cleaved CRMP-2 has a dominant negative effect leading to enhanced neuronal survival.  
Furthermore, NMDAR surface expression was decreased when calpain cleaved CRMP-2 was 
overexpressed.  These findings supported the notion that calpain cleaved CRMP-2 may 
be neuroprotective by reducing NMDAR surface expression and also by inference that over 
expression of CRMP-2 is perhaps neurotoxic by upregulating NMDAR surface expression.  The 
second study potentially linking CRMP-2 to NMDARs reported a biochemical complex between 
CRMP-2 and NR2A and 2B containing NMDARs (Al-Hallaq et al., 2007).  In exploring potential 
regulation of NMDARs by CRMP-2, I began with the hypothesis –based largely on these two 
reports– that a biochemical interaction between NMDARs and CRMP-2 was key to the 
link between CRMP-2 expression on glutamate toxicity and that calpain-mediated cleavage of 
CRMP-2 was an important determinant in the regulation of NMDARs by CRMP-2. 
Further support for my investigation into CRMP-2 and NMDARs came from studies 
on CRMP-2 and neurotoxicity that reported calpain-mediated cleavage of CRMP-2 occurred in 
response to sundry neurotoxic insults including injury, ischemia, and excitotoxic exposure to 
glutamate (Bretin et al., 2006; Chung et al., 2005; Hou et al., 2009; Jiang et al., 2007; Touma et 
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al., 2007; Zhang et al., 2009).  Sequence inspection of the CRMP-2 CBD3 peptide that I had 
identified in Chapter 3 revealed that this peptide was very close to the putative calpain cleavage 
sites on CRMP-2.  Furthermore, the Ca2+ binding protein calmodulin apparently shields CRMP-2 
from calpain cleavage by binding to a sequence with CRMP-2 that is slightly N-terminal to the 
CBD3 sequence (Zhang et al., 2009; Zhang et al., 2007).  Based on these findings, I hypothesized 
that the CBD3 peptide could affect calpain-mediated cleavage of CRMP-2 and thus may have 
neuroprotective effects.  Mechanistically, I envisioned that the alteration in calpain-
mediated cleavage of CRMP-2 could be neuroprotective by altering NMDAR surface expression.  
Based upon these hypotheses, in this Chapter I will seek to determine if TAT-CBD3 can alter 
calpain-mediated cleavage of CRMP-2, affect the functional interaction between CRMP-2 and 
NMDAR, and protect neurons from glutamate toxicity.  Part of the work in this Chapter has been 
presented in previous publications (Brittain et al., 2011a; Brittain et al., 2012a). 
  
4.2.  TAT-CBD3 reduces calpain cleavage of CRMP-2 
I first tested if TAT-CBD3 could alter calpain cleavage of CRMP-2 following glutamate 
activation of calpain.  E19 DIV 7 cortical neurons were pre-treated for 10 minutes with TAT 
peptides and then stimulated for 30 min with 200 μM glutamate and 100 μM D-serine; D-serine 
has been reported to be the dominant co-agonist for NMDARs (Mothet et al., 2000; Shleper et al., 
2005).  Lysates from these cells were then immunoblotted with a CRMP-2 antibody that 
recognizes C-terminal cleaved and full-length CRMP-2.  Blots were also probed for β-Tubulin, 
which served as a loading control.  I observed a 55 kDa cleaved fragment of CRMP-2 as well as 
the 62 kDa full-length CRMP-2 protein (Figure 4.1A), consistent with earlier findings (Bretin et 
al., 2006; Hou et al., 2009).  CRMP-2 cleavage was quantified by densitometry and is reported as 
the ratio of cleaved CRMP-2 to Tubulin (Figure 4.1B).  Exposing neurons to 10 µM TAT-CBD3 
prior to stimulation led to a significant reduction in CRMP-2 cleavage at 0.5, 4 and 24 hours 
following stimulation compared to neurons treated with 10 µM TAT-Control (p < 0.05, Student’s 
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Figure 4.1.  TAT-CBD3 attenuates cleaveage of CRMP-2 following glutamate exposure 
(A)  Western blot of CRMP-2 cleavage following excitotoxic challenge.  E18-19 DIV7 
neurons were stimulated with Glu/Ser for 30 min and lysates made at 4 and 24 h later.  
Cleavage of CRMP-2 is observed by the appearance of a ~55 kDa band representing cleaved 
CRMP-2.  Tubulin loading controls are also shown.  (B)  Summary of CRMP-2 cleavage at 
various times following stimulation.  Cleavage of CRMP-2 is presented as cleaved CRMP-
2/Tubulin (n = 6–12 per condition).  Asterisk indicates significant difference compared to 
time-matched TAT-Control (p < 0.05; Student’s t-test).  
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t-test, n=6-12).  For example, at 24 hours post-stimulation, neurons exposed to TAT-CBD3 had 
~70% less cleaved CRMP-2 compared to neurons exposed to TAT-Control.   
In addition to CRMP-2, I also observed that cleavage of the prototypical calpain substrate 
αII-spectrin (Czogalla and Sikorski, 2005) was inhibited by TAT-CBD3 and that TAT-Control 
did not alter cleavage compared to vehicle treated neurons (Figure 4.2).  This is an important 
finding as it suggests that TAT-CBD3’s inhibition of CRMP-2 cleavage is not specific to CRMP-
2 and likely affects multiple calpain substrates.  I next asked if the reduction of CRMP-2 cleavage 
was specific to induction by glutamate.  This was tested by pre-incubating neurons with TAT-
CBD3 and then inducing non-specific Ca2+-influx with the Ca2+ ionophore ionomycin, which has 
been shown to activate calpain (Lee et al., 2000).  Ionomycin-induced cleavage of CRMP-2 was 
not affected by TAT-CBD3 (Figure 4.3).  This result supports that TAT-CBD3 works upstream of 
calpain activation.  To further support this finding I tested TAT-CBD3’s ability to alter cleavage 
of CRMP-2 in lysates.  Lysates were generated by homogenizing and subsequent lysis of PN1 rat 
brains in RIPA #1 before stimulating calpain activation by incubation with 20 mM CaCl2.  
CRMP-2 cleavage was unaffected by various concentrations of TAT-CBD3, as a control the 
calpain inhibitor MDL-28170 was also used which greatly attenuated cleavage (Figure 4.4).  
Consistent with these results, calpain activity (measured in lysates using the fluorogenic calpain 
substrate t-Boc) was also not affected by incubation with TAT-CBD3 (Figure 4.5).  Collectively, 
these findings suggest that that TAT-CBD3 does not prevent CRMP-2 cleavage due to direct 
modulation of calpain or CRMP-2 per se, rather it appears that TAT-CBD3 acts on a target 
upstream of calpain activation. 
 
4.3.  TAT-CBD3 increases cell viability following an excitotoxic insult 
Having shown that TAT-CBD3 can attenuate calpain cleavage of CRMP-2 and αII-
spectrin following glutamate stimulation this led me to me test if TAT-CBD3 was 
neuroprotective against excitotoxicity.  Calpain and its role in neuronal toxicity has been 
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Figure 4.2.  TAT-CBD3 prevents cleavage of α-spectrin and CRMP-2 following 
glutamate exposure 
Western blot of CRMP-2 and αII-spectrin cleavage following excitotoxic challenge.  E18-19 
DIV7 neurons were stimulated with Glu/Ser for 30 min and lysates made 24 h later.  Cleavage 
of αII-spectrin is observed by the appearance of a ~150 kDa band representing cleaved αII-
spectrin.  Tubulin loading controls are also shown, BDP: breakdown product.  
 
.  
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Figure 4.3.  TAT-CBD3 does not alter cleavage of CRMP-2 in response to Ionomycin 
(A)  Western blot of CRMP-2 cleavage following treatment with Ionomycin.  E18-19 DIV7 
neurons were stimulated with Ionomycin for 2 or 4 h and lysates were made following 
stimulation.  (B)  Summary of CRMP-2 cleavage at 2 and 4 h following stimulation.  Cleavage 
of CRMP-2 is presented as cleaved CRMP-2/Tubulin (n = 5–6 per condition). 
 
.  
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Figure 4.4.  TAT-CBD3 does not alter in vitro cleavage of CRMP-2 
(A)  Equal amounts of lysates prepared from E18-19 brains were treated for 10 min with TAT-
CBD3 (0.1 to 30 µM) or 30 µM TAT-CBD3 + 50 µM MDL28170 and then calpain was 
activated by addition of 20 mM CaCl2.  The cleavage reaction was stopped at 30 min and 
CRMP-2 cleavage assessed by immunoblotting.  (B)  Bar graph representation of CRMP-2 
cleavage, where cleavage is equal to cleaved CRMP-2 / total CRMP-2 (*, p <0.05 vs. all other 
conditions; n = 4–5 per condition). 
 
.  
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Figure 4.5.  TAT-CBD3 does not alter in vitro activation of calpain 
Lysates were pre-incubated with vehicle (0.1% DMS), TAT-CBD3 (10 μM), or MDL-28170 
(50 μM) prior to measuring calpain activity via measurement of cleavage of the fluorogenic 
calpain substrate t-Boc.  Values are normalized to vehicle treated lysates (*, p < 0.05 vs. 
vehicle by one-way ANOVA with post-hoc Dunnett’s test; n=23-24 from 3 experiments). 
 
.  
 
 
.  
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Figure 4.6.  Prevention of glutamate-induced reduction in cell viability by TAT-CBD3 
(A)  Cell viability of E18-19 DIV 7 cortical neurons was determined using an MTS cell 
viability assay.  Neurons were incubated with peptides for 10 minutes prior to stimulation with 
200 μM glutamate and 100 μM D-serine for 30 minutes.  Viability was then measured 24 
hours later, with all values normalized to no stimulation control (n ≥ 32 each from at least four 
separate experiments).  Asterisk indicates significant difference compared to stimulated 
control (p < 0.05).  All values are in µM.  (B)  Viability of stimulated neurons was also 
measured with addition of TAT-CBD3 at various time points following stimulation (n ≥ 16).  
Asterisk indicates significant difference compared to stimulated control (p < 0.05).  The dotted 
line and shaded box illustrates the normalized cell viability ± SEM in the absence of any 
stimulation (from A).   
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extensively studied, but despite these studies it is still unclear how cleavage of individual 
substrates, CRMP-2 for example, affect neuronal survival (Adamec et al., 1998; Bretin et al., 
2006; Brorson et al., 1995; Czogalla and Sikorski, 2005; del Cerro et al., 1994; Dutta et al., 2002; 
Guttmann et al., 2002; Hong et al., 1994; Lee et al., 2000; Rami et al., 1997; Simpkins et al., 
2003).  Cortical neurons were stimulated as mentioned above with pre-treated for 10 minutes with 
TAT peptides.  Cell viability was measured 24 hours later by MTS cell viability assay, which 
measures reductase activity in metabolically active cells.  Within each experiment cell viability 
values were normalized to values obtained for unstimulated control neurons.  Approximately 58 ± 
4% of the neurons survived the Glu/Ser stimulation compared to unstimulated neurons (Figure 
4.6A).  Neurons pre-treated for 10 min with 10 μM TAT-CBD3 and then stimulated with Glu/Ser 
completely survived the excitotoxic treatment.  Significant neuroprotection by TAT-CBD3 was 
evident at 3 and 1 µM but not at 0.1 µM.  In contrast, pre-treating neurons with 10 µM TAT-
Control resulted in cell viability levels (~59 ± 5%, n=48) similar to Glu/Ser-stimulated neurons.  
Treatment of neurons with 10 μM TAT-CBD3 alone, without stimulation, did not affect cell 
viability.  Application of a CBD3 peptide lacking the TAT cell-penetrating sequence did not 
prevent cells from Glu/Ser-induced cell death, suggesting that the CBD3 peptide acts on an 
intracellular target to achieve neuroprotection. 
 An important aspect of neuroprotective agents is their ability to prevent excitotoxic death 
when administered post-stimulation.  To test if TAT-CBD3 is neuroprotective following 
stimulation, neurons were treated with 10 μM TAT-CBD3 for 10 minutes at 0.5, 1, 2, 3, and 6 
hours after Glu/Ser stimulation and cell viability measured as described.  Except for modest, but 
statistically significant, neuroprotection at 0.5 hour following stimulation (Figure 4.6B), TAT-
CBD3 was not effective at later times.  Together, the results suggest that: (1) TAT-CBD3 is 
neuroprotective and (2) the interaction between CRMP-2 and target protein is likely important for 
mediating the early phase of neuronal death observed following excitotoxic insults.    
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4.4.  Lentiviral-mediated knockdown of CRMP-2 is neuroprotective   
My earlier findings showed that TAT-CBD3 protects neurons from an excitotoxic insult 
while also reducing cleavage of CRMP-2 but raised some important questions: (1) is the 
neuroprotection due to inhibition specifically of CRMP-2 and (2) does the activity of TAT-CBD3 
require CRMP-2 to be present?  To address if the neuroprotection was due to CRMP-2, cortical 
neurons were treated with CRMP-2 or scramble shRNA lentiviral particles at 2 DIV.  After 5 
days, the lentiviral-transduced neurons were pre-treated with TAT peptides for 10 minutes and 
then stimulated with Glu/Ser and cell viability measured 24 hours later (Figure 4.7).  Cell 
viability was normalized to control neurons (no stimulation) treated with the same virus 
(scramble vs. CRMP-2 shRNA).  CRMP-2 shRNA lentiviral–transduced neurons exhibited a 
significant increase in cell viability following stimulation compared to scramble shRNA treated 
neurons when pre-treated with TAT-Control (0.75 ± 0.04 vs. 0.52 ± 0.02, p < 0.05, Student’s t-
test, n=16).  Complete neuroprotection was observed in neurons transduced with CRMP-2 
shRNA lentivirus and pre-treated with TAT-CBD3 prior to excitotoxic challenge (1.07 ± 0.07; 
n=16).  That neurons transduced with scramble shRNA lentivirus did not exhibit complete 
neuroprotection with TAT-CBD3 (e.g., compared to ~100% protection in TAT-CBD3 treated 
cells; Figure 4.6A) can likely be attributed to the alteration of survival by the viral load itself.  
Nonetheless, these findings demonstrate that it is CRMP-2 itself that mediates the 
neuroprotection.  Furthermore, as TAT-CBD3 is also neuroprotective, it is likely that TAT-CBD3 
works through antagonizing a function of CRMP-2. 
 
4.5.  Role of CaV2.2 in glutamate toxicity and CRMP-2 cleavage 
My previous results in Chapter 3 have shown that CRMP-2 is an important regulator of 
CaV2.2 and furthermore that TAT-CBD3 in particular targets regulation of CaV2.2 by CRMP-2.  
Based upon these findings, I wanted to rule out the possibility that TAT-CBD3 was acting in 
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Figure 4.7.  CRMP-2 knockdown is neuroprotective  
Cortical neurons grown in culture for 2 days were treated with equal titers of scrambled or 
CRMP-2 shRNA lentivirus.  Neurons were then grown for an additional 7 days prior to 
stimulation as in Figure 4.6.  Neurons were treated with 10 µM of TAT-Control or TAT-
CBD3 prior to stimulation and cell viability was measured 24 hours later.  Values represent 
average of a single experiment which displayed same qualitative results as two separate 
experiments, n = 16.  Asterisk indicates p < 0.05 by Student’s t-test compared to scrambled 
shRNA for same peptide. 
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Figure 4.8.  Blockade of CaV2.2 by ω-conotoxin GVIA is not neuroprotective and does 
not reduce CRMP-2 cleavage in response to glutamate stimulation 
(A)  Western blot of CRMP-2 cleavage following excitotoxic challenge with and without ω-
conotoxin GVIA (ω-CTX, 1 µM).  E18-19 DIV7 neurons were pre-incubated with ω-CTX or 
vehicle for 10 minutes prior to stimulation with Glu/Ser for 30 min and lysates made 24 h later 
( n = 6).  (B)  Neurons were stimulated using the same protocol as in panel b.  Viability was 
then measured 24 hours later, with all values normalized to no stimulation control (n = 19 
from two separate experiments, asterisk indicates p < 0.05 by Student’s t-test compared to 
unstimulated control). 
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these experiments through inhibition of CaV2.2 activity.  E19 DIV 7 Cortical neurons were 
stimulated using Glu/Ser as previously described with or without pre-incubation with 1 µM ω-
CTX for 5 minutes.  Lysates were then made 24 hr following stimulation and CRMP-2 cleavage 
was assessed by immunoblotting (Figure 4.8A).  Treatment with ω-CTX with or without 
stimulation by Glu/Ser had no effect on CRMP-2 cleavage.  Based upon this result it can be 
concluded that Ca2+-influx through CaV2.2 is not a determinant of Glu/Ser-induced cleavage of 
CRMP-2 and that therefore the mechanism of action of TAT-CBD3 cannot be through inhibition 
of CaV2.2.  Having shown that cleavage of CRMP-2 is not dependent on CaV2.2 activity I 
wanted to verify that neuronal survival as well was not dependent on CaV2.2 following Glu/Ser.  
Neurons were pre-incubated with ω-CTX prior to stimulation with Glu/Ser and viability was 
measured 24 hr later.  The blockade of CaV2.2 with ω-CTX did not significantly alter neuronal 
survival of neurons following Glu/Ser which is indicative that TAT-CBD3 is not neuroprotective 
through inhibition of CaV2.2 (Figure 4.8B).  Neuronal survival in neurons which were not 
stimulated, however, was significantly increased compared to unstimulated controls.  It is 
unknown why this increase was observed by may be due to preventing of release of endogenous 
glutamate which could induce a low level of toxicity.  
 
 
4.6.  TAT-CBD3 attenuates NMDAR mediated Ca2+ influx   
The neuroprotective effect of TAT-CBD3 prior to but not following Glu/Ser stimulation 
suggests that TAT-CBD3’s mode of action may occur early in the glutamate toxicity pathway.  
Since Ca2+ entry is an early event in signaling, I hypothesized that TAT-CBD3 may affect 
cleavage by reducing Ca2+ influx in response to glutamate.  During prolonged exposure to 
glutamate, neurons lose their ability to buffer the large influx of Ca2+ resulting in accumulation of 
toxic levels of cytosolic Ca2+ ([Ca2+]c); a phenomenon known as delayed calcium deregulation 
(DCD) (Nicholls, 2004).  To test if TAT-CBD3 alters DCD following glutamate application, the 
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Figure 4.9.  Ca2+ influx in response to prolonged glutamate and acute NMDA is 
attenuated by TAT-CBD3 
(A)  [Ca2+]c was monitored in E18-19 cortical neurons after prolonged exposure to 200 µM 
glutamate + 20 µM glycine using the Ca2+-sensitive Fura-2FF.  Neurons were treated with 
vehicle (0.05% DMSO), 10 μM TAT-Control or TAT-CBD3 for 10 minutes prior to 
stimulation with Glu/Gly.  Arrow indicates time of Glu/Gly application.  Inset graph displays 
the average area under the curve (AUC), in arbitrary units.  Values represent n=116–123 cells 
obtained from 2 separate experiments for each treatment.  (B)  [Ca2+]c was monitored in E18-
19 cortical neurons using the Ca2+-sensitive dye Fura-2 following application of 50 µM 
NMDA+ 100 µM glycine.  Following application of NMDA, neurons were treated with 
vehicle (0.05% DMSO) for 10 minutes and then challenged again with NMDA, before a final 
application ~20 minutes following the first one.  (C-E)  In addition to vehicle, neurons were 
also treated with either 10 µM TAT-CBD3, 100 µM AP-5, TAT-CBD3 + AP-5, or 1 μM ω-
conotoxin GVIA during the 10 minutes in the interim between the 1st and 2nd NMDA 
applications.  (F)  Bar graph summarizing the ratios of the 2nd and 3rd NMDA applications to 
the 1st for the various treatment conditions.  All values represent at least 95 cells from 2–3 
separate experiments.  Statistical significance compared to vehicle treated neurons is denoted 
by an asterisk for P2/P1 (p < 0.05), while the # sign denotes significance compared to TAT-
CBD3-treated neurons for P3/P1 (p < 0.05, one way ANOVA).  Ca2+ imaging experiments 
were performed by Tatiana Brustovetsky. 
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Ca2+-sensitive dye Fura-2FF was used to monitor [Ca2+]c in collaboration with Dr. Nickolay 
Brustovetsky’s laboratory and performed by Tatiana Brustovetsky.  Neurons were incubated with 
vehicle (0.05 % DMSO) or 10 µM TAT peptides for 10 minutes prior to a 200 μM glutamate + 
20 µM glycine (an NMDAR co-agonist (Dingledine et al., 1999; Verdoorn et al., 1987)) 
challenge (Figure 4.9A).  The use of glycine or D-serine for the sake of my experiments appears 
to be interchangeable as I observed similar amounts of glutamate toxicity with either NMDAR 
co-agonists.  This stimulation led to a sustained increase in [Ca2+]c throughout the time course of 
the experiment.  Both vehicle and TAT-Control displayed similar increases in [Ca2+]c during the 
prolonged exposure to glutamate.  In contrast, TAT-CBD3 showed a significant decrease in 
[Ca2+]c compared to vehicle and TAT-Control.  The changes in [Ca2+]c following glutamate 
stimulation, represented by average area under the curve (AUC), was decreased by 78% and 75% 
compared to that observed in TAT-Control and vehicle-treated neurons, respectively (Figure 
4.9A, inset).  The decrease in DCD and Ca2+ influx observed in neurons pre-treated with TAT-
CBD3 supports my hypothesis that TAT-CBD3 decreases glutamate-stimulated Ca2+ influx.  
These findings suggest that the neuroprotective effect of TAT-CBD3 as well as the decrease in 
calpain cleavage of CRMP-2 may occur due to decreased Ca2+ influx in the face of glutamate 
stimulation.  
Based on the above observations that TAT-CBD3 reduces Glu/Gly-induced DCD, I next 
asked if this was through inhibition of NMDAR activity.  This was accomplished by measuring 
Ca2+ influx in response to NMDA.  Changes in [Ca2+]c were monitored using the high affinity 
Ca2+ dye Fura-2 after stimulating neurons with 50 µM NMDA + 100 μM glycine.  A sharp 
increase in [Ca2+]c was observed when NMDA is applied, which returned to baseline upon 
NMDA removal.  When vehicle (DMSO) was applied during the interim between the three 
NMDA stimulations, no change in [Ca2+]c amplitude was observed (Figure 4.9B).  However, 
when neurons were treated with 10 µM TAT-CBD3 during this interim period, the second and 
third responses to NMDA were strongly attenuated (Figure 4.9C). 
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Having confirmed that TAT-CBD3 reduces the NMDA–initiated Ca2+ influx, I next 
asked if the effect was activity-dependent using the reversible NMDAR inhibitor (2R)-amino-5-
phosphonopentanoate (AP-5) (Crunelli et al., 1983).  When NMDA was applied in the presence 
of 100 µM AP-5, no [Ca2+]c increase was observed (Figure 4.9D).  However, upon washout of 
AP-5, NMDA application elicited a [Ca2+]c increase slightly greater in magnitude to that seen 
before AP-5 application.  NMDA stimulated [Ca2+]c increase was completely blocked when TAT-
CBD3 and AP-5 were co-applied but returned following washout of AP-5  (Figure 4.9E).  The 
ratio of the 2nd to 1st NMDA-induced Ca2+ peak (P2/P1) for vehicle treated neurons was 1.05 ± 
0.09 whereas incubation with 10 μM TAT-CBD3 reduced the P2/P1 ratio to 0.25 ± 0.03 (Figure 
4.9F).  The ratio of the 3rd to 1st Ca2+ peak (P3/P1) for TAT-CBD3 neurons was 0.33 ± 0.03 
suggesting only a minimal recovery of active surface NMDARs.  Co-application of TAT-CBD3 
with 100 μM AP-5 led to a P2/P1 ratio of 0.19 ± 0.03 and a P3/P1 of 0.93 ± 0.08 indicating 
recovery of active surface NMDARs.  These findings show that inhibition of NMDARs prevents 
the TAT-CBD3 mediated decrease in NMDA-initiated [Ca2+]c increase. 
I next asked if TAT-CBD3’s inhibition of NMDAR-mediated Ca2+-influx was CRMP-2-
dependent.  Neurons were transfected with CRMP-2 siRNA + GFP at 5 DIV and then Ca2+ 
imaging was performed using a two-pulse NMDA protocol at 7 DIV.  Neurons treated with 
CRMP-2 siRNA exhibited reduced inhibition of NMDAR-mediated Ca2+-influx by TAT-CBD3 
(P2/P1 = 0.60 ± 0.09) vs. untransfected controls (P2/P1 = 0.29 ± 0.06, n = 7, p < 0.05, Student’s t-
test).  This result suggests that TAT-CBD3’s efficacy in reducing NMDAR-mediated Ca2+-influx 
is CRMP-2–dependent, supporting the notion that TAT-CBD3 antagonizes a function of CRMP-
2.  
 
4.7.  TAT-CBD3 reduces NR2B surface expression in dendritic spines 
The NMDAR is composed of two NR1 subunits and two NR2 subunits that form the 
heteromeric ligand-gated ion channel.  The NR2 subunits present in NMDARs in cortical neurons 
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Figure 4.10.  Blockade of NR2B is completely neuroprotective at 7 DIV 
Cortical neurons were grown in culture for 7 days before being stimulated for 30 min with 200 
µM glutamate and 20 µM glycine.  Neurons were pre-incubated with either Ifenprodil or 
Peaqx for 10 min prior to stimulation and throughout the exposure to the excitotoxic insult.  
Values are the average of 32 wells from two separate experiments.  Asterisk indicates 
significant difference compared to no stimulation control ( p< 0.05, one-way ANOVA with 
Dunnet’s post-hoc test).  
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7 DIV are primarily NR2A and NR2B.  Based upon this is it is likely that TAT-CBD3 is targeting 
one or both of these subunits.  CRMP-2 has been shown to interact with both subunits so it would 
not be surprising if TAT-CBD3 target both subunits (Bretin et al., 2006).  Subunit diversity has 
been of particular interest in the field of excitotoxicity as the subunit composition of NMDAR 
appears to alter the extent of glutamate toxicity.(Liu et al., 2007; Mizuta et al., 1998; Zhou and 
Baudry, 2006).  I therefore wanted to determine if TAT-CBD3 displayed subunit specificity.  The 
first step in this was to determine what subunits were responsible for mediating excitotoxicity in 
my cortical neuron culture.  I employed the use of the NR2B and NR2A specific blockers 
Ifenprodil and Peaqx respectively to accomplish this goal (Auberson et al., 2002; Williams, 
1993).  Cortical neurons were treated for 10 minutes prior to stimulation and throughout 
stimulation with 200 µM glutamate and 20 µM glycine for 30 min.  At 7 DIV it was found that 
Ifenprodil, but not Peaqx, was able to completely prevent Glu/Gly-induced toxicity (Figure 4.10).  
This finding suggests that NR2B is completely responsible for glutamate toxicity at this stage of 
culture which is consistent with previous findings (Hardingham et al., 2002; Liu et al., 2007; 
Stanika et al., 2009; Zhou and Baudry, 2006).  An extension of this conclusion is that TAT-CBD3 
targets NR2B-containing receptors.     
As two recent studies showed an association of NMDARs with CRMP-2 and possible 
regulation of cell-surface expression of the NR2B-containing NMDARs by CRMP-2 (Al-Hallaq 
et al., 2007; Bretin et al., 2006), I tested if NMDARs are affected by TAT-CBD3 peptide.  
Additionally, I focused on the NR2B subunit as it appears to be the dominant subunit implicated 
in excitotoxicity in our cortical neuron cultures.  To monitor surface expression of the NR2B 
containing NMDARs, neurons were pre-treated for 10 minutes with 10 μM of either TAT peptide 
followed by a 30 minute stimulation with Glu/Ser and then subjected to biotinylation of surface 
proteins either 30 minutes, 1 or 2 hours after stimulation.  Control neurons were treated with 
peptide for 10 minutes and then incubated for 30 minutes without stimulation before surface 
proteins were biotinylated.  NR2B was mainly detected in the streptavidin-enriched biotinylated 
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Figure 4.11.  TAT-CBD3 does not alter total surface expression of NR2B 
(A)  Representative immunoblots with the indicated antibodies of total lysates (T), 
unbiotinylated fractions (U), and biotinylated fractions (B) prepared from neurons exposed to 
TAT-Control or TAT-CBD3 (10 μM each) for 10 minutes.  (B)  Summary of biotinylated 
(surface) NR2B protein, calculated by densitometry from two experiments.  Values were 
normalized to time matched TAT-Control conditions (n = 6-11 each).  Neurons were left 
untreated (control) or stimulated for 30 min with Glu/Ser followed and biotinylated 0.5 to 2 h 
later.  Levels of surface NR2B were not different in any of the conditions tested (p > 0.05; 
Student’s t-test).   
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fraction (B) with trace amounts in the unbound fraction (U), consistent with a surface-expressed 
receptor (Figure 4.11A).  As a control, the surface expression of the voltage-gated potassium 
channel 2.1 (Kv2.1) was also found primarily in the biotinylated fraction, consistent with our 
previous report that CRMP-2 does not affect Kv channel trafficking (17). As expected, the 
cytosolic proteins CRMP-2 and β-Tubulin were present in the unbound fraction with little to none 
detected in the biotinylated fractions.  NR2B surface expression was calculated as the ratio of 
biotinylated to total NR2B and then normalized to the ratio observed in neurons treated with 
TAT-Control for the times indicated.  There was no difference in the amount of surface expressed 
NR2B between TAT-Control and TAT-CBD3 treated neurons in unstimulated neurons or neurons 
stimulated for 30 minutes with Glu/Ser (Figure 4.11B).  Taken together, these results suggest that 
TAT-CBD3 does not alter surface expression of total NR2B. 
Because biotinylation experiments do not address potential localized or spatially 
restricted changes in surface expression of a protein, I turned to the approach of using the pH 
sensitive GFP superecliptic pHlourin (SEP) to monitor NR2B surface expression (Miesenbock et 
al., 1998).  SEP fluoresces 20-fold brighter in a neutral pH versus acidic or basic conditions: as 
proteins on the surface (high fluorescence, ~ pH 7.5) are internalized (low fluorescence, ~ pH 5.5) 
a strong reduction in fluorescence is observed.  The fluorescence of SEP fused to the extracellular 
domain of NR2B (NR2B-SEP) can therefore be used to observe changes in NR2B-SEP 
containing NMDARs on the plasma membrane (Kopec et al., 2006).  Neurons expressing NR2B-
SEP were visualized using confocal fluorescent microscopy as small punctate structures on 
dendrites (Figure 4.12A), consistent with previous reports showing clustering of NMDARs in 
dendritic spines (Craig et al., 1994; Kornau et al., 1995).  Following acquisition of a 10 minute 
period of baseline, neurons were incubated with peptides for 20 minutes while continually 
measuring NR2B-SEP fluorescence.  At the end of every experiment, neurons were treated with a 
pulse of acetic acid (Figure 4.12B).  This drop in pH (to ~5.5) caused a near complete loss of 
fluorescence and verified that the pH sensitivity of SEP was not altered during the course of the 
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Figure 4.12.  TAT-CBD3 induces activity-dependent down-regulation of surface NR2B in 
dendritic spines 
Representative deconvolved fluorescent images of surface expressed NR2B-SEP on dendritic 
spines (A, B) of transfected neurons before, 20 min after application of TAT-Control, and 1 
minute after application of a short acid pulse (pH 5.0).  Differential interference contrast 
image overlaid with a fluorescent image illustrating dendritic spines rich in NR2B (yellow 
arrowheads) is shown in A (bottom panel).  (C)  Average NR2B-SEP fluorescence intensities 
of spines in the presence of MK801 alone, or peptides alone or in the presence of peptides and 
MK801 at the times indicated.  Each condition represents 37-70 spines from 3 separate 
experiments.  Asterisk indicates a significant difference compared to TAT-Control (p < 0.05; 
one-way ANOVA with Dunnett’s post-hoc).  The ordinate represents average intensity in 
arbitrary fluorescent units (afu).  Scale bars are as indicated.   
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experiment.  Incubation of neurons with 10 µM TAT-Control showed no significant change in 
fluorescence at 20 minutes compared to vehicle.  In contrast, incubation with 10 µM TAT-CBD3 
caused a ~60% reduction in NR2B-SEP fluorescence (Figure 4.12C).  This result suggests that 
CBD3 can alter dendritic surface NMDARs by inducing internalization of NR2B.   
Since NMDAR activity has been linked to surface expression (Barria and Malinow, 
2002; Prybylowski et al., 2005; Roche et al., 2001), I tested if inhibition of NMDAR activity 
could affect TAT-CBD3-induced NR2B internalization.  Concomitant addition of the NMDAR 
antagonist MK801 (50 µM) with 10 µM TAT-CBD3 completely prevented the TAT-CBD3-
induced reduction in NR2B-SEP fluorescence observed at 20 minutes following peptide/drug 
application (Figure 4.12C).  Treatment with 50 µM MK801 alone had no effect on NR2B-SEP 
fluorescence.  These results suggest that internalization of NMDARs induced by TAT-CBD3 
requires an active NMDAR. 
 Whereas biotinylation experiments showed that surface expression of NR2B is not 
altered following TAT-CBD3 exposure, NR2B-SEP fluorescence experiments showed reduced 
NR2B surface expression in dendrites upon treatment with TAT-CBD3.  To address the 
incongruity between these results, I measured NR2B-SEP fluorescence in cell bodies of neurons 
following treatment with TAT peptides (Figure 4.13A).  NR2B-SEP fluorescence was similar in 
somas following application of TAT-CBD3 compared to TAT-Control (Figure 4.13B).  The 
finding that somatic NR2B surface expression is unaltered may explain why no reduction in total 
NR2B surface expression was observed in biotinylation experiments.  These observations suggest 
that TAT-CBD3 induces specific internalization of dendritic NR2B receptors without altering 
somatic receptors.  Collectively, the NR2B-SEP imaging and Ca2+ imaging experiments strongly 
support the conclusion that NMDAR internalization following TAT-CBD3 treatment is activity-
dependent. 
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Figure 4.13.  TAT-CBD3 does not alter NR2B surface expression in neuron soma   
(A)  Representative fluorescent images of surface expressed NR2B-SEP on soma of 
transfected neurons before, 20 min after application of TAT-Control, and 1 minute after 
application of a short acid pulse (pH 5.0).  (B)  Average NR2B-SEP fluorescence intensities in 
soma in the presence of peptides at the times indicated.  Each condition represents 32-34 soma 
from 3-4 experiments.  Asterisk indicates a significant difference compared to time-matched 
TAT-Control (p < 0.05; ANOVA for spines and Student’s t-test for soma).  The ordinate 
represents average intensity in arbitrary fluorescent units (afu).  Scale bar is as indicated.   
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4.8.  TAT-CBD3 inhibits NMDAR-induced current in hippocampal neurons 
The attenuation of NMDA-stimulated Ca2+-influx suggests that TAT-CBD3 acts on the 
NMDAR.  In collaboration with Dr. Gerald Zamponi’s laboratory and performed by Dr. Haitou 
You, we tested if TAT-CBD3 could inhibit NMDA evoked currents in primary neurons.  
NMDAR currents were recorded from rat hippocampal neuron somas (DIV 7-11) using whole-
cell voltage-clamp electrophysiology by stimulating with 50 μM NMDA for 2 seconds with a 30 
second interval between stimulations (Figure 4.14A).  Following 5 minutes of stable NMDA-
stimulated responses (< 5% change between peaks) neurons were perfused with 10 μM TAT-
CBD3.  TAT-CBD3 induced rapid and strong inhibition of NMDA currents with ~70% block 
after 5 minutes (Figure 4.14B).  Washout with bath solution lacking TAT-CBD3 led to partial 
recovery of NMDA currents after 10 minutes.  These findings place TAT-CBD3 as a modulator 
of NMDARs and show that TAT-CBD3 directly inhibits NMDA currents. 
I hypothesized that the mechanism of TAT-CBD3's inhibition of NMDARs is due to 
intracellular disruption of CRMP-2-NMDAR signaling.  This conclusion is supported by the 
finding that application of TAT-CBD3 but not CBD3 sans TAT was neuroprotective.  While 
these findings support the conclusion that the TAT penetration peptide is required for 
neuroprotection by CBD3 it did not directly demonstrate that the target of TAT-CBD3 was 
intracellular. Therefore, we (performed by Dr. You) tested if intracellular application of TAT-
CBD3 inhibits NMDARs.  This was tested by measuring NMDA-induced Ca2+-currents in 
hippocampal neurons with TAT-CBD3 in the recording pipette.  In experiments where TAT-
CBD3 was applied via the recording pipette, there was no observed decrease in NMDAR Ca2+-
currents compared with controls (Figure 4.14C).  This finding suggests that TAT-CBD3 does not 
inhibit NMDARs through an intracellular target, suggesting instead that the observed inhibition 
of NMDARs by TAT-CBD3 may occur through an extracellular mechanism, such as channel 
block.  This also suggests that the conformation per se of the fused version of the TAT with 
CBD3 bestows inhibition on the NMDARs, rather than either sequence alone.  It is unclear 
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Figure 4.14.  TAT-CBD3 decreases NMDA induced current in rat hippocampal neurons 
via an extracellular target  
(A) Representative traces from a single neuron, showing a control NMDA trace evoked by 50 
μM NMDA (see Methods), NMDA current after 5 min perfusion of 10 μM TAT-CBD3, and 
NMDA current after 10 min washout of TAT-CBD3.  (B)  Bar graph summarizing the effect 
of TAT-CBD3 on NMDA current of 8 individual cells; four of those cells lasted long enough 
to finish a 10-min washout period and partially recovered from TAT-CBD3 effect.  (C)  Ca2+ 
currents were recorded from hippocampal neuron somas in the presence of 10 µM TAT-CBD3 
in the recording pipette.  Cells were held for 15 min and compared to cells without peptide in 
the pipette.  Electrophysiology experiments were performed by Dr. Haitao You in the 
laboratory of Dr. Gerald W. Zamponi. 
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whether the previously observed internalization of NMDARs in response to TAT-CBD3 occurs 
through the proposed extracellular mechanism or through a distinct intracellular signaling target. 
 
4.9.  Interactions between NR2B and CRMP-2 
A previous study has reported CRMP-2 as a biochemical binding partner of NMDAR 
NR2A/B subunits (Al-Hallaq et al., 2007), and hence it is possible that TAT-CBD3 may mediate 
neuroprotection by disrupting the interaction between CRMP-2 and the NMDAR, rather than via 
current inhibition.  To explore this interaction and determine if TAT-CBD3 affected it, I 
performed a series of co-immunoprecipitation experiments.  Lysates from embryonic day 19 
cortical neurons grown for 8 DIV culture were exposed to TAT-CBD3 (100 µM) or TAT-control 
(100 µM) peptides or vehicle (1% DMSO) for 1 h and immunoprecipitated with an anti-NR2B 
antibody (recognizes proximal carboxyl-terminus, BD Biosciences) (Figure 4.15A). 
Immunoblotting of these immunoprecipitations with a CRMP-2 antibody (Sigma) failed to yield a 
detectable interaction despite detection of PSD-95, a well-established interaction partner of 
NMDARs (Kornau et al., 1995; Niethammer et al., 1996).  Importantly, the interaction between 
PSD-95 and NR2B was not disrupted by TAT-CBD3, relevant here because disruption of this 
interaction has neuroprotective properties (Aarts et al., 2002; Martel et al., 2009).  The reciprocal 
co-immunoprecipitation with the anti-CRMP-2 (C4G) antibody on membrane enriched fractions 
from postnatal day 2 rat brains (Figure 4.15B) also failed to precipitate NR2B.  It should be noted 
that the CRMP-2 antibody C4G was the same as used in the previous study reporting an 
interaction between CRMP-2 and NMDARs (Al-Hallaq et al., 2007).  To rule out epitope specific 
or conformation specific NMDAR antibodies as the potential reasons for the lack of interaction in 
our cultures, I used two additional NR2B antibodies that have their epitopes in the N-terminus 
(NeuroMab) or in the C-terminus (Millipore) (Figure 4.15C).  These too failed to resolve an 
interaction between NR2B and CRMP-2.  Bacterially purified CRMP-2-GST fusion protein also 
failed to pull down NR2B from rat brain lysates or synaptosomes (Figure 4.15D). 
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Figure 4.15.  CRMP-2 is not found in a complex with NR2B 
(A)  Lysates from E19 DIV 8 cortical neurons were pre-incubated with vehicle (0.5% DMSO), 
100 µM TAT-CBD3 or 100 µM TAT-Control prior to performing co-immunoprecipitations 
using an anti-NR2B antibody.  The commercial suppliers of the antibodies are indicated in 
parentheses.  (B)  PN2 brain fractions were used to perform co-immunoprecipitations using 
anti-CRMP-2 C4G.  (C) Cortical neuron lysates were used to co-immunoprecipitate NR2B 
using two additional NR2B antibodies antibody and immunoblotted as in (A).  (D)  Bacterially 
expressed purified GST (control) or CRMP-2 GST proteins were utilized in pull downs (PD) 
from cortical neuron lysates along with either a monoclonal IgG (control) or NR2B antibody, 
and then the immune-captured complexes were blotted with NR2B and CRMP-2 antibodies.  
Both GST tagged and native CRMP-2 are indicated.  Molecular weight markers are indicated 
in kilodaltons (kDa). 
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4.10.  CONCLUSIONS 
In this Chapter I described the neuroprotective effects of a novel peptide (CBD3) derived 
from the CRMP-2 protein.  Knockdown of CRMP-2 itself was neuroprotective.  Similarly, 
incubation with TAT-CBD3 protected neurons from glutamate toxicity, decreased surface 
expression of NR2B receptors at dendritic spines and reduced NMDAR–mediated Ca2+ influx.  
TAT-CBD3 was also found to inhibit NMDAR-mediated currents in slice recordings and in 
cultured neurons.  Although CRMP-2 was originally discovered as a mediator of axon guidance 
and outgrowth, recent evidence has suggested that CRMP-2 is also important in excitotoxicity 
signaling (Bretin et al., 2006; Hou et al., 2009).  My results, for the first time, establish CRMP-2 
signaling as a bona fide target for prevention of glutamate toxicity.  The apparent mechanism of 
action for TAT-CBD3’s neuroprotective effect in glutamate toxicity is via attenuation of toxic 
Ca2+-influx through NMDARs.  This mechanism along with previous studies suggests that 
CRMP-2 modulates NR2B-containing NMDARs (Al-Hallaq et al., 2007; Bretin et al., 2006). 
Initial support for CRMP-2 as a potential target in neurotoxicity arose from studies 
demonstrating cleavage of CRMP-2 by calpain following various forms of neurotoxicity, 
including focal ischemia (Bretin, Rogemond et al. 2006; Jiang, Kappler et al. 2007; Touma, Kato 
et al. 2007; Zhang, Ottens et al. 2007).  These findings led me to hypothesize that TAT-CBD3 
may alter calpain cleavage of CRMP-2, which in turn may be neuroprotective in a cell-based 
excitotoxic injury model.  Consistent with my hypothesis, I observed strong neuroprotection by 
TAT-CBD3 in neurons stimulated with Glu/Gly.  Despite the finding that TAT-CBD3 also 
reduced calpain cleavage of CRMP-2, this is likely not the mechanism of TAT-CBD3–induced 
neuroprotection as no reduction in cleavage occurred when TAT-CBD3 was added to in vitro 
cleavage experiments.  Rather, it appears that the reduction in cleavage is due to a reduction in 
glutamate-induced Ca2+ influx.   
In addition to CRMP-2, cleavage of other members of the CRMP family of proteins has 
been implicated in neurotoxicity.  Collectively, it appears that cleavage of CRMP-3 and CRMP-4 
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is detrimental to neuronal survival while cleavage of CRMP-2 may be neuroprotective (Bretin et 
al., 2006; Kowara et al., 2005; Liu et al., 2009).  The possible effects cleavage of CRMP-1 and -5 
may have on neuronal survival is at present unclear.  The CBD3 region of CRMP-2 shares 80% 
identity with CRMP3 but only 46% and 40% with CRMP-4 and CRMP1, respectively.  Given the 
sequence disparity between the CBD3 regions for CRMPs 1-4 (Figure 3.20), it would be 
interesting to test if these peptides also have neuroprotective properties.  Furthermore, the use of 
these CBD3 homologues might enable identification of specific residues required for 
neuroprotection. 
A recent study reported that overexpression of a “cleaved” CRMP-2 construct, lacking 
amino acids 509–572 which are cleaved by calpain, reduced the responsiveness of neurons to 
glutamate and increased neuronal survival following glutamate-induced toxicity (Bretin et al., 
2006).  The authors concluded that accumulation of this artificially cleaved CRMP-2 product led 
to a reduction of surface NMDARs, presumably accounting for the observed neuropreservation.  
Their study, however, did not examine whether cleavage of endogenous CRMP-2 could also be 
neuroprotective.  In this study I initially set out to determine if TAT-CBD3 altered calpain 
cleavage of CRMP-2 and neuronal survivial following excitotoxicity.  Whilst our results show 
that TAT-CBD3 reduced cleavage of CRMP-2 and was neuroprotective following an excitotoxic 
insult, this relationship may not be a causal one as it appears that TAT-CBD3-mediated 
attenuation of NMDAR-mediated Ca2+ influx is the likely cause for both neuroprotection and 
prevention of calpain cleavage of CRMP-2.  These findings position CRMP-2 as an important 
novel modulator of both ligand- (i.e. NMDARs) as well as voltage-gated calcium channels.   
Incubation with TAT-CBD3 greatly attenuated DCD during prolonged glutamate 
exposure as well as reduced Ca2+ influx following NMDA application.  Perhaps most interesting, 
however, is the finding that TAT-CBD3 induces activity-dependent internalization of NMDARs 
as inhibitors of NMDARs (MK801 and AP5) prevented TAT-CBD3’s modulation of NMDARs.  
Although a biochemical interaction between NMDARs and CRMP-2 has been reported (Al-
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Hallaq et al., 2007), my attempts to reproduce this interaction were unsuccessful.  It is unknown 
why I was unable to reproduce this interaction, although the interaction may be very weak and 
therefore difficult to observe.  Specifically, the mechanism for TAT-CBD3-induced 
internalization could be via altering the phosphorylation state of NR2B or by enhancing the 
interaction between the endocytosis related AP-2 adapter protein.  For example, the C-terminus of 
NR2B contains the AP-2 adaptor protein binding site “YEKL” that is required for clathrin 
dependent endocytosis (Prybylowski et al., 2005; Roche et al., 2001).  Previous work has shown 
that CRMP-2 interacts with α-adaptin (an AP-2 subunit) and modulates endocytosis of the cell 
adhesion protein L1, this suggests CRMP-2 could also modulate NR2B endocytosis through an 
interaction with AP-2 (Nishimura et al., 2003).  NR2B receptor trafficking is also regulated by a 
PDZ binding domain located just adjacent to AP-2 adaptor binding site (Roche et al., 2001).  In 
addition, phosphorylation of the PDZ binding site by casein kinase II leads to receptor 
internalization (Zhang et al., 2008).  TAT-CBD3-initiated NMDAR removal from the membrane 
could occur via these or as yet undiscovered NMDAR trafficking pathways.  The specific 
removal of NR2B receptors from spines suggests that TAT-CBD3 could be targeting a synaptic 
trafficking pathway, possibly explaining why somatic receptors are not affected.  
In conclusion, the findings presented in this Chapter have identified a novel 
neuroprotective peptide derived from the protein CRMP-2.  This peptide appears to work by 
inhibiting NMDARs and inducing dendritic spine NMDAR internalization culminating in a 
reduction of glutamate-induced DCD and NMDA–stimulated Ca2+ influx.  These findings show 
that CRMP-2 is not only involved in glutamate-mediated neurotoxicity but may be effectively 
targeted to prevent excitotoxicity-mediated neuronal death. 
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CHAPTER 5.  DISCUSSION AND CONCLUSION 
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5.1.  Role of CRMPs in modulating release 
 The pre-synaptic CaV2.2 complex contains many protein components (see Table 1.1.1) 
and may well contain proteins yet to be identified.  In Chapter 3, I characterized the novel CaV2.2 
interacting protein CRMP-2.  These findings included the discovery of a biochemical as well as a 
functional interaction leading to the modulation of CaV2.2.  Based upon this work CRMP-2 has 
emerged as an important regulator of CaV2.2.  The collective findings from Chapter 3 are 
visually summarized in Figure 5.1.  One of the more interesting findings from these series of 
experiments was that CRMP-2 over-expression led to an increase in the stimulated release of 
glutamate.  This finding is consistent with the role of CaV2.2 in regulating glutamate release 
(Wheeler et al., 1994).   
While the interaction between CRMP-2 and CaV2.2 suggests that the regulation of 
neurotransmitter release occurs in response to CRMP-2 expression, other hypotheses are also 
possible.  For example, it is possible that CRMP-2 may have an ultra-structural effect on the 
synapse, leading to changes in neurotransmitter release.  Additional experiments completed in the 
Khanna laboratory, as enumerated next, have specifically suggested this hypothesis may have 
some credence.  Hippocampal neurons were isolated, grown, and transfected with either EGFP or 
CRMP-2-EGFP as described in Chapter 2.  Following this, neurons were loaded with the 
amphipathic dye FM4-64 (Invitrogen) by way of stimulation with KCl.  This loading protocol 
specifically leads to labeling of sites where stimulated endocytosis/exocytosis occur and therefore 
can be used to label active release sites (Pan et al., 2005; Ryan et al., 1993).  These release sites 
are commonly referred to as “boutons” in imaging experiments (Figure 5.2).  It was observed that 
neurons expressing CRMP-2-EGFP had ~3-fold larger boutons compared to EGFP alone.  This 
enhancement in bouton size was observed without a change in the number of boutons.  This 
finding strongly suggests that CRMP-2 is an important determinant in bouton size.  It has 
previously been shown that bouton size correlates with active zone size as well as pre-synaptic 
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Figure 5.1.  CRMP-2 signaling cascade: a novel role for CRMPs in Ca2+ channel 
regulation and transmitter release 
Extracellular signals induce growth cone collapse through activation of various kinases 
pathways.  In Chapter 3, I found that CRMP-2 binds to cytoplasmic loops of CaV2.2 and 
increases its insertion into the membrane, resulting in increased current density culminating 
into an increase in the release of the neurotransmitter glutamate.  In addition, I observed that 
phosphorylation of CRMP-2 by Cdk5 at Ser-522 is required for CRMP-2-mediated 
enhancement of CaV2.2 current.  I then used the CaV2.2-CRMP-2 interaction disrupting 
peptide TAT-CBD3 to prevented CRMP-2-mediated regulation of CaV2.2.  TAT-CBD3 was 
then used in both in vitro and in vivo to target this interaction.  
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Figure 5.2.  An atypical role for CRMP-2: increasing bouton size 
Shown are representative pseudocolor images of EGFP (green) andFM4-64 (red) from 
neurons transfected with EGFP (A) or CRMP-2-EGFP (B).  The arrowheads in A and B 
represent axons along which a line scan was performed to quantify the number of boutons 
(labeled with FM4-64) in EGFP (C) and CRMP-2-EGFP (D) neurons. Boutons were 
identified by counting intensity peaks that traversed the 50% maximum intensity level. 
Representative line intensity staining profiles of the FM4-64 panels in A and B are shown in C 
and D, respectively.  (E)  Summary of the average number of boutons/µm of axon.  The 
density of boutons was not different between EGFP- and CRMP-2-EGFP-expressing neurons 
(p  0.05).  (F)  Histogram of diameters from boutons of EGFP- and CRMP-2-EGFP-
expressing neurons.  The largest diameter of each bouton was measured in a double-blind 
manner; the resulting diameters were grouped into bins of 0.1 µm.  Bouton diameters were 
distributed unimodally in both EGFP- and CRMP-2-EGFP-expressing neurons.  (Inset)  Mean 
bouton size of EGFP and CRMP-2-EGFP showed the average diameter of boutons to be ~3-
fold larger in CRMP-2-EGFP-expressing neurons than in EGFP-expressing neurons (p < 0.05, 
Student’s t test). 
.  
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vesicle quantity (Yeow and Peterson, 1991).  These findings suggest additional work needs to be 
done to explore the role of CRMP-2 in neurotransmitter release.  Specifically, it may be 
interesting to determine if CRMP-2 is able to enhance neurotransmitter release without CaV2.2 
modulation.  This could be accomplished using a Ca2+ ionophore, Ca2+ uncaging or optogenetics 
to bypass CaV2.2 and measure neurotransmitter release independent of CaV2.2.  In addition, it 
may be fruitful to look at electron micrographs of neurons transfected with CRMP-2 to determine 
if the number of vesicles in the pre-synaptic terminal is affected by CRMP-2 expression. 
Mechanistically, it is likely that CRMP-2 is able to enhance bouton size through interactions with 
cytoskeleton proteins.  That CRMP-2’s ability to interact with actin may be responsible for its 
regulation of bouton size is supported by findings showing that mutation of the actin binding 
Wiscott-Aldrich syndrome protein (WASP) leads to larger pre-synaptic terminals (Khuong et al., 
2010).  The interaction between CRMP-2 and actin has had limited exploration, although it is 
known that phosphorylation does not affect actin binding to CRMP-2 (Arimura et al., 2005).  As I 
found in Chapter 3 that the CRMP-2 S522A mutant is unable to enhance CaV2.2, it would be 
interesting to assess whether the S522A mutant is able to still increase bouton size.   
As described in §1.1, the pre-synaptic terminal is proposed to contain a limited quantity 
of slots available for CaV2.2. (Cao et al., 2004; Cao and Tsien, 2010).  These slots are limiting as 
over-expression of CaV2.2 does not alter the amplitude of EPSCs or the contribution of CaV2.2 
therein (Cao and Tsien, 2010).  Based upon the finding that CRMP-2 expression enhances 
CaV2.2-mediated transmitter release, either CRMP-2 alters the number of slots available, 
consistent with an observed increase in bouton size, or enhances the open probability of CaV2.2.  
As single channel recordings of Ca2+ channels are technically difficult, it has yet to be determined 
if CRMP-2’s association with CaV2.2 increases the current through CaV2.2.  While in the current 
dissertation I have described the interaction between CaV2.2 and CRMP-2 and further proposed 
that observed changes in neurotransmitter release occur due to this interaction, the possible role 
of other CRMP-2 interacting proteins in enhancing neurotransmitter release cannot be 
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disregarded.  CRMP-2 interacts with a litany of proteins (see Table 1.2.2) that are present in the 
growing axon tip and synapse, which may lead to the observed changes in neuron biology. 
An additional question of interest is whether CRMP-2 alters Ca2+ channels in other cell 
types, leading to alterations in Ca2+-dependent release.  This is further suggested by my observed 
interaction between CRMP-2 and CaV1.2 in a neuronal cell line (data not shown).  While CaV1.2 
is expressed in neurons, it is also expressed in non-neuronal cells such as cardiomyocytes and 
pancreatic beta cells.  Therefore, it would be interesting to test if CRMP-2 is able to regulate 
release in non-neuronal cells (e.g. insulin release from beta cells).  The results of such 
experiments could lead to the concept of CRMP-2 as a global modulator of release in endocrine 
cells as well as neurons.   
 
5.2.  Role of CRMP-2 as a CaV2.2 trafficking molecule 
 The initial identification of CRMP-2 as a modulator of axon growth and growth cone 
collapse suggested that CRMP-2 maybe vital to maintaining proper cytoskeletal organization in 
the neuron.  Subsequent studies further identified CRMP-2 as directly interacting with and 
modulating tubulin (Fukata et al., 2002).  In addition to regulating the polymerization of tubulin, 
CRMP-2 was found to interact with the kinesin motor protein and through this association 
transport tubulin along neuron processes (Kimura et al., 2005).  The interaction of CRMP-2 with 
kinesin further suggests that CRMP-2 may possibly link any protein it interacts with to kinesin, 
and therefore could regulate the protein’s trafficking.  In order for CRMP-2 to have the observed 
enhancement of CaV2.2 function, the number of channels on the plasma membrane or the open 
probability of CaV2.2 must be increased.  As CRMP-2’s role as a trafficking protein has 
previously been established, I first tested the hypothesis that CRMP-2 aids in trafficking CaV2.2.  
Consistent with this hypothesis, I observed an increase in surface expressed CaV2.2 when 
CRMP-2 was overexpressed.  This suggests that CRMP-2 enhances CaV2.2 current through 
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increasing surface expression of CaV2.2, although it does not rule out that CRMP-2 may also 
regulate the open probability of CaV2.2. 
 My initial biochemical characterization found that CRMP-2 is localized to both 
extrasynaptic and synaptic fractions, which suggests that it may traffick CaV2.2 within these 
regions (Figure 3.2).  I also found CRMP-2 present in both cytosolic and membrane fractions.  
CRMP-2 is localized to the soma, dendrites, and axons and therefore may interact with CaV2.2 in 
any of these regions.  The rather ubiquitous intracellular distribution of CRMP-2 makes it 
difficult to determine the precise subcellular localization of the CRMP-2-CaV2.2 complex.  
While my studies show CRMP-2 enhances CaV2.2 surface expression, it is unknown whether 
CRMP-2 is responsible for gross trafficking of CaV2.2 (i.e. from the soma to the axon) or micro-
trafficking (i.e. from axon tip to active zone).  It is also unknown whether CRMP-2 associates 
with CaV2.2 on the plasma membrane.  This question is particularly interesting as CRMP-2 may 
aid in stabilizing the channel on the membrane, which could be responsible for the observed 
enhancement of CaV2.2 surface expression.     
The strong effect of CRMP-2 knockdown on Ca2+ currents in neurons suggests that 
CRMP-2 is necessary for CaV2.2 function (Figure 3.11).  Of significant interest, CaV2.2 current 
is observed in heterologous systems despite limited CRMP-2 expression in these cells, which 
suggests that rather than directly enhancing CaV2.2 surface expression, CRMP-2 may be dis-
inhibiting a negative regulator of CaV2.2 trafficking.  This negative regulator would likely be 
neuron specific, as CRMP-2 expression appears to enhance surface expression in neurons, but 
may not it heterologous systems.  The negative regulation may also represent a channel recycling 
pathway that, without CRMP-2, may lead to a majority of channels leaving the membrane and 
being degraded.  As CRMP-2 binds to the I-II loop, which has been shown to be an important 
region for proteasome regulation of CaV2.2, this could be a possible mechanism CRMP-2’s 
regulation of CaV2.2 (Waithe et al., 2011).  Assuming that CRMP-2 is responsible for 
overcoming neuronal specific negative regulators of CaV2.2 would also suggest a mechanism 
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distinct from the other CaV2.2 subunits.  Future work should therefore further explore the precise 
mechanism of CRMP-2’s regulation of CaV2.2 and to determine if it truly is neuronal specific.      
 In Chapter 3, I observed that phosphorylation of CRMP-2 by Cdk5 enhances the 
interaction between CRMP-2 and CaV2.2 and that a CRMP-2 S522A mutant is unable to enhance 
CaV2.2 currents.  This suggests that enhanced binding between CRMP-2 and CaV2.2 may be 
important to CRMP-2 trafficking CaV2.2 to the plasma membrane. It is also known that CRMP-
2’s affinity for Numb and tubulin is greatly reduced following Cdk5 phosphorylation (Arimura et 
al., 2005), thus the reduced binding of CRMP-2 to tubulin/Numb maybe a required step in order 
for CRMP-2 to traffick CaV2.2 to the membrane.  Based upon this, I would hypothesize that the 
interaction between tubulin and CRMP-2 may be instrumental for CaV2.2 to be trafficked from 
the Golgi to near the membrane, but upon phosphorylation CRMP-2 releases tubulin and allows 
CaV2.2 to be inserted into the membrane.  This would also explain why both CRMP-2 S522A 
and S522D mutants displayed no enhancement of CaV2.2 current, as proper CaV2.2 trafficking 
likely requires both phosphorylation states of CRMP-2.  This spectulation assumes that S522D 
acts as a true phospho-mimetic; it is also possible that this mutant does not function as native 
CRMP-2 phosphorylated at Ser-522 would function.  It has been previously reported, however, 
that the S522D mutant has a subcellular localization similar to phosphorylated CRMP-2 
supporting this mutant likely acts as a phospho-mimetic (Yoshimura et al., 2005). 
 
5.3.  Role of CRMP-2 in the pre-synaptic Ca2+ channel complex 
 CaV2.2 depends on a variety of protein interactions to traffick to the membrane, associate 
with vesicle fusion machinery, and target to the synaptic terminal.  The protein complement of 
the pre-synaptic Ca2+ channel complex is able to fulfill these needs of CaV2.2 and facilitate its 
role as a regulator of neurotransmitter release.  My results have positioned CRMP-2 as a novel 
member of the CaV2.2 complex which assists with trafficking CaV2.2 to the membrane.  It is 
likely, however, that the interaction between CaV2.2 and CRMP-2 occurs concomitantly with 
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other protein interactions.  It is also possible that these protein binding partners are a prerequisite 
for CRMP-2 mediated regulation of CaV2.2.  As described above, it may be that CRMP-2 allows 
CaV2.2 to overcome a negative regulatory pathway specific to neurons.  Future studies should 
therefore attempt to determine what proteins are present in CRMP-2-CaV2.2 complexes.  This 
could be elucidated using sequential co-immunoprecipitation of CRMP-2 and then CaV2.2 in 
order to isolate proteins interacting with the CRMP-2-CaV2.2 complex.  Mass spectrometry could 
then be performed to identify these proteins. 
 I found that CRMP-2 is able to bind both the I-II loop and the distal portion of the C-
terminus.  These regions have many known protein interactions (as shown in Table 1.1) that 
regulate CaV2.2 trafficking and localization to the synapse.  For example, both CASK and Mint-1 
bind to CaV2.2 in the distal portion of C-terminus, overlapping with the area where CRMP-2 
binds.  It would therefore be interesting to determine if CRMP-2 binding interferes with these 
interactions.  Alternatively, the CBD3 peptide could also be useful for these experiments.  In 
other work by Dr. Wang, in the Khanna laboratory, it was found that CRMP-4 expression also 
leads to enhanced Ca2+ currents (Wang et al., 2010).  This finding suggests that other CRMPs 
may also be present in the pre-synaptic Ca2+ channel complex and hence could also regulate 
CaV2.2 and neurotransmitter release.  A potential caveat to these findings is that CRMPs exist as 
heterotetramers and the effects of other CRMPs may therefore occur through enhancing the 
number of CRMP-2 molecules in the synapse, rather than through direct interaction with CaV2.2.  
Thus, in order to conclude that direct regulation is responsible for the observed increase in Ca2+ 
currents, it will be useful to examine if other CRMPs interact with CaV2.2  
   
5.4.  TAT-CBD3 as a novel therapeutic 
 In Chapter 3 I discovered and characterized the CRMP-2 peptide CBD3 as a novel 
CaV2.2 antagonist.  Rather than directly targeting CaV2.2, CBD3 acts by disrupting the 
interaction between CRMP-2 and CaV2.2 which leads to reduced CaV2.2 currents.  CBD3 
 188 
 
appears to have both an acute and long term effect on CaV2.2 function.  When CBD3 was 
expressed in hippocampal neurons, it antagonized CRMP-2-induced enhancement of Ca2+ 
channel currents.  As CBD3 disrupts the interaction between CRMP-2 and CaV2.2, this supports 
the that conclusion that the interaction between CRMP-2 and CaV2.2 is likely responsible for the 
observed increase in Ca2+ currents.  Subsequent creation of TAT-CBD3 (the cell penetrant 
version of CBD3) allowed me to further investigate the role of the CRMP-2-CaV2.2 interaction 
in both neurons in a dish as well as in whole animals.  Application of TAT-CBD3 was able to 
sharply attenuate CaV2.2 currents consistent with the time scale in which I observed intracellular 
penetrance of a FITC-labeled TAT-CBD3.  TAT-CBD3 was then shown to inhibit CGRP release 
in spinal cord slices and reduce hypersensitivity in an animal model of nociception.  These 
findings strongly support TAT-CBD3 as a novel therapeutic to target CaV2.2 related pathology.  
As Chapter 4 has shown, TAT-CBD3 is also able to target NMDARs which may further enhance 
its efficacy in targeting neurological disorders. 
 Further studies on TAT-CBD3, as are ongoing in the Khanna laboratory, are needed to 
verify its specificity and potential applications.  In order to test for specificity of CBD3 peptides, 
utilizing different cell penetrating motifs such as the model amphipathic peptide (MAP) (Scheller 
et al., 1999) or the membrane translocation sequence (MTS) of Kaposi fibroblast growth factor 
(Lin et al., 1995) may be useful, as I found that neither MAP- nor MTS-CBD3 were able to 
acutely inhibit NMDARs (data not shown).  These peptides could therefore be used to 
specifically inhibit the CRMP-2-CaV2.2 interaction without inhibiting NMDARs.  The peptides 
could then be used to verify that in vivo reduction of hypersensitivity occurred solely due to 
CaV2.2-CRMP-2 inhibition.  Conversely, it may be possible that these CBD3 peptides may still 
target NMDARs (discussed in §5.5), and therefore mutations within CBD3 could remain useful in 
separating the dual targeting of CaV2.2 and NMDARs by CBD3 peptides.  In addition, despite 
showing that TAT-CBD3 does not alter memory retrieval, it must also be tested in an animal 
model of memory acquisition to verify that it does not prevent this vital brain function.  Further 
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animal studies, including long term treatment with TAT-CBD3 (several weeks), are also ongoing 
in the Khanna laboratory.  These studies are dual purposed as they may test for any toxicity 
associated with long term TAT-CBD3 exposure as well as determining whether long term 
treatment can lead to longer-lasting reversal of hypersensitivity.  This last part is of particular 
importance as we observed that a single dose of TAT-CBD lost ~50% of its efficacy within 4 
hours.  Ideally, following long term treatment of TAT-CBD3 perhaps given once-a-day, a patient 
would display complete relief from pain for a prolonged (24 hours) period. 
 Another potential application of TAT-CBD3 and other CRMP-2 peptides is the treatment 
of CRMP-2 related neuropathies.  CRMP-2 has been linked to many neuropathies several of 
which were discussed in §1.2.8.  One disease linked to CRMP-2 that may particularly benefit 
from TAT-CBD3 is the neurodegenerative disorder AD.  One of the potential mechanisms for the 
neuronal death associated with AD has been Ca2+ deregulation (LaFerla, 2002).  As TAT-CBD3 
targets Ca2+ influx via two independent pathways it may be a viable therapy to reduce Ca2+ 
associated neuronal death?  The NMDAR has gained ground as a target for AD specifically due 
to the success of the AD medication memantine, a NMDAR antagonist (Muir, 2006).  Testing 
TAT-CBD3 in animal models of AD may therefore prove fruitful.    
 
5.5.  Role of CRMP-2 in excitotoxicity 
 In Chapter 4, I identified TAT-CBD3 as a novel neuroprotective compound that prevents 
neuronal death by reducing Ca2+ influx through NMDARs (Figure 5.3).  Mechanistically, it 
appears that TAT-CBD3 works through extracellular inhibition of NMDARs, as well as inducing 
internalization of dendritic NMDARs.  I also observed that knockdown of CRMP-2 leads to 
reduced neuronal death following glutamate exposure.  This is consistent with a previous finding 
that overexpression of CRMP-2 leads to enhanced glutamate-toxicity (Bretin et al., 2006).  
However, despite a previous study finding that CRMP-2 is in a biochemical complex with NR2B 
(Al-Hallaq et al., 2007), I was unable to observe this complex. 
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Figure 5.3.  CRMP-2’s role in neurotoxicity: targeting NMDARs with TAT-CBD3 
Extracellular accumulation of glutamate induces hyperactivation of NMDARs leading to toxic 
influx of Ca2+.  This Ca2+ build-up leads to activation of many pathways culminating in 
neurotoxicity including calpain meditated cleavage of CRMP-2.  In Chapter 4 I found that 
knockdown of CRMP-2 using a lentiviral delivered shRNA was neuroprotective.  Furthermore 
I found that application of TAT-CBD3 completely prevented NMDAR-mediated glutamate 
toxicity.  This neuroprotection arose from extracellular inhibition of NMDARs along with 
selective internalization of dendritic NMDARs.  These effects of TAT-CBD3 culminated in 
preventing toxic accumulation of intracellular Ca2+ leading to enhanced neuronal survival.  
Collectively, Chapter 4 has further implicated CRMP-2 as an important determinant in 
neurotoxicity and identified TAT-CBD3 as a novel neuroprotective agent. 
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 There have been several studies linking CRMP-2 to neuropathology (see § 1.2.8).  The 
majority of these studies, however, have been proteomic in nature and thus little information has 
been gleaned on how CRMP-2 contributes to neurological disorders.  One of the few areas where 
CRMP-2 has been explored in past proteomic studies is glutamate-induced excitotoxicity, though 
there are still many unanswered questions regarding CRMP-2 and neuronal survival in 
excitotoxicity.  NMDAR activation leads to both proteolytic cleavage of CRMP-2 and 
phosphorylation of CRMP-2 at Thr-555 by CaMKII (Bretin et al., 2006; Hou et al., 2009).  Of 
further interest, it appears that phosphorylation of CRMP-2 may protect CRMP-2 from being 
cleaved.  This presents a potentially complex pathway where CaMKII activation and subsequent 
phosphorylation prevents simultaneously occurring calpain cleavage of CRMP-2.  CaMKII 
mediated phosphorylation of CRMP-2 is predicted to cause a reduction in axon growth potential 
through a reduced affinity of CRMP-2 for tubulin and Numb (Arimura et al., 2005).  Perhaps 
more intriguing is that it was observed in this study that overexpression of CRMP-2 prevented 
glutamate induced alteration of neuritic processes, while a T555A mutant had no effect (Hou et 
al., 2009).  While this suggests that Thr-555 phosphorylation is not an important determinant in 
neuroprotection, it is unknown, what effect, if any cleavage of CRMP-2 may have on neuronal 
survival.  Alternatively, it has been shown that a calpain cleaved version of CRMP-2 is 
neuroprotective when overexpressed in neurons, possibly via down regulating NMDAR 
responses (Bretin et al., 2006).  This finding is difficult to interpret, however, because expression 
of a similarly truncated CRMP-2 leads to a reduction in neuritic process growth, which can likely 
affect many pathways responsible for glutamate toxicity (Rogemond et al., 2008).  It is more 
likely that expression of this truncated form of CRMP-2 acts as a dominant negative.  This could 
occur either through sequestering native CRMP-2 (through tetramerization) or competing with 
native CRMP-2 for endogenous protein interactions required for neuritic outgrowth (e.g. tubulin 
and actin).  Therefore, the neuroprotection observed following knockdown of CRMP-2 (Figure 
4.7) is entirely consistent with the neuroprotection conferred by the calpain cleaved form of 
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CRMP-2, in that loss of CRMP-2 function observed with the latter construct is neuroprotective 
(Bretin et al., 2006).  It is then perhaps no surprise that over-expression of full length CRMP-2 
enhances neurotoxicity (Bretin et al., 2006). 
 TAT-CBD3’s neuroprotective ability appears to stem from its inhibition of NMDAR-
mediated Ca2+ influx.  This inhibition occurs via an extracellular site of action although I also 
observed that TAT-CBD3 induced internalization of NMDARs specifically in dendrites.  This 
internalization was not due to disruption of the PSD-95-NR2B interaction (4.15).  This suggests 
that TAT-CBD3 has a dual mode of action through both inhibition of NMDARs and 
internalization of dendritic receptors.  Blockade of NMDARs with MK-801 prevented this 
internalization.  Also of interest is that I observed are my findings that AP-5 co-application with 
TAT-CBD3 prevents TAT-CBD3’s inhibition of NMDAR-mediated Ca2+ influx.  Although both 
MK-801 and AP-5 inhibit NMDARs, their mechanisms are entirely different; MK-801 
irreversibly blocks the receptor’s pore while AP-5 reversibly competes with glutamate for the 
glutamate binding site on NR2B (See § 1.3.2).  Because of this, it is unknown whether the 
internalization of NMDARs in response to TAT-CBD3 occurs via an intracellular or extracellular 
site of action.  As neither MAP- nor MTS-CBD3 was acutely neuroprotective, these peptides are 
not able to block NMDAR-mediated Ca2+ influx.  These peptides may thus be useful for 
determining both whether intracellular application of CBD3 induces internalization of NMDARs 
and if long term application is neuroprotective.  If long term application of MAP-CBD3 or MTS-
CBD3 is able to reduce NMDAR surface expression, this would support CRMP-2 as a regulator 
of NMDAR function.  Future studies should explore if CRMP-2 has a direct effect on NMDARs, 
which could be assesed by measuring surface expression of NR2B following CRMP-2 
knockdown.       
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5.6.  Conclusion 
In this dissertation, first, I identified and characterized a novel interaction between 
CRMP-2 and CaV2.2.  I further isolated the CBD3 region of CRMP-2 as important to this 
interaction and utilized CBD3 and its cell penetrant analog TAT-CBD3 to target modulation of 
CaV2.2 by CRMP-2.  TAT-CBD3 was able to successful disrupt CRMP-2’s binding to CaV2.2, 
which resulted in reduced CaV2.2 function and efficacy in CaV2.2-related cell biology and 
physiology.  Second, I identified TAT-CBD3 as a novel neuroprotective agent that works to 
mitigate glutamate-induced Ca2+ toxicity.  This finding led to subsequent mechanistic studies 
identifying a dual mode of action in which NMDARs were inhibited with dendritic NMDARs 
being internalized.   
Collectively, my dissertation work has firmly established CRMP-2 as a novel modulator 
of synaptic Ca2+ channels and has set a solid foundation for the CRMP-2 field to advance both 
mechanistically and translationally forward.    
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